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ABSTRACT
Physiology-based pharmacokinetic models are mathematical models that
characterizethe behavior of a drug and have compartmental equations that are
representative of specific tissues and physiological processes.[1, 2] Doxorubicin is an
anthracycline antibiotic that is effective and widely used in anticancer therapy due to
its potent cytotoxicity. Unfortunately, with that potency comes cardiotoxic side effects
related to cumulative lifetime dose.[3] Specifically, the toxicity is related to the
accumulation of the primary metabolite doxorubicinol (DOXol) in the heart.[4] Since
the toxicity is organ-specific, the best way to characterize the behavioris through
PBPK modeling.[2] Since PBPK models tend to be large systems of ODEs, several
numerical methods were attempted for solving the model before a matrix-based
approach was chosen.[5, 6] The eigenvalue/eigenvector solution was evaluated at
three time points which were then included in a Composite Simpson’sRule numerical
integration for the length of some time interval.[5, 7] The PBPK model, adapted from
a pig model, was fit to mouse data and scaled to predict rat, rabbit, dog, pig, and
human data sets using an allometric scaling equation on the blood:plasma partition
coefficient B : P .[8, 9, 10]
Despite extensive investigation into dose adjustments for DOX, no covariates
were consistently found to improve the efficacy and minimize toxicity except dosing
schedule – infusion rate and duration.[11] The criterion for decreasing incidence of
cardiotoxicity was maintaining a sub-toxic Cmax,heart,DOXol in the heart while
maximizing exposure, represented by area under the concentration-time-curve(AUC).
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Thus, the original mouse data set was ideal since it included both DOX venous blood
concentration and DOXol heart concentration.[12] The model was optimized at 10
time points between 1 minute and 72 hours with the goal of(AUC) maximization
without exceeding Cmax,heart,DOXol. Using these predictions, therapeutic drug
monitoring could be executed by taking the plasma concentration samples during a
patient’s first DOX dose, PBPK model predictions could provideAUC and
Cmax,heart,DOXol data, which could then inform the infusion parameters for the next dose.
Clinical thresholds for Cmax,vb have been established for incidence of adverse effects,
and in future work, perhaps a similar threshold for cardiotoxicitycould also be
established using tissue-specific measures.
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CHAPTER 1
DOXORUBICIN: PHYSIOLOGICAL OVERVIEW
1.1

Introduction

Doxorubicin (DOX) is an anthracycline antibiotic with antineoplastic activity
which was approved by the FDA as a chemotherapy agent in 1974.[13] It was one of the
first two anthracyclines isolated from Streptomyces peucetius, a type of actinobacteria, in
the 1960’s.[14, 15] It has since been one of the most commonly used drugs in cancer
treatment. DOX is highly cytotoxic, making it an excellent anticancer drug but it is also
known to cause extensive damage to healthy tissue.[16] It has been found to be
efficacious in both adult and pediatric populations for a variety of cancer types, including
solid tumors like small-cell lung cancer[17] and osteosarcoma[18], and blood cancers like
non-Hodgkin lymphoma and leukemia.[19, 20] A list of common cancers treated with
DOX is shown in Table 1-1. While this work will focus on the use of DOX in adults, it is
worthwhile to mention that DOX has been a major player in pediatric oncology. The 5
year survival rate for pediatric cancers in general has increased from ≈5% in the 1960’s
to ≈80% in recent years, and anthracyclines like DOX are given in ≈50% of childhood
cancer protocols.[14] It has been said that doxorubicin is the most effective anticancer
drug to be developed, which is evidenced in its continued use today, 50 years after its
discovery.[15] Over the years, with the development of more targeted therapies, it has

1

2
become relatively common in clinical practice to combine novel therapeutics with DOX
rather than to replace DOX with the novel therapeutics.[21, 22, 23, 24, 25, 26] In addition
to continuing to include DOX in current treatment protocols, different formulations of
DOX have been utilized. These include encapsulation in liposomes and nanoparticles for
enhanced and targeted drug delivery.[27, 28, 22, 23] DOX is not administered orally due
to its low bioavailability in that formulation, unpredictable and generally poor
permeability in the intestines.[29] The scope of this work will only consider “free”, or
unencapsulated, doxorubicin, and the current models for DOX will be discussed in a
following section.
Doxorubicin has a triphasic disposition, which means that it has three sequential
half-lives.[30] Typically, a drug with triphasic disposition would be fit to a three
compartment pharmacokinetic model, and such is the case for most models of DOX.[31,
17, 32] In some cases, the sampling frequency is too sparse to capture one of the half-life
phases, and DOX is fit to a two-compartment model.[33] A more in depth analysis of
current pharmacokinetic models of DOX will follow in a later section. For doxorubicin
the first half-life is 5 - 10 minutes, the second half-life is 30-180 minutes, and the third is
24-36 hours.[30, 34] The terminal half-life of DOX is estimated to be between 30.8 hours
to 48.4 hours; the terminal half life of DOXol is estimated to be between 27.8 hours and
66.2 hours[30, 17], with a detectable mean residence time (MRT) of 45.6 hours (range 26
hours - 83.1 hours).[35] When studied over a 48 hour sampling duration, the reported
volume of distribution of DOX was 572 ± 215 L/m2 to 682 ± 433 L/m2 (Mean ± Standard
Deviation).[30, 17] Recall that volume of distribution is a surrogate proportionality
constant to relate drug concentration in blood or plasma to the amount of drug in the
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body.[36] The reported plasma clearance for DOX from the same studies was from 492
±155 ml/min/m2 to 677 ± 229 ml/min/m2.[30, 17] A study that spanned over a 72 hour
sampling duration fell within the estimated plasma clearance at 598 ± 142 ml/min/m2.[30,
37] In terms of rates, the estimated rate of total clearance of DOX is broken down into
three categories - renal clearance, hepatic clearance, and formation clearance. Formation
clearance is the loss of parent drug due to conversion of the parent drug to a metabolite.
The clearance rates for DOX are 30.7 L/hour for total clearance, 0.66 L/hour for renal
clearance, 29.97 L/hour for hepatic clearance, and 0.39 L/hour for formation clearance to
the primary metabolite DOXol.[11] DOX is also known to bind heavily to both tissues
and plasma, with an estimated unbound fraction of about 15%.[11] Overall, DOX
exhibits linear pharmacokinetics.[32]
A considerable obstacle in the clinical efficacy of DOX is its cardiotoxicity.[16]
Myocardial lesions[4], congestive heart failure[18], and cardiomyopathy[38] are all
common conditions resulting from DOX in patients. Both acute cardiotoxicity and
cumulative dose contribute to the adverse effects, which often limits its use to induction
therapy and short-term use under most protocols. The toxicity profile of DOX has lead to
substantial work in identifying equivalent drugs that maintain the therapeutic efficacy of
DOX without the devastating side effects. Anthracyclines like epirubicin and idarubicin
and a similar drug, mitoxantrone, have garnered some success in this search, but DOX
remains the most utilized anthracycline.[39] A lifetime cumulative maximum of 550
mg/m2 has been implemented to help curb morbidity in patients receiving DOX.[40, 19]
A cumulative lifetime dose measurement is used for many drugs, as well as radiation,
whose regimens include prolonged repeated dosing or exposure. Often times these
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cumulative exposures are related to lifetime attributable risk (LAR), which can be used in
risk-assessment analyses for the particular drug or toxin.[41] In cancer therapy, the risk
of adverse damage by the drug and its total dose must outweigh the potential mortality of
the patient. The level to which a lifetime cumulative maximum is set for a drug depends
on the population of patients it is treating. For example, if doxorubicin was effective
against athlete’s foot, the risk of cardiotoxicity would far outweigh the benefit of relief
from athlete’s foot. However, the risk of cardiotoxicity does not outweigh the benefit of
curbing a potentially fatal malignancy. The cumulative lifetime dose of doxorubicin was
determined by relating the cumulative lifetime dose to the incidence of congestive heart
failure in patients.[42] In a small study by Von Hoff et al., increased likelihood of
doxorubicin-induced congestive heart failure (CHF) was found to be linked to increasing
total dose. The incidence of patients developing CHF was 3% at 400 mg/m2, 7% at 550
mg/m2, and 18% at 700 mg/m2. Additionally, Von Hoff et al. found that the occurrence of
CHF in these patients was significantly lower with a once per week dosing schedule than
with a once per 3 weeks dosing schedule of doxorubicin administration.[43] One
interesting observation from Table 1-1 is that the majority of the clinical dose regimens
currently in use are the latter - once per 3 weeks dosing - which leads to a presumably
higher risk for cardiotoxicity. One reason for this could be that the efficacy of DOX has
been observed to be less with lower, more frequent doses of DOX. Some suggest that
since the tumor growth phase is a relatively short window in the scope of the growth
cycle of the cell. Tumor cells are most vulnerable to the cytotoxic effect of DOX during
growth phase. Thus shorter, lower doses - even given frequently - are more likely to clear
more quickly due to the first-order elimination of DOX and the drug effect is less likely
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to coincide with the tumor’s growth phase.[44] Unfortunately, the more effective dosing
schedule does involve longer, less frequent infusions, but that schedule also correlates to
higher incidence of CHF. Finally, the study by Von Hoff et al. revealed that as the age of
the patient increased, the incidence of CHF likewise increased.[43, 42] Data from a large
number of clinical trials compiled by Rahman et al. showed that approximately 25% of
patients having a cumulative dose of 500 mg/m2 experienced CHF. Additionally, some
type of cardiotoxic event occurred in 50% of patients having a cumulative dose of 600
mg/m2, and nearly 100% of patients having a cumulative dose at or above 800
mg/m2.[45] Another meta-analysis of four clinical trials containing ≈ 1200 patients
looked at the cumulative incidence of CHF in patients who received DOX. The study by
Swain et al. found that an estimated 5% of patients at a cumulative dose of 400 mg/m2
experienced CHF, 26% of patients experience CHF at 550 mg/m2, and 48% of patients
experienced CHF at 700 mg/m2.[42] It is evident that while there is some variability in
the percentage of patients who experience CHF following treatment with DOX, the trend
is most certainly that the higher the cumulative dose, the higher the likelihood of adverse
cardiovascular effects.
Considering all the historical data up until this point, it is widely accepted that
550 mg/m2 is the maximum cumulative lifetime dose for DOX that is implemented in
chemotherapy protocols.[14, 15, 3, 39, 46] It has been found that overall, approximately
2% of patients who receive a cumulative dose of DOX between 450 mg/m2 and 550
mg/m2 experience CHF. [39] The accepted maximum cumulative dose of 550 mg/m2 is
likely a compromise between increased percent risk per mg/m2 of therapeutic exposure.
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As shown in Table 1-1, DOX is more frequently used in combination therapy
rather than as a single agent. The maximum tolerated dose (MTD) for a single dose of
DOX is 10 mg/kg, which is a popular dose given in murine studies of DOX.[47] Acute
toxicity is observed in humans at a 12 mg/kg at a single dose.[48] However, clinically,
DOX is always given in cyclic repeated doses, which is also made clear by Table 1-1.[49]
This consideration requires much lower doses than the MTD to be given per event.
Typically, the highest clinical dose of DOX is 75 mg/m2, or 1.9 mg/kg, which is also the
highest dose for repeated dosing shown in Table 1-1.[47]
Traditionally, the drugs used in combination regimens are given at or near their
maximum tolerated doses (MTDs). While this is sometimes necessary due to virulent
nature of cancer, it can introduce a higher risk of dose-related toxicity, which interferes
with clinical success. Chemotherapy drugs given at doses close to their MTD are
generally robust doses with high inter-patient variability in pharmacokinetic parameters,
which could cause significant myeloablation in some patients.[23] Myeloablation refers
to the administration of chemotherapy or radiation therapy that does not allow for
hematologic recovery. In other words, myeloablation prevents the bone marrow from
recovering from the cytotoxicity incurred from the therapy.[50] Support is needed to
recover from myeloablation, including platelet or whole blood infusions, intravenous
immunoglobulin (IVIG), or donor bone marrow or stem cells.[51] While myeloablation is
desired in specific cases such as some bone marrow and stem cell transplants, in most
cases it is avoided. Myeloablation compromises immune response and inhibits the
effectiveness of accompanying chemotherapy or immunotherapy treatments.[23]
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Table 1-1: List of Common Types of Cancer Treated with Doxorubicin from Prescribers’
Digital Reference[49]
Typical Adult IV Dosing
Indication
Single Agent
Acute lymphoid leukemia 60 to 75 mg/m2 every 21
(ALL)
days
Acute myeloid leukemia 60 to 75 mg/m2 every 21
(AML)
days
Breast cancer
60 to 75 mg/m2 every 21
days
Endometrial sarcoma
N/A
Ewing’s sarcoma
Gastric (stomach) cancer
Hodgkin lymphoma
Multiple Myeloma
Neuroblastoma
Non-Hodgkin lymphoma
Osteogenic sarcoma
Ovarian cancer

Small cell lung cancer

N/A

Soft tissue sarcomas
(other)

N/A

Wilms tumor

40 to 75 mg/m2 every 21 to 28 days

60 to 75 mg/m2 repeated 40 to 75 mg/m2 repeated every 21 to 28
every 21 days
days
N/A

Transitional cell bladder
cancer

40 to 75 mg/m2 every 21 to 28 days

45 mg/m2 every 21 days for up to 7 cycles
or until disease progression
2
60 to 75 mg/m every 21 40 to 75 mg/m2 every 21 to 28 days
days
60 to 75 mg/m2 every 21 40 to 75 mg/m2 every 21 to 28 days
days
N/A
25 mg/m2 repeated every 7, 14, or 21 days
in a 28 day cycle
N/A
9 mg/m2 daily for 4 days, every 28 days for
3 to 4 cycles
60 to 75 mg/m2 every 21 40 to 75 mg/m2 every 21 to 28 days
days
N/A
50 mg/m2 every 21 days for 3 to 8 cycles
depending on response
30 to 45 mg/m2 repeated 30 to 75 mg/m2 repeated 2 or 3 days
for 2 or 3 days monthly monthly

Rhabdomyoscarcoma

Thymoma
Thyroid cancer

In Combination Therapy
40 to 75 mg/m2 every 21 to 28 days

N/A
60 to 75 mg/m2 every 21
days
60 to 75 mg/m2 every 21
days

40 mg/m2 daily for 2 days in a 52 day
cycle, repeated based on staging at
diagnosis
40 to 50 mg/m2 every 3 to 4 weeks for 5 to
8 cycles
15 mg/m2 per day as a continuous IV
infusion over 24 hours (CIV) for 4 days
repeated every 21 days for 5 cycles
40 to 75 mg/m2 every 21 to 28 days
40 to 75 mg/m2 every 21 to 28 days
40 to 75 mg/m2 every 21 to 28 days OR 30
mg/m2 every 28 days for up to 3 cycles

60 to 75 mg/m2 every 21 40 to 75 mg/m2 every 21 to 28 days
days
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Overall, there is a delicate balance between maximizing the cancer-killing effects
of a chemotherapy regimen without causing counter-productive damage to healthy cells
and systems. DOX has been and continues to be an integral component of countless
chemotherapy regimens for over 50 years. Evaluating the balance of DOX-induced
cardiotoxicity and life-saving therapeutic effect, from a quantitative perspective, adds
great value to the existing knowledge.
1.2

Mechanism of Action-Cytotoxicity

Although the exact mechanism for how DOX and other anthracyclines enter cells
is not fully known, DOX is thought to enter the cell by passive diffusion through the
plasma membrane.[52] There is also evidence to support that DOX may also enter the
cell through carrier-mediated transport.[29] DOX then binds to proteasomes and breaches
the nucleus through selective transport. Once inside the nucleus, DOX is in proximity to
the DNA. Since DOX usually has a higher affinity for DNA than for the proteasome to
which it is bound, it dissociates from the proteasome to bind to DNA. [52, 53] Once in
the cells, DOX interacts directly with DNA, causing double-strand breaks in the DNA of
rapidly dividing cells. Again, the complete mechanism is not fully understood[32, 54],
despite years of use and study. However, there are two proposed and widely accepted
mechanisms for the cytotoxic actions of DOX — (i) free radical generation and oxidative
damage, (ii) DOX intercalation into DNA which inhibits topoisomerase II, possibly
altering the chromatin structure.[55, 56] The following subsections will describe these
two proposed mechanisms for the cytotoxicity of DOX in greater detail.
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1.2.1

DNA Intercalation
DOX intercalates into DNA which causes a double-strand cleavage, allowing

tyrosine remnants of topoisomerase II to form a covalent bond with the DNA. The
intercalation effectively traps topoisomerase II, inhibiting proper DNA repair.[54, 15]
DNA topoisomerases are large proteins that perform critical actions in DNA strand
separation for transcription, replication, segregation, and genetic compaction into cells.
Compaction poses a topological constraint in DNA replication, as the entire genome of a
single cell, around 3 billion base pairs with an equivalent length of almost 2 meters, into a
roughly 6 µm diameter nucleus. Transcription and replication of genomes by copying
each base by RNA and DNA polymerases requires DNA strand separation. This strand
separation can create DNA super coiling in the flanking regions - regions adjacent to both
the 3’ and 5’ ends of the DNA - where the two DNA strands are separated by
polymerase-helicase complexes. Positive super-coiling occurs in front of the replication
or transcription sites and negative super-coiling occurs behind it. Super coiling, if not
checked by DNA topoisomerases, rapidly stalls replication and transcription and can
cause abnormal DNA structures. In general, topoisomerases prevent super-helical tension
and knotting in DNA compaction.
The human genome encodes for six topoisomerases. Broadly, there are two types
of topoisomerases in humans, Type I and Type II, of which Type I is further subdivided
into Type IA and Type IB.[53] Both types of topoisomerase can undo the detrimental
super-coiling during DNA strand separation, but it has been shown that other
topoisomerases will compensate for the absence of topoisomerase I. However, cells will
die in the mitosis phase in the absence of topoisomerase II, since it is apparently vital for
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chromosome segregation and condensation.[57] Only topoisomerase II can separate
catenanes - interlinked duplex DNA circles. All cells require decatenation at the end of
the replication phase to allow for the proper segregation of newly replicated
chromosomes.[53] After the topoisomerase II-mediated DNA damage, growth arrest
occurs at G1 and G2, which is followed by programmed cell death.[15]
This critical action performed by topoisomerase II makes it an excellent target for
anti-cancer drugs. DOX is a DNA intercalator which acts in two ways to disturb
topoisomerase depending on the concentration present. At low concentrations, DOX
inhibits DNA religation by essentially poisoning topoisomerase II. At high
concentrations, DOX prevents topoisomerase II from binding DNA, suppressing
topoisomerase II.[53] To summarize, DOX is very effective in thwarting DNA
unwinding and strand separation, which stops successful DNA replication and
transcription.
Additionally, a recent study by Yang et al. discovered that DOX does enhance
nucleosome turnover around gene promoters. Enhancement of nucleosome turnover is
consistent with the observed action of DOX, as the enhancement of turnover continues to
increase with time of exposure to DOX. This finding was realized by genetically defining
a murine squamous cell carcinoma line before and after DOX treatment.[54]
1.2.2

Free Radical Generation and Oxidative Damage
DOX has been found to induce the production of reactive oxygen species

(ROS).[58] A semi-quinone is formed when a single electron is added to a quinone
moiety in ring C of DOX. This semi-quinone quickly reduces to its parent compound,
quinone, by reducing oxygen to ROS - hydrogen peroxide H2O2, for example. The semi-
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quinone can also oxidize with the bond between daunosamine and ring A of DOX to
form 7-deoxaglycone through reductive deglycosidation (Figure 1-1). Aglycones are
notably soluble in lipids and intercalate into biological membranes in vulnerable tissues,
forming ROS in close proximity to sensitive targets.[15]

Figure 1-1: Single-electron reduction-oxidation cycling of doxorubicin, taken
fromthe review paper by Minotti et al.[15]

DOX-induced ROS then initiate a number of signaling pathways that lead toward
cell death by accelerating myofilament apoptosis, suppressing myofilament synthesis,
altering cardiac energy metabolism, and causing ultrastructural changes to myocytes.
(i)

DOX-induced ROS activate the protein p53, a known tumor suppressor protein.
p53 protein initiates apoptosis of myocytes through transcriptional p38 MAPKdependent activation. MAPK (mitogen-activated protein kinases) is a target gene
pathway often involved in p53-mediated apoptosis.[58, 59]

(ii) Suppressing myocyte synthesis occurs through the down-regulation of cardiac
progenitor cell (CPCs) regulatory transcription factor GATA-4. It is thought that
sarcomere protein synthesis is inhibited by the DOX-induced down-regulation of
GATA-4. GATA-4 is also critial for postnatal cardiomyocyte survival.[58]
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(iii) Adenosine triphosphate (ATP) is required for most vital processes in the body,
but specific to the heart, ATP is required for the relaxation and contraction of the
heart muscle. DOX diminshes cardiac energy reserves by lowering both
phosphocreatine levels and ATP levels, destabilizing the ratio between the two.
Adenosine monophosphate-activated protein kinase (AMPK) activates the
catabolic pathway that leads to the production of ATP, and DOX reduces the level
of AMPK expression, although the mechanisms underlying this inhibition are not
clear.
(iv) DOX simultaneously motivates calcium release and blocks sarcoplasmic
reticulum reuptake of calcium. This interference notably disrupts calcium
homeostasis,resulting in cytosolic calcium overload.[58] In an in-vitro study by
Kim et al., calcium release from intracellular stores in rat cardiomyocytes was
observed under treatment with different concentrations of DOX. The calcium
release increased at 60 minutes after treatment with 1 µM DOX and at 15 minutes
after treatment with 5 µM DOX.[60] This dose-dependence is consistent with the
findings from the first proposed DOX mechanism of DNA intercalation.[53] The
overload in calcium likely contributes to contractile dysfunction by activating
calpain, a cysteine protease, and stimulating the release of cytochrome c, a
proapototic factor. Calpains initiate protein turnover of structural and regulatory
myofibrillar proteins through cleavage and release of large polypeptide
fragments.[58]
The caveat, as with all antineoplastic agents, DOX can not differentiate between
healthy cells and cancer cells.[16] The cytotoxic activity of DOX is a double-edged
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sword. The properties of DOX that make it a potent and widely-used anticancer agent for
over 50 years are the very same properties that limit its clinical use. DOX has a
particularly devastating effect in cardiac muscle, which has been covered briefly in the
discussion of proposed cytotoxic mechanisms of action above. The dose-dependence of
the pharmacodynamic effects of DOX are elucidated in both of the generally accepted
mechanisms of DOX, making it an interesting compound for study in dose optimization.
The following sections will discuss how the major metabolite of DOX - doxorubicinol plays a greater role in cardiac damage and a lesser role in therapeutic effect.

1.3

DOX Metabolites

DOX is considered a low- to moderate- clearance drug, with clearance values
ranging from 42.8 to 68.1 liters per hour.[46] (Figure 1-2).

Figure 1-2: Main pathways of intracellular doxorubicin (DOX) biotransformation in
mammalian cells, including catalytic enzymes involved in its metabolism. The
downstream effects of the metabolites are also listed. (adapted from Edwardson et al.
[52])
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Within a week of administration, approximately 50% of the dose is eliminated
through bile and 12% through urine.The fraction eliminated through bile consists of
approximately 50% unchanged DOX, 23% DOXol, and the remaining 27% other
metabolites. The fraction eliminated through urine is roughly 66% unchanged DOX and
the remainder metabolites.[4] This is consistent with the clearance rates which were
mentioned in the introduction and originally reported by Pippa et al. The clearance rate
for DOX by hepatic clearance was ≈97% of the total clearance rate.[11] It has been
estimated that approximately 50% of DOX clears from the body unchanged. The
remaining half is converted into three DOX metabolites - doxorubicinol (DOXol),
doxorubicin deoxyaglycone metabolite (DDM), and doxorubicin semi-quinone radical
(DSR) - through three unique metabolic pathways:
(i)

The secondary alcohol metabolite doxorubicinol (DOXol) is formed through
hydroxylation at the C-13 carbon group. This hydroxylation is facilitated by
carbonyl reducing enzymes, which are a heteroogenous group of cytosolic
NADPH-dependent carbonyl reductases (CBR) and aldo-keto reductases
(AKR).[52] Carbonyl reductases CBR1 and CBR3 are also known to contribute to
the reduction of DOX to DOXol, but the extent to which each of these contributes
is uncertain.[55] Accordingly, while both types of carbonyl reducing enzymes are
involved, it has been shown that aldo-keto reductases are the primary enzymes
involved in hydroxylation of DOX in the human heart.[52] Multiple studies have
linked DOXol to cardiotoxicity.[52, 15, 4] Interestingly, since AKRs are fairly
universal, the hydroxylation of DOX to DOXol occurs in all cell types.[52] This
effect has been studied extensively in red blood cells, as well as liver and kidney
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cells.[52, 61] Hydroxylation of DOX to DOXol is considered to be the major
metabolic pathway and has been heavily investigated for decades.[52] Even still,
the extent to which DOX metabolizes to DOXol is unclear (Figure 1-3).

Figure 1-3: Molecular structure of doxorubicin

(ii)

The DOX deoxyaglycone metabolite (DDM) is formed through the one electron
reduction of DOX. The reduction is catalyzed by NADH dehydrogenase
(NDUFS), cytochrome P-450 reductase (CPR), xanthine oxidase, and nitric oxide
synthase (NOS), which leads to the transformation of the quinone moiety of DOX
to a semiquinone radical. This semiquinone radical is stable only in anaerobic
conditions, and when exposed to oxygen, it freely re-oxidizes to regenerate its
parent compound, quinone. The re-oxidation of the semi-quinone radical to the
quinone produce a superoxide anion (O−2 ) and hydrogen peroxide (H2O2) as
byproducts, both of which are reactive oxygen species (ROS). These free radicals
then cause protein aggregation, peroxidation of lipids within cellular membranes,
and sometimes cell death. The oxidation-reduction cycling of DOX has been
observed in the sarcoplasmic reticulum, mitochondria, and the cytoplasm.[52] In
addition to the production of ROS, this redox cycling of DOX has been shown to
produce aldehydes that escape the cell and contribute to DOX toxicity.[14, 52]
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Interestingly, DOXol also goes through a similar redox cycle and thereby
produces similar ROS byproducts and a DOXol deoxyaglycone analog.[40]
(iii) The last, and most poorly characterized metabolic pathway forms the doxorubicin
semi-quinone radical (DSR). Perhaps it is least understood because it only
accounts for ≈1-2% of DOX metabolism. DSR formation occurs through
reductive cleavage of the side-chain carbonyl group and the glycosidic bond, also
producing hydroxyaglycones and 7-deoxyaglycones. It has been proposed that
this reaction is catalyzed by an NADPH-dependent reductase- and hydrolase- type
glycosidases and xanthine dehydrogenase (XDH). These glycosidases likely
include the NADPH quinone oxidreductases (NQO1) and NADPH-cytochrome
P450 reductase (CPR).
These three DOX metabolic pathways vary in extent among different tissue types
and conditions; however, in general, the secondary alcohol DOXol is the principal
metabolite, with substantially lower percentages of the deoxyglycone metabolite and the
semi-quinone radical. The remainder of this section will focus on the metabolite DOXol
and its effects on cells.[52]
1.3.1

DOXol and Cardiotoxicity
DOXol is thought to be the major metabolite and retains the therapeutic and

cardiotoxic effect of the parent drug DOX.[52] The terminal half-life of DOXol is similar
to that of DOX, around 60 hours.[34] It is common for antineoplastic drugs to be
measurable in tissues for a prolonged time following administration and that toxicity is
often related to drug concentration in the tissue.[62, 40] In a study done on tissue from
autopsied human patients by Stewart et al., DOXol was the major metabolite species
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found in all tissues.[40] A study conducted on a small cohort of breast cancer patients
estimated the DOXol/DOX AUC ratio to be 0.26. Area under the concentration-time
curve is a standard measure of drug exposure in pharmacokinetics and will be discussed
more in following chapters.
Due to the known cardiotoxic effect of DOX, the potentially extended residence
time in cardiac tissue is of most interest. This consideration coupled with the substantial
presence of DOXol in cardiac tissue infer that DOXol likely contributes to the
cardioxicity seen in patients receiving DOX.[40] Like DOX, DOXol binds significantly
to plasma and tissues, with an unbound fraction of only 17%.[11]
Table 1-2 shows the median concentration in select tissues from the 35 autopsied
patients. There is sizable variability in the range of values versus the median, which is
likely due to a few factors - (i) the small sample size (n=35) with the caveat that not all
tissues were able to be used for DOX measurement in all patients, (ii) the wide range in
time from last DOX dose to moribund (1-931 days), and (iii) the large difference in
cumulative lifetime dose (30-670 mg/m2).

Table 1-2: Median Concentration of DOX and DOXol in Autopsy Tissue from 35 Human
Patients in Stewart et al. Study; 35 Patients Received Cumulative Lifetime Dose of 30670 mg/m2 with Last Dose from 1 - 931 Days (Source [62])

Heart
Liver
Kidney

Median
DOX Concentration (ng/g)
58 (0-1665)
115 (0-2030)
53 (0-2773)

Median
DOXol Concentration (ng/g)
92 (0-484)
198 (0-674)
104 (0-896)

Each of these factors contribute to the variability in the DOX and DOXol
measurements in tissues. The scarcity of available human autopsy tissue for such
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observation along with ethical considerations are certainly obstacles, but the available
data is nonetheless invaluable for comparison with subclinical studies. [40] As shown in
Table 1-2, the liver and kidney both have higher concentrations per gram than the heart.
Higher DOX and DOXol concentrations in the liver and kidney are also observed in
animal species.[63, 64] However, the liver and kidney are not major sites of toxicity for
patients receiving DOX, which leads to conjecture other factors differentiating DOX and
DOXol behavior in tissues. One such conjecture is that liver and kidney tissues are rich in
binding and inactivating substances due to their excretory and metabolic functionalities,
which prevent DOX and DOXol from causing cellular damage in those tissues.[40] For
example, reduced DOX toxicity is observed in the presence of glutathione - a common
antioxidant found in the liver.[65]
In a study of isolated cardiac tissue from rabbits, DOXol was nearly 30 times
more effectual at suppressing systolic cardiac function. A 90 µM dose given at 50 µg/ml
decreased contractility, a measure of systolic function, by roughly 69% of the baseline
measure. In contrast, a comparable dose of DOX, 350 µM at 200 µg/ml, only depressed
contractility by about 11% of the baseline. The maximum dose of DOX at 700 µM at
400µg/ml only decreased contractility by 29%. Myocardial resting stress, a measure of
diastolic cardiac function, was also tested with both DOX and DOXol using the isolated
rabbit cardiac tissue model. DOX also had a negligible effect on diastolic cardiac
function even at 700 µM dosing, while DOXol increased myocardial stress by
approximately 395%. Therefore, DOXol suppressed both systolic and diastolic
myocardial function more severely than DOX. Calcium pump activity, described as both
Ca2+ stimulated ATPase sarcoplasmic reticulum activity and rate of calcium loading, was
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also evaluated in both DOX and DOXol. DOX was not found to be a strong inhibitor of
calcium pump activity, while DOXol nearly destroyed all calcium pump activity in the
heart tissues.
This study highlights another interesting property of DOX and its metabolite
DOXol - its extent of intracellular uptake. DOXol is known to have less intracellular
uptake than DOX, and yet the major species residing in tissue has been shown over time
to be DOXol.[66] The most reasonable explanation for this inequity is that the
hydroxylation of DOX to DOXol is carried out primarily by aldo-keto reductases
(AKR).[52] AKRs are abundantly present in most human tissues, so it is thought that
during this observed prolonged residence time in the tissue, DOX metabolises to DOXol
over time.
Disappointingly, the aggressive cell-destroying capabilities of DOXol does not
translate to cancer cell destruction. A potency study was conducted in three different
cancer cell lines using a metric called IC50, which is the concentration of an inhibitor
where 50% response is observed. In this case, the concentration of DOX or DOXol
needed to inhibit the growth of colonies by 50% compared to the control group. As
shown by the ratio of IC50DOXol /IC50DOX in Table 1-3, it takes 5 to 28 times as much
DOXol to inhibit the same cancer cell lines as DOX. DOXol is therefore a much less
effective anticancer agent in comparison to DOX. In fact, it has been estimated that
DOXol is 75 times less effective than DOX while apparently contributing heavily to the
cardiotoxicity associated with DOX.[15, 8] It is clear that factors beyond cumulative
lifetime dose are at play in the marked cardiac damage caused by DOX. The profoundly
greater cardiotoxic properties of DOXol and its conversion from DOX to DOXol in the
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tissues. This finding has been applied clinically with the lifetime maximum dose cap
applied to DOX and other anthracyclines.[52] This is one motivation for utilizing
therapeutic dose monitoring in anticancer drugs. Maximizing cancer-killing effect
generally means giving as much drug as can be reasonably tolerated. With the breadth of
data available on popular drugs like DOX, it could be possible to have a more tailored
approach in order to curb some of the devastating side effects.

Table 1-3: IC50 for DOX and DOXol in Three Cancer Cell Lines from a Study by
Olson et al.[66]
Cell line
PANC-1
PD PaCa
WD PaCa

Doxorubicin,
IC50 in µM
1.4 ± 0.2
1.6 ± 0.2
9.8 ± 1.5

1.4

Doxorubicinol,
IC50 in µM
35.4 ± 4.7
44.5 ± 0.5
49.5 ± 1.1

DMF,
IC50−ol/IC50−in
25
28
5

Conclusion

Doxorubicin is a chemotherapy agent which has particularly potent cytotoxic
capabilities, and its three metabolites are thought to also be cytotoxic in varying
intensities. DOXol is the major metabolite and plays the greatest role in cytotoxic
activity.[33] In general, DOXol has a greater cardiotoxic effect and a lesser therapeutic
effect than its parent drug. While DOXol accounts for the greater majority of DOX
metabolites, it has a much lower intracellular uptake than DOX. Conversely, while
DOXol has a lesser effect on cancer cells, it induces a higher toxicity in healthy cells,
particularly cardiomyocytes. Cumulative lifetime dose certainly plays a role in DOX
toxicity, and intracellular uptake occurs with both DOX and DOXol.[66] While DOXol
has a lesser uptake, DOXol is typically found in greater amounts per gram in tissues. This
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is likely due to the gradual conversion of DOX to DOXol in tissues by aldo-keto
reductases which are present in most human tissues, abundantly so in cardiac tissue.[52]
These paradoxes complicate the therapeutic dosing of DOX in cancer patients.
One way these challenges can be better understood is through the mathematical
and statistical modeling using observed pre-clinical and clinical data.

1.5

Outline of Content in Each Chapter

Chapter 1 has outlined the properties of the anthracycline Doxorubicin (DOX) as
a potent chemotherapy agent and also a cardiotoxin. However, the primary metabolite
Doxorubicinol (DOXol) has been found to be the main culprit for cardiotoxicity. The
organ-specific toxicity of the metabolite DOXol in a specific tissue can be estimated
using what is called a physiologically-based pharmacokinetic (PBPK) model.
The overview is intended to frame DOX/DOXol as a good candidate for
pharmacokinetic modeling, specifically under the more physiologically based modeling
methods that will be discussed in later sections.
Chapter 2 will continue with background information, introducing the concepts of
pharmacokinetic modeling. The discussion of pharmacometrics will be agnostic to the
specific drug, DOX, but the defining of terms and methodologies of this type of modeling
is important for understanding the models in this work.
Chapter 3 will take the fundamentals from Chapter 2 and expand on existing
pharmacokinetic models in DOX. However, a classic pharmacokinetic model cannot
capture the specific organ concentrations, which is the interest of this work. Thus, the
latter portion of Chapter 3 will introduce the more modern approach of physiologicallybased pharmacokinetic (PBPK) modeling as it pertains to DOX. A whole-body PBPK
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porcine model of DOX, adapted from literature, will be described in detail. The PBPK
model is comprised of a system of 44 ordinary differential equations for which there is no
exact solution, so numerical methods must be employed to solve the system.
Chapter 4 will walk through the process of testing different numerical methods on
the system. The method needed to be both accurate and efficient, which for large systems
of equations, can be a difficult balance in the programming language R. Once a suitable
method was determined for solving the PBPK model in pigs, the model could be scaled
across species - from sub-clinical species to humans. Sensitivity analysis and the
optimization package ’optim’ in R was used to fit the initial data set. This data set
contained both DOXol heart tissue concentration and venous blood DOX concentration
in mice. Allometric equations were tested on sensitive parameters one representative rat,
rabbit, dog, pig, and human data set to determine the best relationship.
The final chapter discusses the potential application of the process of getting
organ-level concentration predictions using a PBPK model and scaling it to humans.
Therapeutic drug monitoring is used in many drugs similar to DOX in that they almost
always have a narrow therapeutic index. Additional future work could include
pharmacodynamic studies which relate pharmacodynamic response to some organ
specific toxicity and the application of this process to other drugs.

CHAPTER 2
PHARMACOMETRICS OVERVIEW
2.1

Pharmacokinetic Versus Pharmacodynamic

Pharmacometrics is a contemporary discipline that characterizes interactions
between the drug and the patient using mathematical modeling of the physiology,
pharmacology, and disease involved. The term “pharmacometrics” was coined by the
Journal of Pharmacokinetics and Biopharmaceutics in 1982.[67] Pharmacometric
modeling can be generalized as one input-response model that is divided into two pieces pharmacokinetic and pharmacodynamic.[68] Pharmacokinetics is broadly described by
Holford and Sheiner in 1982 as the “study of the movement into, through, and out of the
body.” They went on to summarize the scope of pharmacokinetics as “the processes and
rates of drug movement from the site of absorption into the blood, distribution into the
tissues, and elimination by metabolism.”[69] In short, pharmacokinetics explains the
input phase which characterizes the relationship of controllable drug inputs - dose
amount, dosage form, frequency, and route of administration - and concentration over
time.[68] Broadly, pharmacodynamics describes the effect of the drug once it reaches its
site of action. Specifically, pharmacodynamics considers the factors affecting the
relationship between the drug effect and the drug concentrations at the site of action.
Pharmacodynamics and pharmacokinetics are critically enmeshed with each other, but
they are two distinct components of a pharmacological profile. In short, pharmacokinetics
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is how the body handles the drug and pharmacodynamics is how the drug affects the
body.[69].
While they are considered separate sub-disciplines, they are more powerful when
used together, as they each contain important information needed to capture observed
relationships among dose, concentration, and effects over time, make predictions, and
optimize dose regimens. For example, Figure 2.1 illustrates a simplified schematic of the
input-response process for designing an optimum dose regimen. First, the
pharmacokinetic phase explains how the drug input is related to the exposure - measured
from concentration over time. Once the pharmacokinetic profile is obtained, the
pharmacodynamic phase relates exposure to the effects on the body. The curved arrows
give feedback at each step to adjust the dose regimen based on adverse or desired effect,
which may require a change in concentration, and consequently, an adjustment in dose
regimen, which affects the concentration. Using this model and trial-and-error adjustment
can ultimately conclude in a mathematically optimized dose. The resultant PK/PD
relationships are visualized in Figure 2-2. Pharmacologic effect can only be predicted and
optimized with data from both the pharmacokinetic (concentration vs time) and the
pharmacodynamic (effect vs concentration).[68]

Figure 2-1: Schematic of a PK/PD workflow with feedback for the purpose of
optimizing a dose regimen
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Figure 2-2: Visualization of how the pharmacokinetic relationship of drug concentration
versus time and the pharmacodynamic relationship of effect versus concentration come
together to create an effect over time profile, adapted from Derendorf et al.[68]

2.2
2.2.1

Compartmental Body Models

Compartment Model Concept
In pharmacokinetics and pharmacodynamic modeling, it is conventional to

represent the body as a system of compartments. The simplest type of model is a one
compartment model, which makes the assumption that the human body is one kinetically
homogeneous compartment. It also assumes that any rates between compartments and the
rate of elimination from the body are linear. In most cases, the anatomical analog for the
single compartment in a one compartment model is the plasma or venous blood.
However, the assumption cannot be made then that the one-compartment model is
equivalent to the concentration of the drug in all the tissues and fluids in the body.
Instead, modelers can interpret drug levels in other tissues and fluids in terms of rates of
change. For example, a 25% decrease in the central compartment or plasma concentration
corresponds to a 25% decrease in all other tissues and fluids in the body.[36]
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One-compartment models are especially useful for drugs that distribute rapidly
through the body, but often times drugs will not demonstrate a linear elimination from the
body. In these cases, additional compartments are added to simulate the residence time of
the drug in tissues and its eventual release back into the circulatory system before
elimination.[36] Multi-compartment models tend to have a more defined distributive and
post-distributive phase in their concentration versus time profiles as compared to the onecompartment model which appears to be more constant (Figure 2-3).[36, 70]

Figure 2-3: Adapted from Ratain et al., examples of one-compartment (A), twocompartment (B), and three-compartment (C) concentration-time plot[70]

The distributive phase characterizes the dosing of the drug and its initial
dispersion to respective tissues and fluids in the body. The post-distributive phase
includes the pseudo-equilibrium achieved as the drug is bound, metabolized, eliminated,
transformed, etc. in the tissues and then released back into the circulation. The multiple
compartments generally represent groups of organs, tissues, or fluids, which vary
depending on the drug. In general, the organs, tissues, and fluids that decline more
rapidly during the distributive phase than the post-distributive phase are included in what
is called the central compartment. The peripheral compartments generally include more
poorly perfused tissues in which drug concentrations will increase, reach steady state, and
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slowly return to the venous blood. How these compartments are defined for a model is
drug specific; therefore, the tissues and fluids included in the central compartment for one
drug may be in a peripheral compartment for a different drug. For example, the brain is a
highly perfused, or highly vascular, organ. However, in polar drugs which are unable to
cross the blood-brain barrier, the brain would likely be included in the peripheral
compartment; whereas, in lipid-soluble drugs that can cross the blood-brain barrier, the
brain would likely be included in the central compartment.[68] It is important to note that
although these compartments are mathematically representative of these tissues and
fluids, compartments do not hold any true physiological reality.
The time courses of these drugs in terms of rates, particularly in the peripheral
compartments, may not exactly correspond to any actual flow rates. The compartmental
modeling approach allows for extremely complex systems to be modeled in a reasonable,
simplified way. At best, these peripheral compartments are a conglomeration of
physiological functional groups of tissues and fluids. The central compartment is
generally what is compared or fit to observed data in order to make the descriptive and
predictive models that are actually utilized. Peripheral compartments allow the modeler
to simulate the complex time courses of drug levels throughout the body in an
understandable and reasonably accurate manner.[36]
2.2.2

Compartment Model Equations
Now that the concept of compartments has been introduced, these models can be

discussed from a mathematical standpoint. From the perspective of an engineer, if the
body represents a chemical plant, then the drug is the chemical moving through the
various components in the chemical plant. The compartments can be thought of as the
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components of the chemical plant – transforming, retaining, releasing – the chemical, or
drug. A mass balance can be applied to the system, which is a physical application of the
Law of Conservation of Mass. The mass entering the system must be equal to the mass
leaving the system. This conservation of mass is true for drugs in the body - drug that
enters the body is either stored, transformed, or eliminated from the system eventually.
Each compartment is represented by an equation, which are then coupled into a system of
equations. One can solve for as many unknowns as there are equations in the system;
therefore, for example, there are three equations in a three compartment model, which
allows the modeler to retrieve the unknown – concentration over time – for each
compartment in the system.[71]
The equations for compartment models can be derived from ordinary differential
equations, and the case of the one-compartment pharmacokinetic model is the simplest
example to derive and discuss conceptually. Concentration time course for such a model
is shown in Figure 2-3A. The following discussion will go through the considerations in
the parameters and relationships in a simple one-compartment pharmacokinetic model.
Clearance (CL) is rarely measured directly in clinical practice, but rather it is
calculated by one of the following equations using more measurable values:
𝐶𝐿 =

𝑑𝑜𝑠𝑒

,

(Eq. 2-1)

𝐶𝐿 = 𝐶 𝑖𝑛 ,

(Eq. 2-2)

𝐴𝑈𝐶
𝑅

𝑆𝑆

where AUC, or area under the concentration-versus-time curve, is the drug exposure
integrated over time, Rin is the infusion rate, and Css is the concentration at steady
state.[70] Equation 2-1 is typically more convenient for bolus-type injections since the
clearance is simply dose over exposure as measured by AUC. Equation 2-1 also shows
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the practical relationship between dose and AUC - the lower the AUC for a given dose,
the higher the clearance and conversely, the higher the AUC for a given dose, the lower
the clearance. For continuous infusions, a steady state is achieved in the plasma, so
Equation 2-2 is generally more convenient. The concentration at steady state (Css) can be
obtained from a single plasma measurement once the steady state is achieved. Then,
clearance can be estimated by Equation 2-2 and the relationship observed. The higher the
concentration at steady state given an infusion rate, the lower the clearance, and vice
versa.
Clearance can also be considered a function of both distribution and elimination,
as shown in the following model:
CL = Vdist × k,

(Eq. 2-3)

where Vdist is the volume of distribution and k is the elimination constant. Vdist is the
volume of the compartment, or conceptually, the volume of liquid the dose is diluted, and
k is inversely proportional to the half-life of the drug. Thus, a short half-life implies a
large k value and therefore, a high clearance. A large Vdist implies a large volume to dilute
the dose, and thus a low initial concentration. In general, a large k value and a large Vdist
produce a high clearance rate and fairly low plasma concentrations.[36, 70, 72]
Now that some terms and relationships are defined, the simplest pharmacokinetic
model follows,
𝑑𝑜𝑠𝑒

𝐶𝑃 = 𝑉

𝑑𝑖𝑠𝑡

(𝑒 −𝑘𝑡 ),

(Eq. 2-4)

where Cp represents the concentration in the plasma, which is most commonly the central
compartment. Equation 2-4 assumes that the injection occurs instantaneously and that the
entire dose is also distributed evenly throughout the body instantaneously. Modifications
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of the equation can be made for slower injections or infusions, where two equations
would represent the model over different time intervals:
𝐶𝑃 = 𝑉

𝑑𝑜𝑠𝑒

𝑑𝑖𝑠𝑡 ×𝑘×𝑇

(1 − 𝑒 −𝑘𝑡 )

(Eq. 2-5)

for the interval over which the drug is being administered, where k is still the elimination
constant and T is the time interval over which the drug is administered. When the
infusion ends, the kinetics play out as if an instantaneous bolus as in Equation 2-4 has
occurred at the exact moment the infusion ends. There is an initial concentration of the
existing concentration in the plasma, or Cp, at that time point. That equation for the
concentration over time from the end of the infusion to the end of the time interval is as
follows:
𝐶𝑃 = 𝐶𝑃 × 𝑇 × 𝑒 −𝑘(𝑡−𝑇)

(Eq. 2-6)

These equations explain how this one-compartment model operates under the assumption
that the half-life, and thus k, will remain constant, and the instantaneous rate of change
only depends on the current concentration. A one-compartment model is not often
inadequate for more complex pharmacokinetic data, in such cases, the data is fit to a
multi-compartment model. Which, as discussed in the Compartment Model Concept
section, simply couples equations similar to Equations 2-4 and 2-5 into a system
corresponding to the number of compartments needed to fit the data.

2.3

Pharmacokinetics Concepts

Pharmacokinetic modeling is often described as the characterization of the time
courses of drug concentration through four major processes in the body (i) absorption,(ii)
distribution, (iii) metabolism, and (iv) excretion, commonly referred to as ADME. More
broadly, pharmacokinetics also considers the time course of the concentration relevant
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metabolites of the parent drug and the development of suitable models to describe
observations or predict outcomes.[70, 68]
One way to think of the four processes are in terms of what happens to the total
dose. In Figure 2-4, the equivalence of the dose to the drug in four locations or processes
in the body demonstrates the conservation of mass in a material balance. Figure 2-4 also
shows that the ADME processes are sufficient to encompass any state a drug might be in
transit through the body. The following subsections will discuss each of the ADME
processes through the lens of pharmacokinetics. The following subsections will discuss
each of the ADME processes through the lens of pharmacokinetics.

Figure 2-4: A way of combining the idea of material balance and the four
pharmacokinetic processes (Absorption, Distribution, Excretion, and Metabolism)

2.3.1

Absorption
Absorption in pharmacokinetics is discussed in terms of systemic absorption and

is defined as the course of action an unchanged drug undergoes from the site of
administration to the site of measurement. For example, under this definition, we
consider a drug that is given orally, decomposed by 50% in the gastrointestinal tract, and
then metabolized completely in the liver. If the site of measurement is a vein in the arm,
the unchanged drug never reaches the site of measurement. However, if the site of
measurement is in the portal vein, 50% of the unchanged drug reaches the site of
administration. Any loss of drug between the administration site and the measurement
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site will contribute to a decrease in systemic absorption. There are many possible sites of
loss, especially in orally administered drugs. In those cases, the drug must pass through
the gastrointestinal tract and liver where drugs are often eliminated to some extent
through metabolism or excretion. The loss, or elimination, of unchanged drug on this
passage through the the gut, or any drug-eliminating organ, is referred to as the first-pass
loss.[72] Drugs which have a high first-pass loss require higher doses when administered
orally than when administered intravenously in order to reach the same therapeutic effect.
Drugs, when given intravenously, are able to bypass the gastrointestinal tract and liver
before reaching the circulation. However, absorption is not only applicable to orally
administered drugs, but also to intramuscular, intrathecal, subcutaneous, or any other
extravascular route of administration.[68] The term bioavailability more universally
quantifies the extent of absorption as a fraction or percentage of the administered,
unchanged drug that is absorbed intact and reaches the site of action following any route
of administration.[72]
2.3.2

First-Order Kinetics
The premise of first-order kinetics in terms of absorption following an

extravascular dose is that the absorption of the drug is dependent on the concentration of
the drug at that time.[73] In other words, the absorption rate is proportional to the amount
remaining to be absorbed.[68] The most common approach to modeling absorption is to
assume first order kinetics, which is illustrated in Figure 2-5, where A1 is the amount of
drug at the administration site, A2 is the amount of drug in the body, CL is the clearance,
Vdist represents the volume of distribution, dose is the amount of drug administered, ka is
the absorption rate, and F represents the bioavailability.
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Figure 2-5: Example of a one-compartment model with first-order absorption and also
first-order elimination

The model equations follow:
𝑑𝐴1
𝑑𝑡
𝑑𝐴2
𝑑𝑡

= −𝑘𝑎 ∗ 𝐴1

(Eq. 2-7)
𝐶𝐿

= 𝑘𝑎 ∗ 𝐴1 − (𝑉

𝑑𝑖𝑠𝑡

) ∗ 𝐴2

𝐴2

𝐶𝑝 = 𝑉

(Eq. 2-8)
(Eq. 2-9)

𝑑𝑖𝑠𝑡

The initial conditions for Equations 2-7 and 2-8 are:
A1 = dose ∗ F

(Eq. 2.10)

A2 = 0

(Eq. 2.11)

again, where dose is the amount of drug administered and F is the bioavailability. The
concentration in the central compartment (Cp), or the circulation, can be obtained by
solving Equations 2-7 and 2-8 with initial conditions, Equations 2-10 and 2-11. The
equation for the solution is as follows:[73]
𝐶𝑝 =
2.3.3

𝐹∗𝑘𝑎 ∗𝐷𝑜𝑠𝑒
𝑉𝑑𝑖𝑠𝑡 ∗(𝑘𝑎 −

𝐶𝐿
𝑉𝑑𝑖𝑠𝑡

𝐶𝐿

)

∗ (𝑒 − 𝑉

𝑑𝑖𝑠𝑡

∗ 𝑡 − 𝑒 −𝑘𝑎∗𝑡 )

(Eq. 2-12)

Zero-Order Kinetics
In the case where a drug is absorbed at an approximately constant rate, the absorption

kinetics are said to be zero-order.[68] In other words, a constant amount (i.e. milligrams, moles,
etc) of drug is absorbed per unit time. This is in contrast to first-order absorption kinetics in the
aspect that the absorption is not dependent on the concentration at that time. An example of zeroorder absorption and linear elimination in a one compartment model is shown in Figure 2-6,
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where R0 is the zero-order input (i.e. intravenous injection or infusion), A2 is the amount of drug
in the body, CL is the clearance, and Vdist is the volume of distribution. The model equation
follows:
𝑑𝐴2
𝑑𝑡

𝐶𝐿

= 𝑅0 − (𝑉

𝑑𝑖𝑠𝑡

) ∗ 𝐴2

(Eq. 2-13)

where again, Cp = A2/Vdist, as noted in Equation 2-9. By solving Equation 2-13, the concentration
of the drug in the central compartment Cp can be expressed as: [73]
𝐶𝑝 =

𝑅0
𝐶𝐿

∗ (1 − 𝑒 −

𝐶𝐿
𝑉𝑑𝑖𝑠𝑡

− 𝑡)

(Eq. 2-14)

Figure 2-6: Example of a one-compartment model with zero-order absorption and linear
elimination

The initial conditions for Equations 2-13 and 2-14 are:
R0 = dose

(Eq. 2-15)

A2 = 0

(Eq. 2-16)

where dose is the amount of drug administered. The concentration in the central compartment
(Cp) can be obtained by solving Equations 2-13 and 2-14 with initial conditions, Equations 2-15
and 2-16.

2.3.3.1

Flip-Flop Kinetics
Particularly with orally administered drugs, frequent dosing can limit the effectiveness of

a drug by lowering the likelihood that the patient will adhere to the dosing schedule. This
problem is often referred to as patient compliance, and it is a major consideration in the drug
delivery process. Sustained- and controlled- release formulations are ideal for drugs which
require frequent doses due to its half-life, bioavailability, or other physiological property.[73]
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However, in these cases, absorption is rate-limiting. That is to say, the absorption process is much
slower than the elimination process. The peak concentration tends to occur later and is lower than
in cases of first- and zero- order kinetics. At peak concentration, the rate of elimination increases
and equals the rate of absorption. However, the absorption rate is so slow that there is still a
substantial amount of drug yet to be absorbed well past the time of peak concentration. In this
post-distributive phase, the plasma concentration is declining, since the elimination rate is still
faster than the absorption rate, but the difference between the two rates is small. Thus, the rate of
elimination is approximately equal to the rate of absorption. Eventually, there is no more drug left
to be absorbed and the drug is eliminated from the body. This behavior can be deceptive, as it can
appear that the elimination phase is very slow - when in fact it is the absorption that is slow.[68]
Failing to recognize flip-flop kinetics when modeling orally administered drugs can lead to an
incorrect characterization of the absorption process and an ill-specified model. Therefore, when
possible, intravenous data is utilized to estimate the pharmacokinetic parameters associated with
absorption.

2.3.4

Distribution
Distribution defines the process of reversible transfer of drug between the site of

administration and peripheral tissues.[68] In terms of compartment models, peripheral tissues are
the peripheral compartments in which, during the distributive phase, drug concentrations increase,
reach steady state, and slowly return to the central compartment. Under these terms, the central
compartment is the circulation.[36] The rate of transfer from the circulation is not necessarily the
same rate of transfer back into the circulation. A good example of the difference in these rates is
the enterohepatic cycle. Drug is secreted in the bile, stored in the gallbladder, and then released
into the small intestine, where some of it is reabsorbed into the circulation.[68]
A term mentioned briefly but not well defined in Section 2.3.1 on Absorption was the
Vdist or volume of distribution in the equations discussing clearance and absorption kinetics. The
volume of distribution is not a literal volume of liquid, but rather a surrogate proportionality
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constant to relate drug concentration in blood or plasma to the amount of drug in the body.[72,
36] Formally, it may be more appropriate to call it the apparent volume of distribution. If we
were to consider the actual distribution volume of a drug, it would would be a fraction of total
body water.[36] For the average adult human, total body water (TBW) accounts for 50-70% of
the body weight.[74] TBW is broadly subdivided into extracellular fluid and intracellular fluid.
Intracellular fluids make up for approximately 62.5% of TBW and includes fluid contained within
cells. Extracellular fluids make up the remaining 32.5% and includes plasma and interstitial fluid.
These categories of account for approximately one-fifth and four-fifths of total extracellular
fluids, respectively. Transcellular fluid, that is, fluids such as ocular, cerebrospinal, and
gastrointestinal fluids that are contained in organs, are generally not included in calculations. It is
also important to note that the blood volume is divided between both intra- and extracellular
fluids. Intracellular fluids exist inside the blood cells and extracellular fluids are the blood
plasma.[75] These values are estimates, as fluids in the body are always in flux between different
compartments of the body due to regulative mechanisms that maintain appropriate concentrations
throughout.[74]
Apparent volume of distribution varies by drug based on that specific drug’s
physicochemical properties. For instance, drugs that are more extensively bound to plasma
proteins have apparent volumes of distribution that might be smaller than their actual volumes of
distribution. Conversely, drugs that are more extensively bound to extravascular tissues have
apparent volumes of distribution that might be much larger than their actual volumes of
distribution. Apparent volumes of distribution in humans can range from as small as 0.04L/kg to
greater than 20L/kg among different drugs, some values of which exceed total body size when
taken literally.[36, 68, 72] Now that the distinction between apparent and actual volumes of
distribution has been made, the term volume of distribution will interchangeably refer to the
apparent volume of distribution hereafter.
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2.3.4.1

Membranes
To best explain drug distribution, it is important to discuss the role and function of

membranes. Drug transport, a key component in drug distribution, is defined as the processes and
transport systems that facilitate the movement through membranes. The purpose of the cell
membrane is to maintain homeostasis inside and outside of the cell body. Extracellular fluid is
high in chloride ions and sodium, and low in potassium, phosphates, and protein. Conversely,
intracellular fluid is high in potassium, phosphates, and protein, and low in chloride ions and
sodium. The balance of these substances is required for healthy functioning of the body’s
systems.
A lipid bilayer makes up the majority of the cellular membrane with many proteins either
partially or fully penetrating the liquid. Although some more lipophilic substances will be able to
pass directly through the lipid bilayer, many of these proteins which penetrate the membrane
completely can function as transport proteins.There are two general types of these transport
proteins - channel proteins and carrier proteins. Channel proteins have aqueous spaces throughout
and can allow water and certain ions and molecules to move through freely. Carrier proteins bind
with molecules or ions, and the resultant conformational changes in the protein molecule allow
the substance to pass from one side of the membrane to the other. Both channel proteins and
carrier proteins are selective in which ions and molecules are allowed to pass through them and
by proxy, the membrane.[76] These two types of proteins are important for describing the
transport processes of drugs across membranes. Channel proteins are key players in diffusion and
carrier proteins are key players in both diffusion and active transport. Diffusion and active
transport will be expounded upon in the Transport Processes section. A few terms and
relationships should be briefly defined before discussing the properties of cellular membranes.

Hydrophilic and hydrophobic are terms that refer to properties of substances that are
attracted to or repelled by water, respectively. Likewise, lipophilic and lipophobic are
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terms that refer to properties of substances that are attracted to or repelled by lipids,
respectively. A substance that is soluble in water and poorly soluble in non-polar lipids
could be described as both hydrophilic and lipophobic. Conversely, a substance that is
soluble in non-polar lipids but not soluble in water could be described as hydrophobic
and lipophilic. In other words, the pairs of terms are interchangeable. One way to
quantify the lipophilicity of a substance is to measure its partitioning between n-octanol,
which is an organic solvent whose properties mimic tissue membranes, and water.
Substances with higher partition coefficients have higher lipophilicity and vice versa.[68]
2.3.4.2

Permeability
Permeability is defined as the measure of a drug’s ability to cross a membrane. A

drug is considerable highly permeable if it can pass through a membrane quickly and less
permeable if it cannot. Quantitatively, permeability is expressed as ease of penetration of
membrane in terms of velocity (distance per time). This unit comes from the concept of
the net rate of transport of drug across a membrane as shown in Figure 2-7.

Figure 2-7: Schematic of the contributing factors of the net transport rate across
membranes in the cell - the permeability of the membrane, the surface are of the cell, and
the concentration difference inside and outside the cell

If we consider a simple example of two compartments (C1 and C2) separated by a
membrane, the three components of net rate of transport are the concentration difference,
the surface area (SA)of the membrane, and the permeability of the substance (P ). Since
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net rate of transport is measured in units of volume per time, the surface area of the
membrane is in units of area, and the concentration difference between either side of the
membrane is unit-less, then the permeability is in units distance per time or velocity. The
concentration difference is treated like a scalar for the net rate of transport; when the
concentration difference is zero, the system is at equilibrium and there is no net exchange
between the two compartments and the equation in Figure 2-7 goes to zero.[68] Just like
in chemical equilibrium, a net change of zero does not mean there is no movement
between the compartments C1 and C2, just that the movement is equal in both directions.
The surface area of the membrane has a notable effect on the net rate of transport. Based
on the illustrated equation in Figure 2-7, doubling the surface area effectively doubles the
net rate of drug transport. Keep in mind that the permeability is a property of the drug and
remains constant.
Size, lipophilicity, and degree of ionization (charge) are the three molecular
properties that most affect the passage of a drug across a given membrane. Cell
membranes tend to be inflexible which prevents drug molecules of a certain size or steric
conformation to pass through the membrane. For instance, some membranes do not allow
for water-soluble molecules to pass through, so they must take the paracellular pathway
and slip through the tight channels between cells.[68] Molecular size is an obvious
limitation for transport and has an underlying effect on all other molecular properties
related to transport processes. Since the majority of the cell’s membrane is made up of
the lipid bilayer it is not surprising that a drug’s lipophilicity is another major constraint
on membrane permeability.[76] Typically, the lower the lipophilicity, the less its
permeability and vice versa. However, molecular size does have an overarching effect on
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the permeability. It will not matter how lipophilic the drug is if it is too large to easily
pass through the membrane. For instance, for permeability across skin, if the molecular
weight of a compound is doubled with the same lipophilicity, the permeability decreases
almost 300-fold. An common example of the interaction of size and lipophilicity in terms
of permeability is the movement of drugs to and from the central nervous system (CNS)
via the blood-brain barrier (BBB).[68] The blood-brain barrier is formed by the brain
endothelium and creates a diffusional restriction in order to protects the particularly
sensitive spinal cord and brain from unwanted substances circulating in the blood. The
barrier property of the BBB also controls the influx and efflux of substances needed by
and excreted from the brain and rigidly controls the ion homeostasis which is vital for
neuronal signaling throughout the body.[77] The blood-brain barrier is composed of tight
junctions between the endothelial capillary cells which prevent paracellular transport and
glial processes surrounding these capillaries which are highly resistant to polar
substances. To recap, the more polar the drug, the more hydrophilic and the more
lipophobic.[68]
The third major player in drug permeability across membranes is its charge or
degree of ionization. While there are many ways the interaction between a given drug and
a given membrane could be affected by charge, that effect is generally significant. As
described before, molecular size, lipophilicity, and now charge, are connected in their
effect on the drug’s permeability. The larger and more hydrophilic a molecule it is, the
slower its permeability, with only a few exceptions. If the molecule is charged, the
permeability of the molecule is even slower. However, some drugs are only charged at
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certain pH values, or a physiological pH. This makes the degree of ionization important
for understanding the permeability of a drug.[68]
These pH dependencies are often purposeful in drug delivery systems to transport
a drug to a target site. Anti-cancer agents are particularly good candidates for pH
dependent drug delivery systems. Anti-cancer therapy aims to treat a specific target with
cytotoxic agents without harming tissues along the route to the target. Additionally,
issues with circulation stability and tumor-targeting can be solved by encapsulating or
coating drugs within other compounds can change the surface charge of the drug and
allow it to pass through or pass by certain membranes. It can also allow drugs to reach the
target without being metabolized or released until it reaches a location in the body with a
certain pH.[78]
Most drugs are weak acids or bases and exist in an equilibrium between ionized
and un-ionized states. The pH partition hypothesis is a common theory that was derived
from the observation that higher total concentration of a drug is generally found on the
side of a membrane where the pH favors a greater degree of ionization for that drug. The
pH partition hypothesis states that only non-polar, un-ionized drugs can pass through the
membrane. It also states that at equilibrium, the concentrations of un-ionized species are
equal on both sides of the membrane. Finally, it states that at equilibrium, although the
concentration of un-ionized species are the same, the total concentration can still be
wildly different depending on the degree of ionization of the drug at the local pH. Most
of the observed evidence for the pH partition hypothesis comes from studies specific to
anatomical locations where there is a high variation of pH (renal excretion studies,
gastrointenstinal absorption studies, etc.) The hypothesis fails to explain all observations,
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so using it as a general rule can lead to inaccurate assumptions, especially in anatomical
locations where there is less variation in pH.[68]
2.3.4.3

Transport Processes
The transport of drugs across cell membranes is falls into one of two categories diffusion

or active transport. Diffusion describes the random movement of individual molecules of a
substance either through intermolecular spaces in a membrane or through carrier protein. The key
difference between the two is that diffusion occurs along the concentration gradient and active
transport occurs against the concentration gradient. A concentration gradient is simply a physical
area over which the concentration of a substance differs. Substances will diffuse from an high
concentration to a low concentration until it reaches a state of equilibrium.[76, 68]

2.3.4.4

Diffusion
The first of the two processes, diffusion, is driven by the propensity of molecules

to move down the concentration gradient. Diffusion is a phenomenon that occurs
naturally, so no work is expended by the system. The movement of molecules across
membranes is resultant of kinetic energy and is therefore passive. Diffusion always goes
down the concentration gradient and therefore never occurs in the direction from low
concentration to high concentration.[68] Diffusion across cell membranes takes place by
either simple diffusion or facilitated diffusion. Simple diffusion can occur across cell
membranes by two pathways transcellularly and paracellular. Transcellular transport
describes the passage of a lipophilic drug through the lipoidal membrane of the cells and
is the most common drug transport route. Paracellular transport accounts for the transport
of drugs between cells, through the paracellular pathway, when they are too polar to cross
the lipoidal cell membrane.[68, 76] The term simple diffusion indicates that the kinetic
movement of the ions or molecules passing through the membrane do so without
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interacting with carrier proteins. Conversely, facilitated diffusion does require the
interaction of a carrier protein in order to cross the cell membrane. The molecules or ions
passing through the membrane chemically bind to the carrier protein which shuttles them
across.[76] Hence, facilitated diffusion is often referred to as carrier-mediated diffusion.
This process is still passive, however, since the carrier proteins that are carrying the
molecules or ions of interest still move down a concentration gradient. No work is
expended by the system since the movement across the membrane is resultant of kinetic
energy.[68]
2.3.4.5

Active Transport
The second type of process, active transport, requires work to be exerted by the

system since the molecules or ions crossing the cellular membrane are going against the
concentration gradient. In active transport, the drug moves from an area of low
concentration to an area of high concentration. Recall that diffusion, which is passive,
occurs when a drug moves from an area of high concentration to low concentration. This
property is the fundamental difference between the two types of transport. Some common
substances that are actively transported are sodium ions, iron ions, potassium ions,
calcium ions, chloride ions, urate ions, and select sugars and amino acids. Active
transport is subdivided again into two categories - primary active transport and secondary
active transport, depending on the source of energy used to transport. Primary active
transport describes cases when the breakdown of adenosine triphosphate (ATP) or some
other high-energy phosphate compound is the source of energy for the transport.
Secondary active transport describes cases where the energy for transport is derived from
stored energy created during primary active transport. This energy is stored in the form of
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ionic substances between the two sides of the cell membrane. Both primary and
secondary active transport utilize carrier proteins. Recall that carrier proteins are also
used in facilitated diffusion, but in active transport, the carrier protein functions
differently. In active transport, the carrier protein is able to contribute energy to the
transported molecule or ion to move it against the concentration or electrochemical
gradient.[76]
One example of primary active transport is the sodium-potassium pump, which is
vital for controlling cell volume. As mentioned in the previous section on Membranes
(Section 2.3.4), extracellular fluid is high in sodium and low in potassium, while
intracellular fluid is low in sodium and high in potassium. The sodium-potassium
(Na+ − K+) pump is responsible for maintaining the sodium and potassium concentration
differences and also establishing a negative electrical voltage inside the cell. The (Na+ −
K+) pumps sodium ions outward from low concentration intracellularly to high
concentration extracellularly through the cellular membrane.
Simultaneously it pumps potassium ions inward from low concentration
extracellularly to high concentration intracellularly. Note that both potassium and sodium
ions in this case are moving against their respective concentration gradient. [76]
There are two general types of secondary active transport - counter-transport and
co-transport. Each of these will be explained with an example for clarity. Countertransport refers to secondary active transport in the direction opposite of the primary ion.
The sodium-calcium counter-transport occurs in nearly all cell membranes, where sodium
ions are transported into the cells and calcium ions are transported out of the cells. In this
case, since both ions are bound to the same carrier protein. Note here, the sodium ion is
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moving down its concentration gradient. The transport uses stored energy from the
sodium electrochemical gradient by allowing the sodium ions to flow along their gradient
in exchange for the calcium ions entering.
Co-transport mechanisms are used for glucose and several amino acids, since they
tend to be transported into cells against large concentration gradients. In the sodiumglucose co-transport, the transport protein has two binding sites on its exterior side, one
for sodium and one for glucose. Similar to the sodium-calcium counter-transport
mechanism, the energy is derived by allowing sodium to flow along its electrochemical
gradient. A unique characteristic of this transport carrier protein is that a conformational
change will occur in the protein only when both glucose and the sodium ion are bound at
their exterior binding sites. This conformation change then happens automatically and
allows both the sodium ion and glucose to pass into the cell.[76]
2.3.4.6

Extent of Distribution
There are two factors that affect the concentration of drug in the plasma, or

central compartment, after the drug has been successfully distributed throughout the
body. The first is the dose administered, and the second is referred to as the extent of
distribution. The extent of distribution is dependent on the apparent volume of
distribution.[68] The apparent volume of distribution (Vdist) which was discussed earlier
in this section and refers to a proportionality constant which relates drug concentration in
the plasma to the amount of drug in the rest of the body.[36] Here, it can be defined
mathematically as the amount of drug in the body at equilibrium (A) divided by the
plasma drug concentration (C):
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𝑉𝑑𝑖𝑠𝑡 =

𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑟𝑢𝑔 𝑖𝑛 𝐵𝑜𝑑𝑦 𝑎𝑡 𝐸𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚
𝑃𝑙𝑎𝑠𝑚𝑎 𝐷𝑟𝑢𝑔 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛

𝐴

=

(Eq. 2-17)

𝐶

Knowing the volume of distribution (Vdist) and the plasma volume (Vp) allows for
the estimation of the fraction of drug in the body that is within the plasma:
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑏𝑜𝑑𝑦 𝑤𝑖𝑡ℎ𝑖𝑛 𝑝𝑙𝑎𝑠𝑚𝑎 =

𝑉𝑝
𝑉𝑑𝑖𝑠𝑡

(Eq. 2-18)

If Equation 2-18 represents the fraction within the plasma, then Equation 2.-9
(following) provides the fraction outside the plasma, or in the rest of the body:
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑝𝑙𝑎𝑠𝑚𝑎 =

𝑉𝑑𝑖𝑠𝑡 −𝑉𝑝
𝑉𝑑𝑖𝑠𝑡

(Eq. 2-19)

In general, the larger the apparent volume of distribution, the smaller the fraction
in plasma. Figure 2-8 may clarify why the apparent volume of distribution differs for
different drugs.

Figure 2-8: Simple two-compartment model, which implies that all drug in the body is
contained in the plasma compartment (left) and the tissue compartment (right) with
physiologic volumes of Vp and Vt, respectively

At equilibrium, the amount of drug, A, in each compartment is expressed in terms
of the plasma concentration, C, the physiologic volumes of the two compartments, Vp and
Vt, and the tissue-to-plasma partition coefficient ratio, denoted as Kp, by the following
equation:
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𝐴 = 𝑉𝑝 × 𝐶 + 𝑉𝑡 × 𝐾𝑝 × 𝐶

(Eq. 2-20)

where the first term on the right-hand side of the equation represents the
amountof drug in the plasma and the the second term represents the amount of
drug inthe tissue.[68] Conceptually, this equation reads:
𝐴𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑏𝑜𝑑𝑦 = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑃𝑙𝑎𝑠𝑚𝑎 + 𝐴𝑚𝑜𝑢𝑛𝑡 𝑖𝑛 𝑇𝑖𝑠𝑠𝑢𝑒

(Eq. 2-21)

where the first term on the right-hand side of the equation represents the amount of drug
in the plasma and the the second term represents the amount of drug in the tissue.[68]
Conceptually, this equation reads:
Vdist × C = Vp × C + Vt × Kp × C,

(Eq. 2-22)

And dividing by C, we get
Vdist = Vp + Vt × Kp

(Eq. 2-23)

From Equation 2-23, we interpret the product term Vt ×Kp as the apparent volume
of distribution for that tissue, when viewed from measurement of drug in the plasma.
Following that logic, any number of compartments could be added on to complete the
mass balance of drug amount in the body, with each compartment having its own
physiologic volume and tissue-to-plasma partition coefficient Kp. Adding n compartments
to Equation 2-23 would look like the following:
Vdist = Vp + Vt,1 × Kp,1 + Vt,2 × Kp,2 + ... + Kp,n × Vt,n

(Eq. 2-24)

Values of Kp can be large for some tissues and small for others, which clarifies
why the sum of the apparent volume of distribution terms (see Equation 2-23) could sum
to a value much larger than the actual body volume.[72, 68] Consider the adipose tissue,
which makes up about 20% of total body volume.[79] If a Kp value of adipose tissue for
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this drug is 5 or greater, the adipose tissue alone has already equalled or exceeded the
literal total body volume.
2.3.4.7

Binding
The capacity of a drug to bind to blood components, plasma proteins, and tissues

is a major factor in the distribution of a drug throughout the body. Total plasma
concentration measurements include both bound and unbound drug.[68] However, an
important distinction to make about interpreting total drug concentration is that only
unbound drug can diffuse through membranes and exert a pharmacological effect.[72]
Drugs that cannot pass through the cell membrane cannot reach the sites of activity,
storage, or metabolism.[68] However, drugs that are bound to plasma proteins become
too large to pass through the cell membrane, which means that the concentration of
unbound drug drives drug transport, not the total concentration.[36, 68, 72] The ratio of
unbound drug to total drug is referred to as the fraction unbound. The fraction unbound is
also defined mathematically as,
𝐹𝑢 =

𝐶𝑢
𝐶

(Eq. 2-25)

where Cu is the concentration of unbound drug in the plasma and C is the total plasma
concentration. For most drugs, the fraction unbound is constant throughout the infusion,
so it matters very little whether total drug concentration or unbound drug concentration is
measured. However, in some conditions, the fraction unbound will change. For instance,
if the binding sites reach saturation or are altered in some way. Binding can be altered by
another drug competing for the same binding protein. Patient characteristics including
renal or hepatic impairment, recent surgery, or pregnancy, can alter the binding and
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therefore, the fraction unbound. In these cases, measurement of the unbound
concentration is necessary.[68]
There can be a wide variation in the volume of distribution for a specific drug
between patients.[72, 80, 68] Some reasons for this phenomenon that will be discussed
include (i) binding within blood, and (ii) binding in tissues. The following paragraphs
will discuss how binding in each location affects the variation among patients, even for
the same drug.
2.3.4.8

Binding Within Blood
Drugs can bind to many different types of blood components, including plasma

proteins and blood cells. This binding can cause the concentrations in plasma (C), whole
blood (Cwb), and the unbound concentration in plasma water, (Cu) to be widely
different.[72] Plasma contains proteins that bind to drugs and its concentration is
comprised of bound and unbound drug. Serum concentration is usually close to identical
to that of the plasma concentration. Although the protein composition of serum is slightly
different than that of plasma, they mainly differ in method of measurement. Plasma
concentration is measured by adding an anticoagulant to whole blood and precipitating
out the blood cells. The concentration in the supernatant fluid, plasma, is then measured.
Serum concentration is measured by centrifuging whole blood after it has already clotted
and removing cells and material that forms any clots. Usually the clots are primarily
fibrin, and the binding of most drugs to fibrin or fibrinogen is negligible. The
concentration of the remaining serum is then measured. Whole blood refers to the
aggregate of red blood cells, white blood cells, platelets, and assorted plasma proteins.
Typically, an anticoagulant is added and the drug is extracted into an organic phase after
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denaturing the plasma proteins. The blood drug concentration represents the average over
the whole sample, since concentrations in individual components or cell fractions can be
varied. The technique for measuring blood drug concentration is more involved, so
plasma concentration is the most typical measurement used due to ease of analysis. A
major goal in measuring drug concentration is to relate it to therapeutic response and
toxicity, and often times, while perhaps the simplest method, it is not the best
representation. Nonetheless, plasma concentration remains the most reported in
pharmaceutical literature.[68]
2.3.4.9

Transporters and Binding in Tissues
The tissue-to-plasma equilibrium constant, Kp, value mentioned in the

introduction to this section defines the ratio between drug concentration in tissues to drug
concentration in the blood or plasma.[79] When discussing the relationship between Kp
and the apparent volume of distribution, it was stated that Kp could be large or small
depending on the properties of the tissue it represented. The main property that
determines the Kp value for a certain tissue is the extent to which a drug tends to bind to
that tissue. This process along with uptake and efflux transporters affect the
determination of the Kp value for a specific tissue.[68]
Binding to tissue occurs when, although a drug may have a great affinity for
binding to plasma proteins, it has a greater affinity for binding to tissue components.
However, the binding of a drug to tissue components cannot be as readily measured as
the binding of drug to plasma. This is because the integrity of the tissue’s structure must
be disrupted in order to directly measure the drug in tissues. However, tissue binding can
be inferred from plasma measurements using the following mass balance: [68]
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Vdist × C = Vp × C + VT W × CT W

(Eq. 2-26)

where VT W is the aqueous volume outside the plasma where the drug is distributed and
CT W is the corresponding drug concentration outside of plasma. Conceptually, Equation
2.26 is interpreted as:
Amount in Body = Amount in Plasma + Amount Outside of Plasma
Drug outside of plasma is assumed to be drug in tissue. By dividing Equation 2-26 by C,
which is the drug concentration in the plasma,
𝐶𝑇𝑊

𝑉𝑑𝑖𝑠𝑡 = 𝑉𝑝 + 𝑉𝑇𝑊 ×

𝐶

(Eq. 2-27)

Just as Equation 2.25 describes the fraction unbound in plasma, the fraction unbound in
tissues Fu,TW is related by:
𝐶

𝐹𝑢,𝑇𝑊 = 𝐶 𝑢,𝑡

(Eq. 2-28)

𝑇𝑊

where again, Cu,t is the drug concentration unbound in tissue and CTW is the drug
concentration outside of the plasma.
Since distribution equilibrium is reached when the unbound drug concentration in
plasma Cu and the unbound drug concentration in tissues, Cu,t are equal, we get the
equality:
𝐶𝑇𝑊
𝐶

=

𝐹𝑢
𝐹𝑢,𝑡

,

(Eq. 2-29)

which we can then substitute into Equation 2-28 to get:
𝑉 = 𝑉𝑝 + 𝑉𝑇𝑊 ×

𝐹𝑢
𝐹𝑢,𝑡

(Eq. 2-30)

The relationship in Equation 2-30 demonstrates that when Fu increases, the volume of
distribution increases, but when Fu,t increases, the volume of distribution decreases.
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2.3.4.10 Rate of Distribution to Tissues
Upon administration of a drug - intravenous, oral, or otherwise - the systemic
absorption and distribution to tissues takes some amount of time. Tissue distribution
takes place to varying extents at different rates depending on the drug and the respective
tissue.[68] The extent of the drug’s partitioning into adipose tissues, the drug’s ability to
cross membranes, and the drug’s likelihood to bind with blood or tissues are all factors
that determine the distribution pattern of a drug. The ability of the drug to be delivered
into the tissue by the blood is also a determining factor. Extravasation is a term used to
describe drug uptake into tissues from the blood. Extravasation will move toward
equilibrium between the blood and the tissue. The rate-limiting factors for distribution
can be one of two processes - perfusion or permeability. Rate-limitation by perfusion is a
delivery limitation, and rate-limitation by permeability is a limitation in membrane
passage. Perfusion rate limitation tends to occur when the tissue membranes give
virtually no barrier to entry for the drug. As expected, this type of rate-limitation is more
likely to occur with small, highly lipophilic molecules that pass through the lipid bilayer
readily. Most drugs, excluding macromolecules, can also move easily through more
loosely-knit membranes such as capillary walls of muscle tissue. However, as the
resistance to drug transport across the cell membrane increases, the source of rate
limitation shifts from perfusion rate limited to permeability rate limitation. In this case,
the problem is not the delivery of the drug to the tissue or the removal of the drug from
the tissue, but the passage across the cell membrane.
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2.3.5

Metabolism
Before discussing metabolism, another important concept in pharmacokinetics,

elimination, should be mentioned. Elimination is the irreversible loss of drug from the
site of measurement. Elimination of drugs from the body occurs through a number of
pathways - through biliary excretion, urinary excretion or bio-transformation to other
substances, but in pharmacometrics, is generalized into two processes - metabolism and
excretion.[36, 68]
Metabolism is likely the most straight forward definition in terms of the four
pharmacokinetic processes. Metabolism here maintains a traditional definition of the
conversion of one chemical species to another. In most cases, the resulting metabolites
are converted irreversibly and are considered part of the total elimination of the parent
drug from the body. In notably fewer cases, the metabolite conversion is reversible and is
converted back to the parent drug. This process is called metabolic interconversion. In
these cases, metabolism is only considered a route of elimination to the degree in which
that metabolite is eliminated and thus, unable to convert back to the parent drug.[68]
Elimination of parent drug is sometimes called formation clearance of the metabolite.[11]
In most cases, metabolism will inactivate the drug, but some metabolites are
pharmacologically active. Some metabolites are even more pharmacologically active than
the parent drug. In some cases, a pharmacologically weak, or even inactive, drug with a
may be administered for the purpose of the metabolite exacting the therapeutic effect on
the target. These types of compounds are referred to as prodrugs.[81] Prodrugs are
inactive compounds that are converted to active species in the body. Soft drugs are the
antithesis to prodrugs in that they are pharmacologically active compounds that are
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quickly metabolized after systemic absorption to minimize adverse effect on the body.
The pharmacologic profiles of metabolites produced can vary. Some may have profiles
similar to the parent drug, while others may behave completely differently or even
produce adverse effects. Thus, the pharmacokinetics of any metabolites produced by a
drug warrant therapeutic concern. When observing the body’s response to a drug, the
time course of all active substances in the body must be considered.[68]
Oxidation, reduction, hydrolysis, isomerization and conjugation are the most
common metabolic reactions.[68, 81] The reaction pathway that occurs has the primary
goal of making the compound easier to excrete from the body. The enzymes involved in
perpetuating these reactions are found in most tissues in the body but are notably more
concentrated in the liver.[81] It follow that while metabolism occurs in many tissues in
the body, the primary site of metabolism is the liver.[81, 82]
Some capacity limitation exists for most drugs, which is caused the limited
number of enzyme sites. However, at the therapeutic concentration, which is what is
actually given in practice, only a small percentage of the enzyme sites are occupied. In
these cases, the metabolism rate of the drug is directly proportional to the concentration
of drug in the body. In order words, its metabolism follows first-order kinetics.[81] Many
of these capacity-limited reactions are described by the following Michaelis-Menten
equation:
𝑑𝐶

− 𝑑𝑡 =

𝑉𝑚𝑎𝑥 × 𝐶

(Eq. 2-31)

𝐾𝑚 +𝐶

𝑑𝐶

where − 𝑑𝑡 describes the rate of decline of drug concentration at time t, Km is the
Michaelis constant, and Vmax is the theoretical maximum rate of the process. The
Michaelis constant Km for a drug can be obtained by determining C when

𝑑𝐶
𝑑𝑡

=

55
1
2

𝑉𝑚𝑎𝑥 .[83] It is easily seen that Km is in fact equivalent to the drug concentration at

which the rate of the metabolism is one-half of Vmax. There are special cases of the
Michaelis-Menten equation - (i) where the Michaelis constant Km is much larger than the
drug concentration C and (ii) where the drug concentration C is much larger than the
Michaelis constant Km. In the first case, Equation 2.31 is reduced to:
𝑑𝐶
𝑑𝑡

=

𝑉𝑚𝑎𝑥
𝐾𝑚

×𝐶

(Eq. 2-32)

Equation 2-32 takes the form of first-order elimination kinetics – which would make the
rate constant

𝑉𝑚𝑎𝑥
𝐾𝑚

.[36] Drug elimination is often observed to have first-order

kinetics, so it follows that the majority of drugs have therapeutic concentrations
that are much smaller than the Michaelis constant Km. This observation consistent
with the relatively low percentage of enzyme sites that are occupied by drugs and
metabolites at therapeutic concentrations.[68] The second, less common case of
Michaelis-Menten kinetics results when Km is much larger than the drug
concentration. In this second case, Equation 2.31 is reduced to:
𝑑𝐶

− 𝑑𝑡 = 𝑉𝑚𝑎𝑥

(Eq. 2-33)

Under this condition, the rate does not depend on the drug concentration such that the
constant rate is equal to Vmax.[36] The other special case of the Michaelis-Menten
equation follows zero-order kinetics since the rate is independent on the drug
concentration.[36, 68]
2.3.6

Excretion
Excretion is the second elimination process - defined as the irreversible loss of the

unchanged drug from the body.[68] The primary difference between elimination by
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metabolism and elimination by excretion is that the drug is actually removed unchanged
rather than removed by bio-transformation.[68]
The kidneys are the primary organs that excrete water-soluble compounds. The
liver plays a smaller role than the kidneys in terms of excretion. Excretion through bile
occurs to the extent that the drug is not reabsorbed by the GI tract in the enterohepatic
cycle. Certain drugs and their metabolites are extensively excreted in bile. The drugs that
undergo biliary excretion require active transport against a concentration gradient across
the biliary epithelium. Another obstacle to biliary excretion occurs when plasma
concentrations are high.[84] A transport maximum may be reached when more
transporters are occupied, especially in the presents of substances with similar
physiological properties.[76] Drugs that are most likely to be excreted by the liver
through bile include drugs with a molecular weight greater than 300 grams/mole, having
both polar and lipophilic groups. Smaller molecules are not readily excreted in bile.
Although the liver is the lesser component in excretion, its indirect affect through
metabolism is notable. Hepatic metabolism will often convert drugs to more water
soluble compounds, thus allowing the kidneys to clear the drug through urine.[84]
The glomerulus is a a filtration component in the kidney that is comprised of a
complex bundle of capillaries lined with a delicate mesh of endothelial proteins.[85]
About 20% of the plasma that reaches the glomerulus in the kidney is filtered through the
glomerular endothelium. Most water and electrolytes are reabsorbed into circulation.
However, polar compounds, including most drug metabolites are generally unable to
diffuse through the renal tubules to be reabsorbed. These polar, water-soluble compounds
are then excreted by the kidneys.
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The governing concepts of membrane clearance that were discussed in the earlier
section on absorption hold true for renal excretion.[84] Recalling the concept of fraction
unbound, only unbound drug is contained in plasma reaching the glomerulus. Drug that is
bound to plasma proteins are too large to diffuse through the pores of the glomerular
endothelium and remain in circulation.[68, 76]. Along the lines of membrane clearance
and absorption, we recall that the degree of ionization also plays a role in the passage of
drugs across membranes. The pH of the solute a compound is in determines the
ionization state of a weak acid or base, which includes most drugs.[78] Drugs that are
weak acids or weak bases exist at some equilibrium between their ionized and un-ionized
states. Urine pH varies widely,from 4.5 to 8. Lower urine pH, or more acidic urine,
increases re-absorption of drugs that are weak acids and decreases the re-absorption of
drugs that are weak bases. More acidic urine will also decrease the excretion of drugs that
are weak acids and increase the excretion of drugs that are weak bases. The inverse is
true for urine with a higher, more basic pH. With a few exceptions, the contribution to
excretion of sweat, saliva, and respiration is relatively small.[84]
2.3.7

Summary of Pharmacokinetic Concepts

2.3.7.1

Absorption
The absorption of a drug in pharmacokinetics is defined as the process by which an

unchanged drug moves from the site of administration to the site of measurement.[68] Common
routes or sites of administration include oral, intramuscular, intravenous, and subcutaneous. The
most common site of measurement is an arm vein.[72, 73]

2.3.7.2

Distribution
The distribution of a drug in pharmacokinetics is defined as the process of reversible

transfer of drug from one location to another in the body.[68] Drug moves to and from the site of
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measurement and the peripheral tissues. The distribution process is observed at the site of
measurement, usually the plasma.[68]

2.3.7.3

Metabolism
The metabolism of a drug in pharmacokinetics is defined as the conversion of one

chemical species to another chemical species.[83, 81] Metabolism is one of the two elimination
processes. However, unlike excretion, metabolism can sometimes be reversible. In drugs where
metabolism is reversible, the extent of elimination of the drug is only to the degree of which the
metabolite is eliminated and unable to return to the original drug.[68]

2.3.7.4

Excretion
The excretion of a drug in pharmacokinetics is defined as the irreversible removal of an

unchanged drug from the body.[68] Excretion is the second of two elimination processes. The
main organs that participate in the excretory process are the liver and the kidney, but a marginal
amount of excretion is carried out through sweat and exhalation.[72, 36] However, renal filtration
accounts for the majority of drug excretion.[84]

2.3.7.5

Absorption and Disposition
The elimination of a drug from the body is linked on a physiologic and anatomic basis to

both systemic absorption and distribution. Disposition is a term used to encompass the
distribution and elimination of a drug from the body. An overarching term for this pair of
processes is needed since it is often difficult to distinguish whether a decline in the plasma
concentration of a drug is due to distribution or elimination. Another way to describe disposition
is all kinetic processes successive to systemic absorption. From the previous two Subsections
2.3.5 and 2.3.6, it is important to emphasize that elimination consists of both metabolism and
excretion. Figure 2-9 illustrates how the processes overlap using a simple two-compartment
example.[68] Thus, the ADME process can be described as absorption (A) and disposition,
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where disposition includes distribution (D) and the elimination processes metabolism (M) and
excretion (E).

Figure 2-9: Disposition is a collective term that refers to the processes of distribution and
elimination; elimination includes two of the ADME processes metabolism and excretion

2.4

Pharmacodynamics Concepts

Since the focus of this work is primarily pharmacokinetic modeling without the
pharmacodynamic component, this section will outline important terms and goals in
pharmacodynamic modeling. It should not be left without mention, but for the scope of
the work, a general overview with some examples should be adequate background.
The relationship between the systemic exposure of a drug and the body’s response
to that exposure defines the pharmacokinetics of the drug. Drugs interact with different
organs and tissues within the body to produce a therapeutic effect. In order to achieve the
therapeutic effect, there must be an adequate exposure at the target site. The target site is
the location in the body that the drug is expected to “treat”.[68] For instance, in anticancer therapy, the drug’s target site is the tumor.[86] However, in many cases, the
administration site is far from the target site within the body. Another example of this
could be an anti-psychotic drug, administered orally, then absorbed into circulation in the
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gut, and delivered across the blood-brain-barrier to the brain.[77] Further, the target site
may not be a plausible site of measurement (i.e. the brain, a tumor in the pancreas), so
measurements of concentration in systemic circulation is often the surrogate site of
measurement. These measurements are under the assumption that some fractional or
scalar amount of the drug is at the target site. The assumption in classical
pharmacodynamics is that any response caused by the administration of the drug is solely
due to the parent drug, not its metabolites. Metabolites should of course be kept in mind,
but the collective effect of the drug is measured as one lump effect unless otherwise
specified.[68, 36]
2.4.1

Types of Pharmacodynamic Response
The term response is used to embrace a wide range of measurements depending

on the purpose of the drug. Thus, responses can be classified in a number of different
ways. Arguably the most important classification from a clinical standpoint is if the
response is desired or harmful. However, this distinction may not always be
straightforward.[68] For instance, the anticoagulant warfarin decreases clotting which can
lead to a desired response - decreased likelihood of an embolism - or a harmful response internal hemorrhage.[87] Broadly, pharmacodynamic responses fall into three categories
- (i) clinical responses, (ii) surrogate endpoints, and (iii) biomarkers. The following
paragraphs will discuss each class of pharmacodynamic response. Clinical responses (i)
can be either objective or subjective. An objective clinical response could be measures
like increase in survival time or decreased number of vomiting episodes, while a
subjective clinical response could be “quality of life” or a sense of nausea. While these
are useful, even some objective clinical responses can take years to manifest and thus,
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tend to show great variability. These objective clinical responses often do not allow for
intervention or guiding therapy.
For that reason, surrogate endpoints (ii) are useful to get simple, immediate
measurements to guide therapy or verify that the treatment is actually having an effect.
Surrogate endpoints are simple measurements that are not necessarily a direct response to
the drug but correlate to the clinical effect.[68] Anti-hypertensive drugs are a good
example of this concept. The clinical response to prolonged hypertension may be
increased incidence of stroke, but it would take many years and a large population to
gather the incidence of strokes to see if the drug actually decreases the risk. Instead,
taking blood pressure measurements can serve as surrogate endpoints since it has been
proven that lower blood pressure over time decreases the incidence of strokes.[88] Blood
pressure measurements are on the causal pathway to the clinical response, so they are an
excellent example of a surrogate endpoint.
Biomarkers (iii) make up the third and final category of pharmacodynamic
responses. Generally, biomarkers are measurable effects produced by the drug. However,
in practice, biomarkers are chosen that have some diagnostic or prognostic relevance.[68]
For instance, blood glucose levels are good biomarkers for drugs like metformin and
insulin that treat diabetes and insulin resistance.[89] Other biomarkers are used to
monitor general adverse effects from the drug like liver function tests, kidney function
tests, and white blood cell counts. These biomarkers are broadly referred to as safety
biomarkers.[68]
In reality, drugs produce more than just one effect, so a biomarker need not be
related to the actual clinical effect. It could be said, then, that all pharmacodynamic
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responses are biomarkers unless that have either been accepted as clinical response or
have been shown through scrupulous evaluation to predict therapeutic outcome and thus
accepted as a surrogate endpoint. The biomarkers that are most likely to be accepted as a
surrogate endpoint are those which are on the causal pathway between drug action and
clinical response. In other words, these biomarkers measure an effect which has been
shown to affect some disease state or clinical outcome.[68]
2.4.2

Assessment of Response
With the exception of endogenous compounds such as insulin, cortisol, and

thyroxin, drugs are not naturally occurring in the human body. Thus, in most cases, there
is no baseline amount of drug concentration in the body to take into account. However, in
pharmacodynamic response, there does exist a baseline measurement. The blood
pressure, glucose level, white blood cell count, and bilirubin levels from a particular
patient while not on the drug serve as the baseline measurement, while the same
measurements from a particular patient while on the drug serve to characterize the drug
effect on the patient.[68] Baseline can be a difficult variable to identify due to the
rhythmic or cyclic physiologic changes that the body goes through daily, weekly,
monthly, or even hourly.[68, 76] For example, circadian rhythm has been shown to effect
baseline cortisol levels.[90] The menstruation cycle in females certainly affect baseline
hormone levels depending on the time of the month.[91]
For many drugs, there is also a placebo effect that factors into assessing the
pharmacodynamic response. Placebo effect occurs when a patient receives what appears
to be a certain drug treatment, while it is actually an inactive compound. What follows is
a psychosocial phenomenon where the desired outcomes of the treatment actually come
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from the patient’s anticipation of the outcome rather than the actual drug treatment. There
is evidence that taking a placebo effects activates neurotransmitters in dopaminergic,
opiodergic, and vasopressinergic pathways in the brain which may mimic the desired
effect, as if the patient received the active compound instead of a placebo. The effect of
the active compound is not present, but there could be subtle improvements or changes
that should be accounted for in the placebo arm of a study.[92] This is especially true
when any of the endpoints are subjective or patient-reported. Therefore, several
components must be considered when assessing the pharmacodynamic response to a
drug, as illustrated in Figure 2-10.[68]

Figure 2-10: Illustration of the consideration of placebo response and baseline in
addition to drug response when assessing the measured pharmacodynamic response of a
drug

2.4.3

Graded Versus Quantal Response
Pharmacodynamic responses can be either graded or quantal. The magnitude of

graded responses can be scaled or graded on a continuous spectrum within an individual,
sometimes related to plasma or tissue concentration. Quantal responses, also referred to
as all-or-nothing responses, do not occur on a continuous basis but discretely. It occurs,
or it does not occur.[68]
When the measurable pharmacodynamic response is graded, concentration versus
time and effect versus time data for each individual is combined to relate concentration
versus effect. When a gradient of concentrations are investigated, a continuous
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concentration-versus-effect profile can be achieved. Graded dose-response models are
useful in determining whether the inter-individual variation (IIV) is due to
pharmacokinetic or pharmacodynamic causes. However, if the response is dichotomous
(i.e. movement versus no movement, survive versus succumb, etc.), then a quantal doseresponse relationship can be investigated. Instead of relating intensity of effect to dose,
quantal dose-response relationships can elucidate the percentage of a population that is
affected.[93]
2.4.4

Examples of Notable Pharmacodynamic Models
Two general types of pharmacodynamic models are direct effect models [94] and

the indirect effect models [95]. Interestingly, the “early days” of pharmacokinetics and
pharmacodynamic modeling in the context of these types of mathematical modeling only
date back to the early 1960’s. A majority of the pharmacodynamic models in use today
have been somehow derived from one of these two types of models.[96] The following
subsections will describe the more developed forms of each model type - the Direct
Effect Model and the Indirect Response Model - in some detail and will attempt to make
the pharmacodynamic concepts a little more tangible.
2.4.4.1

Direct Effect Models

2.4.4.1.1

The Levy Equation

Direct effect models are derived under the assumption that drug effect is linearly
related to the logarithm of dose.[94, 96] Equation 2-34 by Gerhard Levy in 1964 shows
the linear relationship of effect E with the logarithm of dose R,
E = m × log(R) + e

(Eq. 2-34)

where m is the slope and e is the intercept term.[94] In a later work in 1966, Levy
derived the following model:
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𝐸 = 𝐸0 −

𝑚𝑘
2.303

𝑡

(Eq. 2-35)

where m is the linear slope which characterizes the effect-log concentration relationship
from Equation 2-34, E0 is the theoretical intercept, and k is the first-order rate constant
for elimination of the drug.[97] Equation 2-35 was derived from Equation 2-34 and
describes the relationship of single compartment drug pharmacokinetics and in vivo
effects over time. Equation 2.35 was henceforth known as the Levy equation and was
upheld by clinical data for drugs like the alkaloid tubocurarine that showed exponential
decline following intramuscular dosing and linear decline in the resultant muscle
relaxation. Later, the Levy equation led to the application of these linear and log-linear
type model to in vivo data. These models were simple to calculate by linear regression
and could provide slope values which translated to pharmacodynamic parameters.
Unfortunately, the Levy equation fails in some cases. The Levy equation is deficient if
the effect is not linear - less than 20% of the maximum effect Emax - or log-linear between 20% and 80% of the Emax. Thus, the model cannot be extrapolated to capture the
maximum effect Emax.[96]
2.4.4.1.2

Emax Model

These weaknesses led to the introduction of the Hill equation for the
characterization of in vivo concentration-response relationships by John G. Wagner in
1968.[98] The Hill equation is based on receptor occupancy theory, and when
concentration equilibrium conditions are assumed, the rate of change of the drug-receptor
complex is represented by the following equation:
𝑅𝐶 =

𝑅𝑇 × 𝐶𝑎𝑐𝑡𝑖𝑜𝑛
𝐾𝐷 + 𝐶𝑎𝑐𝑡𝑖𝑜𝑛

(Eq. 2-36)
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where RT is the receptor density, KD is the equilibrium dissociation constant, and Caction is
the concentration at the site of action.[96] One assumption of receptor-occupancy theory
is that the drug effect is directly proportional to the fraction of occupied receptors:
E = γ × RC

(Eq. 2-37)

where RC is the drug-receptor complex and γ is a proportionality constant. Under that
assumption, combining Equation 2-36 and 2-37 can be rearranged to fit a form of the Hill
equation:
𝐸 =

𝐸𝑚𝑎𝑥 × 𝐶𝑝
𝐸𝐶50 + 𝐶𝑝

(Eq. 2-38)

where Emax is substituted for (γ × RT ), and EC50 is a sensitivity parameter that
represents the drug concentration that causes 50% of maximum effect.
Equation 2-38 is commonly referred to as the Emax model and is one of the most
frequently used direct response models in pharmacodynamics.[73] One
assumption of all forms of the Emax model is that maximum effect Emax and peak
concentration Cmax occur simultaneously. The premise of this assumption is that
the plasma drug concentration and the relevant peripheral concentration reach
rapid equilibrium after dosing. However, this overlap does not always occur.
There are a number of physiological reasons that drug effect would lag behind
peak drug concentration. This disparity led to the development of models that
capture the delay in terms of physiological mechanisms following peak
concentration.[96] The first of these was the biophase model.
2.4.4.1.3

Biophase Model

The term “biophase” was conceived in 1955 by Robert Furchgott to describe the
drug site of action.[99, 96] Sheiner et al. then developed a novel modeling approach in
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1979 which incorporated a hypothetical “effect” compartment, which was termed the
biophase model. The biphase model is defined by the following equation:
𝑑𝐶𝑒
𝑑𝑡

= 𝑘𝑒𝑜 × 𝐶𝑝 − 𝑘𝑒𝑜 × 𝐶𝑒

(Eq. 2-39)

where keo is a first-order distribution rate constant, Ce is the intensity of pharmacological
effect, and Cp is the plasma concentration. The premise of the biophase model is that the
delay in maximum drug effect and peak concentration is due to the time it takes for the
drug in the plasma to be distributed to the target site or site of action. Adding the
hypothetical compartment for the quantification of the actual effect at the drug site of
action (i.e. the biophase) accounts for the delay by prolonging the time it takes for the
effect to occur using the rate constant keo. The biophase model is illustrated in Figure 211.[96, 73] Many current, more mechanistic pharmacodynamic models today use effect
compartments to resolve delays in treatment effect.[96, 100]

Figure 2-11: Simple schematic of the biophase model originally developed by Sheiner et
al.[101], where Cp represents the concentration in plasma compartment, Ce represents the
hypothetical effect compartment, and keo is the first order distribution rate constant
between compartments
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2.4.4.1.4

Indirect Response Models

The concept of Indirect Response (IDR) models was first introduced by E.J.
Ariens in 1964 with the suggestion that drugs may not interact directly with receptors at
target sites to cause drug effects.[95] Instead, the drug may interact and affect the
behaviour of endogenous compounds in the body. It could be the subsequent effect that
those endogenous compounds have on the target site. In other words, the drug indirectly
affects the site of action by directly affecting substances that act on the site of action.[96]
Indirect Response models are also frequently used as another way to account for temporal
lag between drug response and drug concentration.[73] There exists four formalized
Indirect Response Models that were formalized by William Jusko’s group in the early
1990’s[102] and later found to be useful for characterizing many clinical
pharmacodynamic effects.[103]
2.4.4.1.5

IDR Model I
𝑑𝑅𝑖𝑑𝑟

= 𝑘𝑖𝑛 (1 −

𝑑𝑡

2.4.4.1.6

= 𝑘𝑖𝑛 − 𝑘𝑜𝑢𝑡 (1 −

𝑑𝑡

) − 𝑘𝑜𝑢𝑡 × 𝑅

(Eq. 2-40)

𝐼𝑚𝑎𝑥 × 𝐶𝑝

)×𝑅

(Eq. 2-41)

) − 𝑘𝑜𝑢𝑡 × 𝑅

(Eq. 2-42)

𝐼𝐶50 + 𝐶𝑝

IDR Model III
𝑑𝑅𝑖𝑑𝑟
𝑑𝑡

2.4.4.1.8

𝐼𝐶50 + 𝐶𝑝

IDR Model II
𝑑𝑅𝑖𝑑𝑟

2.4.4.1.7

𝐼𝑚𝑎𝑥 × 𝐶𝑝

= 𝑘𝑖𝑛 (1 −

𝑆𝑚𝑎𝑥 × 𝐶𝑝
𝑆𝐶50 + 𝐶𝑝

IDR Model IV
𝑑𝑅𝑖𝑑𝑟
𝑑𝑡

= 𝑘𝑖𝑛 − 𝑘𝑜𝑢𝑡 (1 −

𝑆𝑚𝑎𝑥 × 𝐶𝑝
𝑆𝐶50 + 𝐶𝑝

)×𝑅

(Eq. 2-43)

where Ridr represents the response, Imax is the maximal effect of inhibition, IC50 is the
concentration that triggers the half-maximal effect of inhibition, Smax is the maximal
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effect of stimulation, SC50 is the concentration that triggers the half-maximal effect of
stimulation. These four models apply to a wide range of clinical applications, but for the
scope of this discussion, a few applications of IDR Model I will be briefly outlined.[73]
One notable application of IDR Model I as shown in Equation 2-40 was its use in
modeling the pharmacokinetic-pharmacodynamic (PK/PD) relationship of warfarin.
Warfarin inhibits the production of prothrombin, which is a plasma protein that is
converted to the clotting factor thrombin during the coagulation process. By inhibiting
prothrombin, a delayed anticoagulant effect is carried out in the blood.[104, 73] Another
common drug for which the IDR Model I in Equation 2-40 is applied is ibuprofen.
Ibuprofen inhibits prostaglandin E2, which is known to temper immune response by
regulating the expression of cytokines.[105] By controlling the expression of cytokines,
ibuprofen reduces the inflammation which causes fever, and the measured
pharmacodynamic response is fever. This is a clear example of how ibuprofen indirectly
decreases fever, the pharmacodynamic response, by directly affecting cytokine
expression.[106]
2.5

Summary of Pharmacokinetics and Pharmacodynamics

Previous sections have discussed how pharmacokinetics and pharmacodynamics
have separately contributed to the understanding of a complete pharmacological profile
of what the body does to the drug and what the drug does to the body, respectively.[69]
This section will discuss the combination of pharmacokinetics with response over time,
which has more formally come to be known as pharmacokinetic / pharmacodynamic
(PK/PD) modeling. PK/PD modeling unites a pharmacokinetic model with a
pharmacodynamic model to capture the full relationship between drug administration and
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response with time.[68] Figure 2-12 illustrates both the distinct differences and interdependence between PK and PD modeling.

Figure 2-12: Schematic of the inter-relation of pharmacokinetic and pharmacodynamic
modeling (adapted from Zou et al.)[73])

One main distinction is that pharmacokinetics deals with the drug specific and
delivery system specific parameters associated with the system, while pharmacodynamics
deals with the physiological system specific parameters. Pharmacokinetic models tell the
story from dose administration to target and out of the body. Pharmacodynamic models
take it from delivery to the target and describes the drug effect and pharmacodynamic
response.[73] There is no doubt that PK/PD modeling has tremendously aided in drug
discovery, drug delivery, and general progress in understanding the effects of
therapeutics on the body. However, there still exist some caveats that must be considered
when applying a PK/PD model to a drug or clinical concern. There are many assumptions
made in the development of PK/PD models that cannot be easily validated. These hardto-validate assumptions are less of a concern for some of the simple examples noted
earlier in this chapter, which have known mechanistic pathways. However, there are
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more complex PK/PD relationships in advanced therapies that are in development today
for which this challenge must be overcome. For instance, antibody-drug conjugates
(ADCs) are complexes with a monoclonal antibody (mAb) and a linker loaded with a
cytotoxic compound.[73] These types of drugs are of great interest as a novel approach to
cancer therapies as new mode of delivering cytoxotic agents in a more targeted manner.
One example of model of an ADC is a PK/PD model Brentuximab-Vedotin antibodydrug conjugate developed by Tsuchikama et al. in 2018. The assumption was made that
the cell-killing effect in the tumor was directly related to the drug concentration.[107]
However, without the ability to observe the distribution cascade directly, the validity of
this assumption is in question.[73] As the field continues to advance alongside medical
technology, 86 there may be more opportunity to validate these types of assumptions or
better understand the mechanisms of action. It should also be noted that these
assumptions made in PK/PD modeling are not random guesses, but instead are based on
some pharmacological or physiological observation or knowledge. However, the
limitations of the models must be noted so that future information can inform future
models. Another obstacle in PK/PD modeling that is more relevant to the work to follow
is the extrapolation from sub-clinical species (i.e. mice, rats, etc.) to humans. Fortunately,
there are several current, reliable methods for minimizing error in scaling parameters
across species. One more obvious method would be choosing an appropriate animal
species for scaling to humans. It is known that dogs are the best preclinical species for
assessing cardiac safety in humans.[73] Mini-pigs are considered the best preclinical
species for dermal absorption in humans.[108] Additionally, using allometric scaling
across multiple species from preclinical species to humans can be used to improve
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predictions by minimizing error and increasing accuracy.[73] Simple allometry is a
generally accepted method for small molecules that are renally excreted - which is the
case for doxorubicin.[9] Some of these animal-to-human scaling relationships have
already been developed and are more quickly accepted. The predictive power of PK/PD
models informed by previous observations and carefully collected data is a valuable asset
to pharmacology and the practice of medicine today. As mentioned previously, the
advancement in new technologies can help improve the understanding of
physicochemical properties of drugs and their delivery systems. Improved understanding
will do nothing but bolster the predictive ability of future PK/PD models.[73]

2.6
2.6.1

Additional Considerations in PK/PD Modeling

Disease Modeling
Disease modeling is needed to understand whether therapeutic drug effects are

curative, symptom mitigating, disease-modifying, or effective at all. Understanding how
diseases behave and progress without medical intervention is vital to characterizing the
effect of a drug in terms of treating the ailment. Disease modeling is sometimes referred
to as natural history progression modeling. These types of models act as a control group
to observe differences between treated and untreated group.[109] Disease modeling in
humans can be precarious in terms of ethics. Clearly, it would be unethical and even cruel
to withhold treatment from a human simply to study the natural progression of some
disease.[110] In some cases, models are scaled from natural disease progression data
gathered from sub-clinical species like mice, rats, pigs, etc. However, it is generally
known that animal models do not scale perfectly to humans. Allometric scaling, a type of
inter-species scaling, can be used to estimate model parameters extrapolated to
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humans.[10] Additionally, data from disease models in animals can give insight into
general disease behavior, which is sometimes used to build out probability models and
simulations.[110] In addition to cancer, natural progression models are also widely used
in long-term, progressive diseases with poor prognoses. These include neurodegenerative
diseases like Muscular Sclerosis (MS)[111], Alzheimer’s Disease (AD)[112], and
Duchenne Muscular Dystrophy (DMD)[113] for which there are scarce pharmacological
interventions available.
2.6.1.1

Modeling Tumor Dynamics
Many functional forms have been developed to characterize natural tumor growth

in terms of ordinary differential equations. The most basic - linear, exponential, logistic,
and Gompertz will be briefly explained below. Linear growth presumes that the natural
growth of the tumor follows a constant zero-order growth rate as shown in the example
curve in Figure 2-13A and the following equation:
𝑑𝑇
𝑑𝑡

= 𝑘𝑔

(Eq. 2-44)

where kg is the tumor growth rate constant. Exponential growth assumes that the growth
rate follows a first-order growth rate. That is, the growth rate is proportional to the tumor
burden, as shown in Figure 2-13B and the following equation:
𝑑𝑇
𝑑𝑡

= 𝑘𝑔 × 𝑇

(Eq. 2-45)

where kg is the tumor growth rate constant and T is the tumor burden.
The first two growth models, linear and exponential, assume that tumor growth
has no upper limit. The tumor either grows at a constant rate or grows faster as the tumor
volume becomes larger. However, the logistic and Gompertz growth models make a more
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biologically realistic assumption that the tumor is limited by some carrying capacity or
that the growth rate decreases over time.

Figure 2-13: Examples of the general shapes of the four basic functional forms that
natural tumor growth models take - linear (A), exponential (B), logistic (C) and
Gompertz (D) (adapted from Yin et al.)[114]

Realistically, the tumor cannot grow to an infinite volume, as tumors are in some
organ or tissue in the body that has a finite volume that can only yield to a certain extent.
The logistic model assumes that the natural tumor growth is limited by a carrying
capacity. In other words, the tumor has some limit (Tmax) to its total tumor burden, as
shown in Figure 2-13C and the following equation:
𝑑𝑇
𝑑𝑡

= 𝑘𝑔 × 𝑇 × (1 −

𝑇
𝑇𝑚𝑎𝑥

)

(Eq. 2.46)

where kg is the growth rate constant, T is the tumor burden, and Tmax is the maximum
tumor burden. As T increases, the growth rate is scaled by a smaller and smaller fraction
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(T/Tmax). Once T is equal to Tmax, the third term in Equation 2-46 goes to zero. The growth
rate, then, goes to zero, which indicates no further growth can occur.
Similarly, the Gompertz model assumes that the tumor growth rate declines as it
approaches its maximum tumor burden Tmax. This is easy to see in the example curve in
Figure 2-13D and in the following equation:
𝑑𝑇
𝑑𝑡

= 𝑘𝑔 × 𝑇 × ln (

𝑇𝑚𝑎𝑥
𝑇

)

(Eq. 2.47)

where again, kg is the tumor growth rate constant, T is the tumor burden, and Tmax is the
maximum tumor burden. From Equation 2-47, the growth rate is scaled by the natural
logarithm of the proportion of T to Tmax. As long as Tmax is larger than T, the growth rate
is positive. As T approaches the value of Tmax, the growth rate becomes exponentially
smaller until it reaches zero when T is exactly equal to Tmax .[114]
2.6.1.2

Disease Progression
Accurate disease modeling is vitally important for understanding clinical

presentation, endpoints, and progression. Modeling disease progression in terms of
clinical pharmacology joins the understanding of the disease model and the
pharamacokinetic and pharmacodynamic profiles. Broadly, clinical pharmacology seeks
to master the use of medicine to treat disease. Adding pharmacokinetic and
pharmacodynamic modeling methods have allowed for more powerful, quantifiable
characterization of time course of drug concentration and effect in both individuals and
populations.[109] As mentioned previously in this section, these quantitative disease
progression models help discern between symptom-mitigation and disease-modification
in terms of drug action and effect. This depth of understanding is integral for regulatory
decisions and therefore, patient care.[109] In the previous discussion about different
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types of pharmacodynamic drug responses, it could be important to know if the response
is related to the half-life or clearance of the drug.[68] Some drugs do not alter the course
of disease progression but only gives temporary relief to some symptom of the greater
illness. Disease progression models are much like pharamacokinetic or pharmacodynamic
models as multiple observations can be made on the same patient. Instead of a plasma
sample or white blood cell count, some metric of disease status is measured over time.
Disease status over time can be combined with PK/PD modeling for a more holistic
picture of the interrelation of disease and treatment.[109] This discussion of disease
progression models in terms of clinical pharmacology leads into the clinical application
of PK/PD modeling.
2.6.2

Clinical and Therapeutic Relevance
All drugs are developed to treat some ailment. Likewise, all drugs have some

adverse side effect. Some adverse effects are mild, as in the potential gastrointestinal
discomfort following a dose of aspirin. Others have the potential to be much more 91
dangerous, as in the case of doxorubicin and its notorious cardiotoxicity. However, any
drug at the wrong dose can be deadly - for instance, a 200 - 300 milligram dose of aspirin
could relieve a mild headache. A 10 gram dose could be fatal. [68] The greater objective
for developing these PK/PD modeling methodologies is for the benefit it can have in the
clinical setting. In much earlier years of medicine, the manner in which the correct dosing
regimen was determined was through trial and error. While the eventual correct schedule
can be determined under that method, many patients are at risk for suffering some level
of unnecessary adverse effects. To compare, 0.125-0.25 mg of digoxin is given daily to
treat congestive heart failure while morphine sulfate must be given in doses of 10-50 mg

77
up to 6 times a day to treat pain in terminal cancer patients. These treatment regimens
were determined using this trial-and-error approach, which likely caused at the very least
discomfort to the patients involved. Additionally, this approach adds almost nothing to
the underlying understanding of effective dosing regimens for similar drugs.[68]
In the early 2000’s PK and PD models have become a standard piece of
regulatory applications for new drugs or new recommendations for current drugs.[115]
As shown in Figure 2-14 which shows a flow chart of the drug discovery process from
pre-clinical studies to post-marketing surveillance. At each stage of the process, some
form of modeling is being done to guide the experimental design of the trials conducted
along the way. Developing a PK/PD model is a step-wise process.

Figure 2-14: Simplified flow chart of the drug discovery process highlighting the
contribution of PK and PD models at each phase of the process (adapted from Derendorf
et al.[68])

First, the baseline natural disease model is developed. Next, the concentration
versus time and the concentration versus effect data provide the basis for training a model
to characterize the drug effect. The model’s predictive power on a different dose or
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treatment schedule can then be tested using a cross validation method (holdout, k-fold,
etc.).[116] Once the model is considered sufficient, additional post-hoc studies can be
done to glean relevant information. The addition of PK/PD methodologies have created a
more rational framework for making decisions concerning drug administration. In
addition to the fundamental concepts of 92 pharmacokinetics and pharmacodynamics that
have been discussed at length in this chapter, a few basic concepts have added to this
rational framework.
First, it was understood that the intensity of a drug effect tends to increase with
increased exposure. This is intuitive. However, the intensity of the drug effect reaches a
capacity at which the increase in effect no longer matches the increase in concentration.
In other words, there is some maximum effect that a drug can produce. From that, it was
accepted that while a very high exposure will cause a very large drug effect, some of the
effects will be undesirable. This is because drugs act on more than just one part of the
body, despite the drug effect being intended for just the site of action. Even if the type of
response is the same, the maximum effect that can be reached may be quite different from
even a similar drug. Taking analgesics for example, aspirin and morphine both provide
pain relief. However, while even a maximum dose of aspirin could likely not relieve
intense pain from severe trauma, morphine could. These ideas combined produced the
concept of a therapeutic window. The paradox of the therapeutic window is that too low
of an exposure leads to insufficient therapeutic response and too high of an exposure
leads to unwanted side effects. The narrower the therapeutic window, the smaller the
margin of safety. Continuing the digoxin and morphine sulfate example, we now know
that both of the drugs have a narrow therapeutic window. Morphine is eliminated from
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the body quickly. Instead of giving a large dose at one time, which could cause excessive
respiratory depression and even death, a frequent dosing schedule of smaller doses allows
for the maintenance of a concentration that manages pain. Digoxin is eliminated slowly,
so a once-daily administration is adequate

CHAPTER 3
PK/PD OF DOX AND DOXol
Since doxorubicin (DOX) is used so broadly in cancer treatment, it is imperative
that the understanding of its interaction with the body is continually improving. Better
modeling techniques should aid in more precise dosing regimens and ultimately better
outcomes for patients. While pharmacokinetic and pharamcodynamic models are often
used in tandem, the majority of the models created for DOX are PK focused. However,
since DOX is used in such a wide range of cancers, the range of pharmacodynamic
models are too broad to discuss in detail. This section will cover current PK models of
DOX, but will only give general general mention of pharmacodynamic details.

3.1

Current Models of DOX and DOXol

A variety of PK models have been developed to explain the problem of DOX
dosing (Table 3-1 and Table 3-2), but there is a range in the appropriate number of
compartments needed to accurately model DOX and its major metabolite, doxorubicinol
(DOXol). Some models aim for a more simplistic approach and exclude the metabolite
entirely. For example, Piscitelli et al. developed a simplified model, explaining the PK of
DOX as either a two-compartment or a three-compartment based on select covariates like
body surface area and age. This model lumped DOX and DOXol into one agent instead
of trying to investigate the PK of each individually.[17]

80

81
Table 3-1: Observed or Reported Half-Life Values for Sub-Clinical Species and Humans
from Literature
Observed half-life values
Species
Dose
Mouse
10mg/kg IV bolus
Rat
6mg/kg slow IV bolus
Rabbit
5mg/kg IV bolus
Human
60mg/m2
Human
N/A
Human
20-100mg/m2
Human
50mg IV bolus
Human
15mg/m2 IV bolus
Human
30mg/m2 IV bolus
Human
50mg/m2 IV bolus
Human
25mg/m2 IV bolus
Human
75mg/m2 IV bolus
Human
60mg/m2 IV bolus

t1 1/2
25.2min
5.3min
4.6min
4.8min
5.2min
12min±8 min
10min±45sec
3.18min
3.38min
4.8min
4.8min(3.6-6.6)
4.8min(3.6-5.4)
4.8min

t2 1/2
10hr
3hr
1.92hr
2.57hr
1.98hr
3.3hr±2.2hr
1.42hr±6 min
35.53min
43.79min
1.37hr
3.7hr(1.3-15.4)
2.4hr(0.5-4.5)
2.57hr

t3 1/2
N/A
17.3hr
N/A
48.4hr
31.9hr
29.6hr±13.5hr
28.75hr±4.67 hr
8.98hr
26.46hr
20.42hr
31.5hr(21.0-67.3)
33.0hr(21.0-55.9)
48.4hr

Source
[33]
[45]
[117]
[35]
[118]
[32]
[119]
[120]
[120]
[120]
[121]
[121]
[35]

Table 3-2: Observes or Reported AUC Values for Sub-Clinical Species and Humans
from Literature
Observed AUC values
Species
Mouse
Mouse
Rat
Rabbit
Rabbit
Rabbit
Rabbit
Human
Human
Human
Human
Human
Human
Human
Human

Dose
10mg/kg
5mg/kg
5mg/kg
5mg/kg
3mg/kg
3mg/kg
3mg/kg
50mg/m2
30mg/m2
15mg/m2
45-72mg/m2
50-75mg/m2
60mg/m2
50mg/m2
50mg/m2

AUCDOX (ng×h/ml)
1463
1818±45
516±44
1223.2±98.7
407.64±119.57
1216.67±116.67
615±35
1426.5
951.34
519.5
1834±1007
2055±929
1973.9
1660±680
1630±560

AUCDOXol (ng×h/ ml)
N/A
N/A
666.8±100.4
666.8±100.4
244.584±152.186
N/A
N/A
N/A
N/A
N/A
2529.7±2699
N/A
1298.4
N/A
N/A

Source
[33]
[126]
[127]
[128]
[129]
[117]
[117]
[120]
[120]
[120]
[17]
[130]
[35]
[131]
[131]

Another model by Kontny et al. incorporated a fourth compartment for DOXol in
addition to a three-compartment model for DOX.[32]Perez-Blanco et al. further refined
the model to a three-compartment model for DOX with two-compartments for
DOXol.[31].
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More compartments for drug plasma concentration does not necessarily equate to
a better model. Most data collected for pharmacokinetic studies can be fit to several
different models, but it is a matter of finding the best fit to describe the drug’s action.
Interestingly, the models of DOX that fit a two-compartment model have low initial
doses, as shown in the Cusack rat model, the Brenner rabbit model, the Johansen rat
model, and the third Erttmann human model in Table 3-3. Note that the third Erttmann
model was given in 15 mg/m2 doses every 10 hours, which is the lowest dose given in
any of the cited models.[120] It is possible that a higher concentration must be reached in
order for the third elimination phase to be apparent in data. This dose-dependence has
been evidenced previously in literature.[122] In addition, the granularity of the model has
a great deal to do with the quality and quantity of the samples and therefore the data
entered into the model.[70] Although PK models like the aforementioned may have
tolerably explained the drug’s PK characteristics, none of them so far have ascertained
the complex metabolic activity and toxicity of DOX.
A more extensive list of existing models of DOX in literature are listed in Table
3-3. There is a major effort in recent years to encapsulate DOX in liposomes and other
nanoparticles in order to increase maximum residence time for better exposure or
decrease the interaction of DOX with healthy cells outside of target site for less
toxicity.[123, 124, 22, 28, 27, 125] However, the scope of this dissertation will be limited
to un-encapsulated DOX, also referred to as “free doxorubicin”. Because of the pivot
toward encapsulating DOX in recent years, some of the PK models of DOX in the
following section may seem aged. However, the models collected in this review are some
of the most recent free DOX models in literature.
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Table 3-3: Summary of Existing Models of Un-Encapsulated or “Free” DOX in SubClinical Species and in Humans, as Reported from Literature
Existing Pharmacokinetic Models of DOX
Species

Treatment

Compartments in Model

Source

Mouse

10mg/kg IV bolus

2 or 3

[33]

Rat
Rat
Rabbit
Rabbit
Pig
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human Child
Human Child

6mg/kg IV bolus
2mg/kg IV bolus
3mg/kg IV bolus
5mg/kg IV bolus
50mg/m2 over 3 min IV
40-60mg/m2 IV bolus
26.6-35mg/m2 IV bolus
60mg/m2 over 40 hours IV
70mg/m2 IV bolus
45-72mg/m2 IV bolus
20-110mg/m2 IV bolus
50mg/m2 IV bolus[134]
60mg/m2 IV bolus
50mg/m2 IV bolus
N/A
10-75mg/m2 IV bolus

3
2
2
2
3
3
3
2
3
3
3+1 for DOXol
3+2 for DOXol
3
3
3+1 for DOXol
3+1 for DOXol

[45]
[127]
[129]
[117]
[132]
[120]
[120]
[120]
[133]
[17]
[32]
[31]
[35]
[131]
[118]
[135]

3.2

Inter-Patient and Inter-Dose Variability

Another obstacle that makes DOX more complicated as a cancer therapy is its
significant inter-individual variability on clearance, exposure as measured by area under
the concentration-time curve (AUC), and volume of distribution.[17] The
pharmacokinetic profiles of both DOX and DOXol are Inter-individual variability (IIV) is
a term used to describe a drug that displays significant differences in bioavailability and
toxicity among patients. Inter-patient variability is used clinically to understand the risk
of over-dosing or under-dosing a patient based on factors like body mass index (BMI),
certain gene expression profiles, or renal function. Additionally, inter-occasion variability
(IOV) describes variability in parameters or behavior between doses on the same
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individual. The three parameters that will be discussed in this portion of the chapter will
be variation in DOX (i) clearance, (ii) volume of distribution, and (iii) exposure (AUC).
These three parameters are certainly interrelated. The volume of distribution is directly
proportional to clearance, scaled by the elimination constant K as described in Equation
2-3. This relationship is based on the idea that volume of distribution is the volume in
which the drug is diluted.[68] DOX is eliminated linearly with first-order kinetics[31].
This means that the clearance is concentration dependent. A smaller volume of
distribution for the same amount of drug results a higher concentration which effects
clearance.[68] Further, the AUC and clearance are inversely proportional as shown in
Equation 2-1. The lower the calculated AUC, the higher the clearance. The inverse is also
true.[68] Practically, lower clearance means that the drug spends more time in the body
and has a higher exposure (AUC). Variations in clearance are readily cited in the
literature and may seem more heavily discussed in the following section, but it makes
sense that high variability in clearance infers high variability in related parameters. Early
conventional pharmacokinetic analyses reported from 2-fold to 5-fold inter-individual
variability in DOX clearance in adult cancer patients with no noteworthy hepatic or renal
impairment. This variability was present even after adjusting clearance values for body
surface area (BSA).[46] Issues with IIV and IOV in DOX clearance still pose dangers in
terms of cardiotoxicity and therapeutic effect.
Although this work is focused on free doxorubicin in adults, the extensive use in
children with malignancies gives way to rich data on properties of DOX that are also of
interest for adult populations. In a study of DOX in children, a significant difference was
found in the clearance rates between boys and girls. Boys in this study had a considerably
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higher mean clearance of 591 ml/min/m2 compared to the girls whose mean clearance
was 471 ml/min/m2.[19] An earlier study found that girls had a significantly higher
concentration peak Cmax than boys in the same cohort.[32] Additional studies found that
higher body fat percentage and an overweight body mass index correlated to lower
clearance rates and higher Cmax values.[118, 44]
The same study also found a significant difference in clearance between groups of
children under 2 years old (infants) and over 2 years old. Infants had a higher mean
clearance rate of 538 ml/min/m2 while children 2 and older had a mean clearance of only
446 ml/min/m2 as shown in Table 3-4.[19] This finding is supported by other DOX
studies in children. One study reported a significantly higher mean clearance in children
younger than 10.5 years.[32] When studied in induction therapy for children acute
lymphoblastic leukemia, the most common childhood malignancy, patients with lower
clearance rates were statistically more likely to achieve complete remission.[19] This
finding suggests that the residence time of DOX in the body is correlated to directly
anticancer 100 effect and therefore, patient outcome. The danger, however is that longer
residence time could correlate with higher cardiotoxicity.
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Table 3-4: Observed or Reported Clearance Values for sub-Clinical Species and
Humans from Literature
Observed DOX Clearance
Species
Mouse
Mouse
Rat
Rabbit
Rabbit
Rabbit
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human Infant
Human Child

Dose
10mg/kg IV
5mg/kg IV
2mg/kg IV
3mg/kg IV
5mg/kg IV
5mg/kg IV
50mg/m2 IV
20-110mg/m2 IV
40-100mg/m2 IV
75mg/m2 IV
25mg/m2 IV
40-75mg/m2 IV
40-75mg/m2 IV
40-75mg/m2 IV
60mg/m2 IV
75mg/m2 IV
75mg/m2 IV

Clearance
0.150 L/hr
4.5±0.1
4.08 L/kg/hr
7.74 ± L/kg/hr
8.196±0.432 L/hr/kg
4.24±0.462 L/hr/kg
32.0 L/hr
53.3 L/hr
63.6±22.7 L/h
44.1 (36.2 - 79.9) L/h
21.4(16.1-27.8) L/h
30.4 ± 6.3 L/hr/m2
49.6 ± 14.1 L/hr/m2
28.0 ± 9.5 L/hr/m2
56.8 L/hr (24 - 119)
32.28 L/hr/m2
26.76 L/hr/m2

Source
[33]
[126]
[127]
[129]
[117]
[117]
[131]
[32]
[136]
[121]
[121]
[130]
[130]
[130]
[35]
[19]
[19]

In Table 1-1 from the previous section, it is made evident that DOX is rarely used
as a single agent. It has been observed to be more effective when given in combination
therapy - most often with alkaloids like vincristine or vinblastine[137], the folate
antagonist methotrexate[138], and the cytotoxic agent cyclophosphamide. [49, 17, 139]
One study found that when given in combination with cyclophosphamide, DOX
clearance was reduced by approximately 30%, which is consistent with the
literature.[136] Prolonged clearance times has been shown to increase therapeutic effect
in single-agent doxorubicin. It would be interesting to speculate whether the increased
efficacy of DOX when in combination with other agents is due to some synergy between
these other anticancer agents or the prolonged residence time due to reduced clearance. It
is likely that in reality there is some combination of both scenarios.
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Aside from the covariates like age, gender, body composition, and concombinant
therapy that may effect the clearance of DOX, a wide range of studies in several species
have reported a great deal of variation within relatively homogeneous groups. A
comparison of several pharmacokinetic studies done by Kontny et al. reported a mean
clearance value of 53.3 L/h for DOX with 17.7% inter-individual variability and interoccasion variability of 21% in human cancer patients.[32] Another large study conducted
by Rudek et al. found the mean clearance of DOX to be 63.6 L/hr with a standard
deviation of 22.7 L/hr.[136] A comparative dose study in 16 adult female breast cancer
patients was done by Twelves et al. to see how the pharmacokinetic parameters behaved
at different doses (Table 3-5).

Table 3-5: Observed or Reported Volumes of Distribution at Steady State of DOX for
Sub-Clinical Species and Humans from Literature
Volume of Distribution at Steady State of DOX
Species

Vdist,ss

Source

Mouse

101.0 ± 3.8 L/kg

[126]

Mouse
Rat
Rabbit
Rabbit
Rabbit
Human
Human
Human
Human
Human
Human

2.009 L/kg
194 ± 19 L/kg
0.79 ± 0.11 L/kg
2.65 ± 0.50 L/kg
112.4 ± 0.77 L/kg
20-30 L/kg
681.6 ± 433 L/m2
1081 L
2198 L
33.1 L/kg
9.3 ± 0.97 L

[33]
[127]
[117]
[117]
[129]
[32]
[17]
[121]
[121]
[35]
[131]

For a dose of 25 mg/m2 , the mean clearance was 21.4 L/hr with a range of 16.1 27.8 L/hr. For the 75 mg/m2 dose, the clearance was 44.1 L/hr with a range of 36.2 to
79.9 L/hr.[121] Despite the small sample size, there is a noteworthy difference in the
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clearance rates and the range of clearance rates observed. There is evidence in the
literature that other pharmacokinetic parameters of DOX are dose-dependence, so this
difference in clearance rates between dosing regimens is not surprising.[122] Another
study in a randomly divided group of 26 sarcoma patients found significant difference
between the three groups of patients. Two sets of data were used to train the model and a
third set was used to test the model. The first training set had a mean clearance of 30.4 ±
6.3 L/hr/m2 , the second training set had a 49.6 ± 14.1 L/hr/m2 , and the test set had a
mean clearance of 28.0 ± 9.5 L/hr/m2 . A statistically significant difference was found
between the second training set and the other two sets, respectively.[130] These clearance
values along with several other literature examples are listed in Table 3-4. Note that some
clearance values are normalised by weight in kilograms or body surface area (BSA) while
others are not. There is some debate as to whether normalising the dose of anticancer
agents by the patient’s BSA or weight, which is the standard of practice, actually
decreases the inter-individual variability. Some patients still experience severe toxicity
while others experience little to none at the same normalised BSA-based dose.[118] This
discrepancy further drives the need for more individualized dosing regimens for drugs
with narrow therapeutic windows.

3.3

PK Modeling Solutions to DOX Drawbacks

Although the pharmacokinetic profile of DOX consistently exhibits significant
inter-individual and inter-occasion variability, as of late, only one significant covariate,
decreased dose in hepatically impaired patients, has been successful in improving dose
adjustment.[11, 10] However, most chemotherapy drugs require dose adjustment for
hepatic impairment since most anticancer agents, including DOX, are metabolized in the
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liver.[140] This finding does not necessarily add to the knowledge of how to improve
dosing in patients that are not hepatically impaired. As mentioned earlier, there has been
some investigation into potential factors that affect key pharmacokinetic parameters such
as body composition[118], age[32, 135], or even pH of urine.[117, 133] Despite these
efforts, there are no universally accepted covariates that have modernized the guidance on
dosing of DOX.
The literature does support that variations in infusion duration significantly impacts
the exposure (AUC) and maximum concentration Cmax in humans.[44] It is widely
accepted that many DOX parameters are both dose-dependent and also schedule
dependent.[136, 120] If there are no recommended dose adjustments for DOX based on
typical covariates, optimizing the infusion duration and dose could be an avenue for
improving therapeutic efficacy and reducing the cardiotoxic side effect. Several studies
have cited that lower doses given frequently reduce incidence of cardiotoxic events in
patients receiving DOX. Likewise, doses given over a long infusion duration tend to
decrease incidence of cardiotoxic events.[124, 141, 142] Additionally, avoiding high initial
DOX concentrations correlate with lower cumulative cardiotoxicity, regardless of lifetime
dose.[120]
The focus of this work is to set up a framework for adjusting infusion rate and
duration in order to simulate a number of scenarios to which the cardiotoxicity risk and
therapeutic reward could be evaluated. As mentioned, the lower, more frequent dose or a
lower dose over time has been observed to lower incidence of cardiotoxic events.
Additionally, it has been shown that tumors are only in the 103 growth phase of their cell
cycle for a short window of time. The therapeutic effect of the drug at the site of action
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only acts on cancer cells in the growth phase. It is possible that some of the tumor killing
effect is lessened when shorter infusions are given, regardless of magnitude of dose, since
the drug effect has missed the window of time where the cell is vulnerable.[44] This work
proposes evaluating exposure (AUC) and peak concentration (Cmax) at different doses varying rate and duration - to provide a simulation framework for any clinical target.
The cardiotoxicity of DOX is largely attributed to the accumulation of its primary
metabolite DOXol in the heart.[11] Getting any reasonable estimation of the amount of
DOX that is metabolized and binds to heart tissue requires a more mechanistic or
physiological model. Despite its cardiotoxicity and inter-patient clearance variability, the
therapeutic value of DOX as a cancer drug has kept it a first-line chemotherapy agent for
over four decades. The risk of potential toxicity seemingly outweighs the potential negative
result of foregoing the drug.
Up to this point, the plasma drug concentration of DOX has been the central
measurement of the models discussed in this work. PK/PD models typically use the plasma
as the site of measurement and extrapolate or infer information about peripheral tissues
based on the plasma drug concentration. Physiologically-based pharmacokinetic (PBPK)
models incorporate more specific physiological parameters, additional compartments for
specific tissues, and more mechanistic approaches to a full body model. This section will
explore the use of PBPK models used for full body models that incorporate the drug’s
interaction within specific tissues. These models incorporate more than drug plasma
clearance, including the absorption, deposition, metabolism and excretion (ADME) of the
drug within the body’s systems. PBPK models are promising for DOX and DOXol because
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of its inclusion of tissues and organ systems, which will hopefully address its extensive
deposition in tissues.

3.4

Investigating PBPK Models of DOX

More physiological, and therefore mechanistic, modeling has come to the
forefront in pharmaceutical discovery and development in recent decades.[143] Modeling
systems dynamics has been used for decades to improve process control in industrial
settings. Likewise, the idea of modeling physiological systems has been around since the
early- to mid- 1900’s. It has become markedly more popular in recent times due to its
utility in drug discovery and development.[2] Modeling biological systems dynamics can
help describe the body systems’ response to perturbation — pharmaceutical or otherwise.
Developments in computational capabilities and pharmaceutical insight has allowed for
this discipline to better account for both drug and patient outcomes with more
computationally burdensome models.[144] The computational burden for PBPK models
is greater due to the increased dimensionality of the models, as well as the increased
complexity of the equations and systems of equations needed to detail more mechanistic
models.
Physiologically-based pharmacokinetic (PBPK) models are similar to more
empirical, classic PK models in that they can produce important PK parameters like
clearance and volume of distribution.[2] In addition, PBPK models include more in-detail
physiological processes and parameters that are within the constraints of realistic
physiological values.[143] Like classical PK modeling, these additional components are
integrated into the model using theoretical compartments, each having their own general
and intercompartmental clearance values based on its place in systemic function (Figure
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3-1).[1] However, these compartments are less “theoretical” than in classical
pharmacokinetic models and actually represent specific organs.[143] A more
physiologically consistent model yields a mechanistic mathematical framework that can
accommodate in-vitro in-vivo extrapolation (IVIVE) techniques for predicting drug
specific parameters. They detail not only concentration-time data in plasma, but also in
organs and tissue relevant to the specific drug and system in question. PBPK models are
also quite useful for extrapolating an oral or intravenous dose from healthy volunteers to
a diseased population, as long as applicable physiological properties of that target
population are available.

Figure 3-1: Example of a PBPK schematic, showing how each organ, represented as
compartments, are connected by the circulatory system

The compartments are also connected by venous and arterial blood compartments
which mimic or represent the actual circulatory system.[2] An optimized PBPK model is
capable of quantitatively predicting and defining exposure in blood, organs, and tissue,
which is vital for efficacy and toxicity analysis.[1] Exposure information for tissues,
especially the heart, is key to understanding the full profile of DOX and its enigmatic
cardiotoxic effect. However, in order to create a PBPK model, it is necessary to have a
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reasonable understanding of the mechanism of the drug and its interaction with the
system. A delicate balance must be struck between including important drug-system
interactions without over-parameterizing the model.
In order to obtain that balance, the four most important components to understand
are drug absorption, distribution, metabolism, and excretion (ADME). Absorption and
distribution describes the passive/active transport or diffusion of the drug across
membranes in the cells of various organs and tissues throughout the body. A general
obstacle for this element of the model is predicting transport rates in each compartment.
For small molecules like DOX, absorption and distribution are often concurrent.
Metabolism for small molecules usually describes the enzymatic metabolism from the
parent 106 drug to its metabolites, whether by CYP or non-CYP enzymes. Finally,
excretion explains the renal and biliary elimination.[1] Data for current PBPK models is a
conglomerate of data from previous literature and experimental data from animal studies.
There is an abundance of data in previous literature for DOX because of its
extensive use in cancer therapies. In vitro and in vivo studies have been done on both
animals and humans over the past few decades. These studies have provided
concentration values in plasma and tissues at a range of times post-infusion. This data
was collected through timed blood draws or analysis of organs of sacrificed animals.
Some of the earliest studies even give post-mortem organ concentrations collected from
autopsy of human patients.[40] Despite the fact that a great deal of data is available for
DOX, there is still much to overcome in constructing an acceptable PBPK model. As
mentioned before, it is unclear the exact mechanism that governs the cytotoxic activity of
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DOX.[32] There is also no definitive extent of metabolism[55], leaving these crucial
values as unknowns to be speculated and estimated for the best possible model.

3.5

Middle Ground - Minimal PBPK Modeling Approach

With current pharmacological knowledge of DOX, it seems nearly impossible to
create an exhaustive PBPK model without having to estimate to the point of becoming
arbitrary. Despite this, Dubbelboer et al. at Uppsala University in Sweden built a
favorable model for DOX using previously collected data from two pre-clinical studies
done in pigs. The Dubbelboer model was a semi-PBPK model, broadly meaning they did
not incorporate every organ and system explicitly.[8] Another more common term for
semi-PBPK models are minimal PBPK (mPBPK) models.[143] Instead, they focused on
the most relevant interactions and processes and included the necessary tissues to
reasonably encompass the drug’s passage through applicable biological systems.[8] There
has been a heightened interest recently in simplifying the structure of PBPK models for
smoother applicability and increased transparency around what can be reasonably
predicted.[143] The Dubbelboer model is such a model - using six tissue compartments,
two blood compartments, and two excretion compartments as shown in Figure 3-2.
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Figure 3-2: PBPK schematic of doxorubicin from the “binding specific” pig model
created by Dubbelboer et al. 2017; arterial blood is denoted by the red arrows and boxes,
venous blood by blue arrows and boxes, non-metabolizing tissues are in green, and
metabolizing tissues are in gold

Arterial and venous blood made up the two blood compartments, and urine and
bile made up the two excretion compartments. As there are far more than six tissue types
in the body, the authors saw it fit to give autonomous compartments to the lung, liver,
and kidney while lumping the GI tract, slow perfused tissue, and rapid perfused tissue
into the remaining three compartments respectively. They based the tissue grouping on
the physiological similarity of the tissue and its proposed interaction with DOX. These
six compartments were then divided into two classes – metabolizing and nonmetabolizing tissues.
From the animal studies and previous literature, they concluded that the
metabolism of DOX to DOXol occurs primarily in tissue. They dealt with this in the
model by isolating the two currently known locations of metabolism—the kidney and
liver. With generic knowledge of passive diffusion and transport in hepatic and renal
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cells, the metabolism from DOX to DOXol is incorporated into all metabolizing tissue
compartments only as depicted in Figure 3-3.

Figure 3-3: Liver compartment schematic describing movement, metabolism, and
excretion of DOX and DOXol in metabolizing tissues

Concentration changes in each compartment and between compartments are
described with ordinary differential equations as shown in Appendix A. However, in the
Dubbelboer model, the heart compartment was left out of the specific compartments and
presumably lumped into other tissue compartments. While this may seem surprising
considering the established concern around cardiotoxicity, Dubbelboer’s model was
designed to 109 investigate ways to model the intracellular binding of DOX rather than a
full analysis of the effect of DOX and DOXol on pigs.[8] Additionally, previous work by
Dubbelboer suggests that the interest in DOX in pigs was for the study of DOX as a
primary agent for the treatment of hepatocellular carcinoma.[145]
This rationale was supported by conjectures from literature, mentioned in Section
1.3.1.[63, 64, 52, 66] Including a heart compartment as a metabolizing compartment like
the liver and kidney gives a more realistic structure for capturing the cumulative effect of
DOXol on the heart. The schematic of the heart compartment is shown in Figure 3-4.
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Note that the structure is identical to that of the liver in Figure 3-3, except the heart does
not have the excretion component. All other compartments remained unchanged, and due
to the quite small percent of body weight that the heart makes up, its volume was
subtracted from the slow perfused compartment to maintain the mass balance. Parameter
values for each species can be found in Appendix G and will be discussed more in later
sections.

Figure 3-4: Heart compartment schematic describing movement and metabolism of DOX
and DOXol in metabolizing tissues

In the updated model shown in Figure 3-5, not only was a heart compartment
added, but the heart compartment is also a metabolizing compartment. It is true that
higher concentrations of DOXol are found in the liver and the kidney than in the heart,
gram for gram, in both animal species and in humans.[63, 64] However, aldo-keto
reductases, the primary enzymes involved in the hydroxylation of DOX to DOXol, are
present in all tissues.[52] The heart tissue is thought to be more vulnerable to the
cytotoxic effect of DOXol than the liver and kidney since the latter two possess binding
and inactivating compounds such as glutathianone which curb the toxic effect.[65] As
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such, the liver and the kidney are not typically sites of toxicity, while the heart
profoundly is.

Figure 3-5: PBPK schematic of doxorubicin, adapted from the pig model created by
Dubbelboer et al. 2017 to add a heart compartment as a metabolizing compartment;
arterial blood is denoted by the red arrows and boxes, venous blood by blue arrows and
boxes, non-metabolizing tissues are in green, and metabolizing tissues are in gold

There was no need to alter any of the other compartments in the original
Dubbelboer model for two reasons. First, the model fit the data well without adding
metabolism to any compartment, and it was not meaningful to add another compartment
since the majority of the DOX-induced cardiotoxicity is related to the heart.[8] As
mentioned earlier in this section, it is important to keep the number of equations and
parameters to the fewest needed for ease of application and transparency.[143] The final
model equations can be found in Appendix B. This approach appears to be the most
practical in the case of DOX, as this model sufficiently describes the passage of DOX
through the body. In general, necessary assumptions are made in order to reasonably
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simplify the model while incorporating only the relevant details that affect the drug
interaction. This prevents unneeded limitations on the system from cluttering the model
and creating statistically insignificant variables for the sake of a more holistic model.

3.6

Conclusion

DOX is a crucial component in many cancer treatment protocols, and its
continued use in patients is inevitable. However, as it stands, many patients are still
under-dosed or over-dosed because dosing is often left to best estimates. A standard dose
based on body weight or body surface area assumes that all patients will react in the same
way to the drug. In reality, especially for drugs like 111 DOX, there is great disparity in
the uptake, clearance, and metabolism among individuals. Optimizing individualized
doses for patients based on identified characteristics will improve the overall therapeutic
value of this already efficacious drug. Individualized dosing of DOX will also decrease
the occurrence of cardiac damage in patients. The hope is to continue increasing the
efficacy of treatment against their disease while minimizing cardiotoxic side effects.
The use of pharmacometrics will be key in the development of these
individualized treatment protocols. Identifying key factors for variability and better
understanding the clearance of DOX can someday be achieved through physiologicallybased PK modeling. As shown, a semi-PBPK approach seems like the best method
currently.
The semi-PBPK model proposed by Dubbelboer gave excellent insight on the
plasma and respective tissue concentration without over-parameterizing. Since DOX
considerably deposits in tissue, a physiological approach that incorporates tissue
compartments along with blood compartments is ideal. However, biological and
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physiological systems are complicated, intertwined systems that produce complex time
courses. As shown in Chapter 2, even a drug with a relatively simple time course requires
three coupled differential equations to capture the concentration-time profile of the
plasma.[70, 36] Creating a whole-body model, even a minimal whole-body model, could
require many more compartments and thus equations to adequately describe the system.
As systems of equations get larger and more complex, it is more likely that an analytical
or exact solution for that system is not possible. For these large systems of equations,
numerical methods must be employed to solve the system. Some of the methods used to
effectively solve the PBPK model of DOX described in this section will be discussed in
Chapter 4.

CHAPTER 4
NUMERICAL METHODS FOR PBPK MODELING
Physiologically-based pharmacokinetic (PBPK) models are used to describe the
concentration versus time profile of a drug or substance in a subject. While classic
pharmacokinetic (PK) models only detail plasma concentration, a physiologically-based
model, as its name suggests, uses physiological parameters to model the concentration in
relevant organs and tissues. These organs, similar to a classic PK model, are generalized
as compartments. Each compartment has a corresponding ordinary differential equation
(ODE) with time as the independent variable that describes the rate of change of drug
concentration in each compartment.
Unlike a classic PK model, a PBPK model requires more than a few
compartments to describe the mass balance of the drug in the body. Thus, a very large
system of ODEs is often associated with a PBPK model. However, the dimensionality of
PBPK models can be computationally burdensome and inefficient. This is especially true
in the programming language R, which is designed for statistical and data analysis, not
necessarily for computation speed. It is generally known that ‘for’ loops and other
conditional statements tend to be slow in the R language. R remains an extremely
powerful open-source, free access tool across many fields. It remains one of the most
flexible languages with a user-friendly interface R Studio, package building capabilities
through Git, reporting features like RMarkdown, and app building capabilities through
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RShiny. The R program is also extended by means of packages built and maintained by
users themselves, which gives endless possibilities for the scope and expertise of its use.
Despite its drawbacks, 112 113 the flexibility of the R language was the main rationale
for using it for these models.[146]

4.1

Traditional Numerical Methods

For large and complex systems of equations, numerical methods must be
employed to solve the system. Some common numerical methods used to solve these
systems include Euler’s Method, Runge-Kutta Fourth Order method and Runge-Kutta
Fehlberg Adaptive Step method. The following sections will cover these traditional
methods since they were coded in R and applied to the PBPK model of interest.
For large and complex systems of equations, numerical methods must be
employed to solve the system. Some common numerical methods used to solve these
systems include Euler’s Method, Runge-Kutta Fourth Order method and Runge-Kutta
Fehlberg Adaptive Step method. The following sections will cover these traditional
methods since they were coded in R and applied to the PBPK model of interest.:
4.1.1

Euler’s Method
Euler’s Method is the most rudimentary technique for approximating the solution

of initial value problems. The general concept of Euler’s Method is to utilize multiple
small line segments to approximate some actual curve y(t) versus t, assuming local
linearity. Euler’s Method is also called a tangent line approximation since each of these
small line segments are tangent to the slope at that time point. Each step is based on the
previous step’s computed value.[147] Its simple construction is the basis for many other
more complex approximation techniques. However, with its simplicity there are also
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limitations, and due to these limitations, it is not always the appropriate method for real
world problems. The goal of Euler’s Method is to find the approximate solution to a wellposed initial value problem. Accordingly, the objective of Euler’s Method is to solve the
well-posed 114 initial value problem,
𝑑𝑦
𝑑𝑡

= 𝑓(𝑡, 𝑦), 𝑎 ≤ 𝑡 ≤ 𝑏, 𝑦(𝑎) = 𝛼

(Eq. 4-1)

Euler’s Method does not give a continuous approximation of the solution y(t).
Instead, approximations of y are made at mesh points, which are values of t within the
interval [a, b]. The approximations of y at other values of t within the interval can be
derived through interpolation using the approximation generated at the mesh points.
Because of this, a condition of Euler’s Method is that mesh points are equally spaced
throughout the interval. The uniform distance between mesh points is referred to as a
step-size, denoted here as h, which is the value of t(i+1)−ti. This condition is ensured by
choosing a positive integer value N, setting step-size h = (b − a)/N, then selecting the
mesh points
𝑡𝑖 = 𝑎 + 𝑖ℎ,

(Eq. 4-2)

for each i = 0, 1, 2, …, N.
Euler’s Method can be derived from Taylor’s Theorem, and that derivation can be
found in Section 5.2 of Burden’s Numerical Analysis.[5] The resulting equation for
Euler’s Method is
𝑤0 = 𝛼,
𝑤𝑖+1 = 𝑤𝑖 + ℎ𝑓(𝑡𝑖 , 𝑤𝑖 )
for each i = 0, 1, ..., N – 1.

(Eq. 4-3)
(Eq. 4-4)
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This is called the difference equation associated with Euler’s Method. With
Euler’s method, truncation and round-off error is not a major issue for systems with a
short range of integration because relatively small time steps can be used without
excessive computation time.[5]
Euler’s Method was the first approximation technique tested on the system of
ordinary differential equations related to the PBPK model. The benefit of trying 115
Euler’s Method first is that linearity of the system is not necessary, so long as the initial
value problem is well-posed. Euler’s Method is simple and easily to implement.
However, as mentioned above, there are serious limitations to Euler’s Method, which
posed issues with the large, multifaceted ODE system needed to describe the PBPK
model.
Euler’s Method becomes unstable with a larger step size, so high accuracy and
low relative error is only possible with very small time steps. For problems where the
interval is reasonably small, one can use a small step size without suffering a long
computing time. However, in the case of many pharmacokinetic models, the interest in
the solution is the effect of the drug over some span of time. It was quickly apparently
that the PBPK model here needed a much smaller time step than was reasonable to
compute using Euler’s method. The computational burden was high due to the small time
step needed to capture the rapid change in concentration around each dose and the desired
length of time to capture the clearance of the drug and metabolite from the system. These
features of the PBPK model made Euler’s Method computationally costly, with the ratelimiting step being the step size h. To make this method generalizable for PBPK models,
a more efficient method was needed.
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4.1.2

Runge-Kutta Methods
Methods like Euler’s Method have the benefit of using the higher-order local

truncation error, but have other drawbacks as mentioned in the previous section. RungeKutta Methods also have the benefit of higher-order local truncation error but forego the
time-consuming process of calculating and evaluating the derivatives of the equation.
Runge-Kutta Fourth Order evaluates each equation four times per time step while
Euler evaluates each equation only once per time step. To make Runge-Kutta Fourth
Order more advantageous, a higher accuracy should be achieved at a step size four times
larger than for Euler’s Method. The formula for Runge-Kutta 116 Fourth Order contains
a weighted average of f(t, y) at points within the interval tn ≤ t ≤ t n+1 and is given by
𝑤0 = 𝛼,
𝑘1 = ℎ𝑓(𝑡𝑖 , 𝑤𝑖 ),
𝑘2 = ℎ𝑓 (𝑡𝑖 +

ℎ
1
, 𝑤𝑖 + 𝑘𝑖 ),
2
2

𝑘3 = ℎ𝑓 (𝑡𝑖 +

ℎ
1
, 𝑤𝑖 + 𝑘2 ),
2
2

𝑘4 = ℎ𝑓(𝑡𝑖+1 , 𝑤𝑖 + 𝑘3 ),
1
𝑤𝑖+1 = 𝑤𝑖 + (𝑘1 + 2𝑘2 + 2𝑘3 + 𝑘4 ),
6
for each i = 0, 1, ..., N − 1. This summation 1/6 (k1 + 2k2 + 2k3 + k4) is taken as an average
slope. In the equations above, k1 is the slope at the left side of the interval, k2 is the slope
at the midpoint using Euler’s formula from tn to tn + h/2, k3 is a second estimate of the
slope at the midpoint, and k4 is the slope at the right side of the interval, tn + h. As long as
the solution has five continuous derivatives, Runge-Kutta Order Four has a local
truncation error proportional to h5 for a finite time interval the global truncation error of
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at most O(h4). Compared to Euler’s method in the previous section, which has local
truncation errors proportional to h, h2 ,and h3 , Runge-Kutta Order Four should be two to
three orders of magnitude more accurate than Euler’s method and other Taylor derived
methods.[5]
The relative simplicity of the Runge-Kutta Order Four method and the improved
accuracy was the rationale for applying it to our PBPK model. As mentioned before, for
the same accuracy, the Runge-Kutta Order Four should be as accurate as Euler’s Method
with a step size four times as large. In practice, however, the step size still needed to be
extremely small to capture the rapid change following the dose. With the increased
complexity, the run times per iteration were actually much slower than with Euler’s
Method with only marginally better accuracy. It was apparent that there was a possibility
that the ODE system was having issues with stiffness.
4.1.2.1

Stiffness
A stiff differential equation is defined as an equation which becomes numerically

unstable when solved using certain numerical methods, unless an extremely small time
step is used. All approximation methods for initial value problems mentioned here, and in
general, include error terms that are derivatives of higher order than the solution to the
equation.[148] When the magnitude of the derivative increases but the magnitude of the
solution does not, there is no predictable error bound that can be used to estimate the
accuracy of the approximation. In these cases, the error can grow such that it dominates
the calculation. An equation having this property is said to be a stiff equation.[7]
Our large system of equations evidently had some stiff and some non-stiff
portions of only certain equations. In some cases, the volume that the concentration was
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divided by was much smaller in one compartment and much larger in others. For
example, when a concentration spread over a large volume, say the arterial blood, entered
a smaller compartment like the cellular sub-compartment of the kidney, there would often
be up to an order of magnitude of difference between the two volumes. As the drug
entered the compartment, the concentration or amount would spike orders of magnitude
as it was moved into a much smaller volume. This rapid change may happen at some time
point in one equation, while the major change in the venous blood would occur mainly at
the dosing intervals. In a complex system of 40 equations, these concentration spikes
could happen at many different times. The primary issue, however, was the rapid change
in concentration at each dose, which required a very small time step to capture the
injection profile, followed by a period of very little change as the drug cleared the
system. The very small time step needed over the first time interval was unnecessary for
the remainder of the time interval, but without it, the injection profile was not well
captured.
Of course, the human body is not divided into literal compartments, but the
physiological challenge of representing the systems of the body must be discretized in
some way. While these volume changes may not pose a problem in reality, these
compartmental surrogates for human organs pose a mathematical challenge to overcome.
The identification of the PBPK system as stiff led us to move on to more adaptive
methods that were designed to better control the error bound.
4.1.3

Adaptive-Step Runge-Kutta-Fehlberg
To address the issue of stiffness in the PBPK system, adaptive-step methods were

investigated. Adaptive methods incorporate error control, which adds an estimate of
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truncation error without requiring the approximation of higher-order derivatives of the
function.[7] In general, adaptive step methods will alter the step size as it moves through
the time interval, based on the amount of change occurring in the sub-interval. The
general idea is that given some tolerance ϵ > 0, the fewest number of mesh points could
be used to guarantee that the global error |y(ti)− wi| does not exceed the tolerance E
anywhere in the solution. This concept of setting a tolerance to which the error cannot
exceed is sometimes referred to as inequality in terms of error control.[5] While in
general the global error cannot be determined directly, there is a close correlation
between the local truncation error and the global error. To briefly summarize the idea, the
general concept of adaptive step methods is to use the fewest data points while not
exceeding a certain upper bound on error, which almost always requires that the step
sizes be unequally spaced. When considering computation time, this optimization of
number of mesh points is unnecessary for simple problems. In those cases, it may be
possible to use a fairly large step size with adequate accuracy and a short computation
time. However, in the case of stiff differential equations, the extremely small step size
needed to control the error in some subintervals carries high computational burden when
forced to apply a constant step size to the entire time interval.[148] As mentioned
previously, in cases of pharmacokinetic models, one of the components of interest is the
clearance of the drug, which can take anywhere from hours to days. For a stiff system in
this context, the extremely small time step for an interval of many hours or days is not
practical.
After already structuring the system for Runge-Kutta Method Order Four, the
Runge-Kutta-Fehlberg Method was a logical adaptive step method to implement first.
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The Runge-Kutta-Felhberg method estimates the local error of a fourth-order RungeKutta method,
25

1408

2197

1

𝑤𝑖+1 = 𝑤𝑖 + 216 𝑘1 + 2565 𝑘3 + 4104 𝑘4 − 5 𝑘5 ,

(Eq. 4-5)

by using a Runge-Kutta method with local truncation error of order five
16

6656

28561

9

2

𝑤
̃ 𝑖+1 = 𝑤𝑖 + 135 𝑘1 + 12825 𝑘3 + 56430 𝑘4 − 50 𝑘5 + 55 𝑘6

(Eq. 4-6)

Where the coefficient equations are
𝑘1 = ℎ𝑓(𝑡𝑖 , 𝑤𝑖 ),
𝑘2 = ℎ𝑓 (𝑡𝑖 +
𝑘3 = ℎ𝑓 (𝑡𝑖 +
𝑘4 = ℎ𝑓 (𝑡𝑖 +

ℎ
1
, 𝑤𝑖 + 𝑘𝑖 ),
4
4

3ℎ
3
9
, 𝑤𝑖 +
𝑘1 + 𝑘2 ),
8
32
32

12ℎ
1932
7200
7296
, 𝑤𝑖 +
𝑘1 −
𝑘2 +
𝑘 ),
13
2197
2197
2197 3

𝑘5 = ℎ𝑓 (𝑡𝑖 + ℎ, 𝑤𝑖 +

439
3680
845
𝑘1 − 8𝑘2 +
𝑘3 −
𝑘 ),
216
513
4104 4

ℎ
8
3544
1859
11
𝑘6 = ℎ𝑓 (𝑡𝑖 + , 𝑤𝑖 −
𝑘1 + 2𝑘2 −
𝑘3 +
𝑘4 −
𝑘 )
2
27
2565
4104
40 5
This Runge-Kutta method with the above coefficients define the Runge-Kutta
Fehlberg method and require only six evaluations of the function. This particular 120
method has an advantage over more arbitrary Runge-Kutta methods combining fourth
and fifth order. Such methods require at least four evaluations of the function for the
fourth-order method and six evaluations for order five, bringing the total to a minimum of
ten evaluations of the function per time step. This significantly decreases the computation
time.
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The difference in the two local truncation errors |w˜i+1−wi+1| is interchangeably
denoted as R and compared to the tolerance ϵ set by the user at the ithstep. This
comparison essentially determines the action to be taken on the step size using an
adjustment factor q. The value of q is used differently at each ith step depending on
whether or not R is greater than the defined tolerance ϵ. That is to say, whether the error
at that step is acceptable to the user.
If R > ϵ, the initial choice of the step-size h at the ith step is rejected and the
calculation is repeated using a different step-size qh. If R ≤ ϵ, then the error is within the
tolerance and the computed value at the ith step is accepted. The step size is changed to qh
for the (i + 1)st step.
Repeating function evaluations is costly, so q is usually chosen conservatively to
lessen the chance of R exceeding ϵ. For example, for the Runge-Kutta-Fehlberg method
with n = 4, is a common choice for calculation q. This convention was used when
evaluating the PBPK model of interest.[7]
𝑞 = (2|𝑤̃

1

∈ℎ

𝑖+1 −𝑤𝑖+1

= 0.84 (|𝑤̃

)4
|

(Eq. 4-7

1

∈ℎ

𝑖+1 −𝑤𝑖+1

)4
|

∈ 1

= 0.84 (R) 𝑛 ,

(Eq. 4-8)
(Eq. 4-9)

There are some optional additions to the algorithm that help eliminate large
changes in step size from one step to the next. This is done to reduce time spent using
small step sizes in regions with irregular derivatives of the function and avoid very large
step sizes that could skip over sensitive regions. If the only concern is error control, only
the step-size decrease procedure is needed and the step-size increase procedure could be
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omitted from the algorithm.[5] In the case of our PBPK model, the computation time was
a major inhibitor, so both procedures were implemented in the algorithm to save time.
When we executed the Runge-Kutta-Fehlberg Method, the accuracy improved
considerably. However, despite efforts to save computation time, it was still extremely
slow. The time step remained very small throughout the time interval, making it
somewhat infeasible for the model fitting and parameter estimation necessary for the
future purposes of our model. After much consideration and adjusting the model, it was
best to move on to another method for solving the system.
4.1.4

Summarizing Traditional Methods
The first method used to solve the system was Euler’s Method, since it is simple

and its structure is common to many other more complicated methods. It is a great option
for solving a system of linear equation as an initial value problem. However, the system
was unstable except for very small time steps. Computation was unacceptably slow due
to the length of the time interval needed for PBPK modeling. For better stability, the
Runge-Kutta Order Four was implemented to solve the system. This method evaluates
the function four times at each time point with the rationale that for the same accuracy as
Euler’s Method, a Runge-Kutta Order Four could use a step size four times larger. This
feature was attractive. Unfortunately, very small time steps were still necessary to solve
the system, and the complexity of the method actually slowed the computation down in
R. It was at this point that we realized the system had an issue with stiffness, so an
adaptive-step method – Runge-Kutta-Fehlberg Method – was applied. Using this method
greatly improved the accuracy of the solution and handled the stiffness. However, the
computation time was still too slow for practical purposes of model fitting.
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4.2.

Eigenvalue/Eigenvector Solution

The final method uses the eigenvalue/eigenvector solution to a system of linear
ODEs.[149] At its core, R has a suite of operators for matrix calculations. Because of its
design, matrix manipulation is computationally fast in R. Computation speed is critical
for model fitting and parameter estimation, especially for large models, because of the
need to calculate the solution many times. When using R, solving a system of equations
as a matrix should compute faster than when written directly as a system of subsequent
equations.[146]
In this method, the ODEs are represented as an n x n rate coefficient matrix (A) of
blood flow rates divided by compartment volume and an n x 1 initial condition matrix (x)
define a system of homogeneous equations.[7, 149]
x′=Ax

(Eq. 4-10)

In the homogeneous case, some of the injection profile is lost. The model only
captures the flow of drug through the body and its clearance, as if at t0, the full injection
amount exists in the venous blood compartment. The model realistically could only
capture bolus type infusions or quasi-instantaneous injections. This can be remedied by
the addition of a rate vector g(t), but this also makes the system non-homogeneous.
For a non-homogeneous system, the additional vector is added as shown below.
This column vector g(t) represents injection rate as a function of time. This systemnot
only allows for the infusion profile to be captured but also allows for more realistic
scenarios.
x′=Ax +g(t)

(Eq. 4-11)
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Very large systems of ODEs are often difficult to solve analytically, so in order to
show our method is accurate for large systems, we will walk through a smaller example
from Elementary Differential Equations by Boyce et al.[7] This simple example will be
written and solved in R and compared to the analytical solution to verify the accuracy of
the method choice and the code. The example will take the place of the formula for the
method, since it is a much clearer illustration than the direct definition.
4.2.1

Simple Homogeneous Example
Consider the simple homogeneous case,
−2 1
) 𝑥 = 𝐴𝑥.
1 −2

𝑥′ = (

(Eq. 4-12)

The coefficient matrix A is real and symmetric, and we assume that x = ξert , we
obtain the algebraic system,
−2 − 𝑟
1

(

1
) (𝜉1 ) = (00).
−2 − 𝑟 𝜉2

(Eq. 4-13)

The Eigenvalues satisfy
(−2 − r)(−2 − r) − 1 = r2 + 4r + 3 = (r + 3)(r + 1) = 0

(Eq. 4-14)

so r1 = −3 and r2 = −1. For r = −3, Equation 4.13 becomes
(

1 1 𝜉1
) ( ) = (00).
1 1 𝜉2

(Eq. 4-15)

Hence, ξ2 = ξ1 and the corresponding eigenvector ξ(1) corresponding to the
eigenvalue, r1 = −3 can be taken as
𝜉 (1) = (11)

(Eq. 4-16)

Similarly, for r = −1, Equation 4-13 becomes
(

−1 1
) (𝜉1 ) = (00).
1 −1 𝜉2

(Eq. 4-17)
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Hence, ξ1 = ξ2 and the corresponding eigenvector ξ(2) corresponding to the
eigenvalue r2 = −1 can be taken as
1
𝜉 (2) = (−1
)

(Eq. 4-18)

Thus, a fundamental set of solutions for the system in Equation 4.12 is
1
𝑥 (1) (𝑡) = (11)𝑒 −𝑡 , 𝑥 (2) (𝑡) = (−1
)𝑒 −3𝑡 .

(Eq. 4-19)

and the general solution is
1
𝑥 = 𝑐1 𝑥 (1) (𝑡) + 𝑐2 𝑥 2 (𝑡) = 𝑐1 (11)𝑒 −𝑡 + 𝑐2 (−1
)𝑒 −3𝑡 .

(Eq. 4-20)

The general solution of the homogeneous case is key to obtaining the particular
solution for the non-homogeneous case. The fundamental matrix Ψ(t) is the starting point
for nearly all methods of solving non-homogeneous systems. Ψ(t) obtained from the
general solution by the following method.[7]
4.2.2

Simple Non-Homogeneous Example
Suppose that that x(1), ..., x(n) form a fundamental set of solutions as in Equation

4.19 for the equation
x′ = P(t)x

(Eq. 4-21)

on some interval α < t < β. Then the matrix
(1)

𝑥1 (𝑡) ⋯
Ψ(t) = ( ⋮
⋱
(1)
𝑥𝑛 (𝑡) ⋯

(𝑛)

𝑥1 (𝑡)
⋮ )
(𝑛)
𝑥𝑛 (𝑡)

(Eq. 4-22)

whose columns are the vectors x(1), ..., x(n) is said to be a fundamental matrix for the
system. So, for the example above, the fundamental matrix is
−𝑡

Ψ(t) = (𝑒 −𝑡
𝑒

𝑒 −3𝑡 )
−𝑒 −3𝑡

which is useful for solving the non-homogeneous system,

(Eq. 4-23)
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−𝑡
−2 1
𝑥′ = (
) 𝑥 + (2𝑒3𝑡 ) = 𝐴𝑥 + 𝑔(𝑡).
1 −2

(Eq. 4-24)

We use Variation of Parameters to solve this system. The solution x of this system
is given as x = Ψ(t)u(t), where u(t) satisfies Ψ(t)u(t) = g(t), or
−𝑡

(𝑒 −𝑡
𝑒

′
𝑒 −3𝑡 ) (𝑢1 ) = (2𝑒 −𝑡 )
−𝑒 −3𝑡 𝑢2′
3𝑡

(Eq. 4-25)

By left-multiplying the fundamental matrix on both sides, the ut (t) vector can be
obtained. This approach is used in the consequent code, but for now, the following
equations are obtained by row reduction.
3

3

𝑢1′ = 𝑒 2𝑡 − 2 𝑡𝑒 3𝑡 , 𝑢2′ = 1 + 2 𝑡𝑒 𝑡 .

(Eq. 4-26)

x = Ψ(t)u(t)

(Eq. 4-27)

Hence,

1 1
1 4
1
1
1
1
= 𝑐1 ( ) 𝑒 −𝑡 + 𝑐2 ( ) 𝑒 −3𝑡 + ( ) 𝑡𝑒 −𝑡 + 2 ( ) 𝑒 −𝑡 + ( ) 𝑡 − 3 ( ) .
5
1
−1
1
−1
2

(Eq. 4-28)

The determine the integration constants, the system should be solved at some time
point in the interval. For the remaining points in the solution, the integration constants c1
2

and c2 do not change. For instance, when x0 = 0, t = 0, constants c1, c2 are - 3 and
3
2

, respectively. [7] Those constants will remain true as long as the initial conditions and

equations do not change.
Once these integration constants are determined, this process provides a solution
to the system at any specified time. Its major limitation being it only produces a solution
for the last time point, which should be a reasonably small time interval in order to
capture the change in y adequately. However, we are able to use that solution as the initial
condition for the next iteration of the function.
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4.2.3

Numerical Integration: Series of Eigenvalue/Eigenvector Solutions of
Initial Value Problems
This small non-homogeneous system is solved in preparation for the ultimate goal

of the solving a large system of equations. This larger physiological system will be
solved over a fairly long time interval since the clearance of the drug from the body, a
behavior of interest, can be many hours or days long depending on the half-life of the
drug. Because this large time interval is much greater than a suitable interval for a single
iteration of our Eigenvalue/Eigenvector solution described in the previous section.
Instead, the solution to a sufficiently small time interval will become the new initial
condition for the next iteration of the method. These exact solutions are then to be
integrated over using a numerical integration method. Numerical integration is needed
since in some cases, there is no explicit or easy obtainable anti-derivative to be calculated
for the equations of the system. [150]
Numerical integration is based on a summation technique called numerical
𝑏

quadrature, which simply means using a sum ∑𝑛𝑖=𝑜 𝑎𝑖 𝑓(𝑥𝑖 ) to approximate ∫𝑎 𝑓 (𝑥)𝑑𝑥.
The method requires choosing a set of distinct points on the interval [a, b]. From the
chosen points, numerical quadrature calls for integrating over a Lagrange interpolating
polynomial. Common methods that use Lagrange interpolating polynomials with equally
spaced points include the Trapezoidal Rule and Simpson’s Rule. These types of methods
are in the family of Newton-Cotes formulas. More detail and derivations for these
techniques in Section 4.3 of Burden’s Numerical Analysis.[5] Using a Taylor Series
expansion and the Weighted Mean Value Theorem for Integrals gives Simpson’s 1/3
Rule:
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𝑥

ℎ5

ℎ

2
∫𝑥 𝑓(𝑥)𝑑𝑥 = 3 [𝑓(𝑥0 ) + 4𝑓(𝑥1 ) + 𝑓(𝑥2 )] − 90 𝑓 (4) (𝜉(𝑥)).
0

(Eq. 4-29)

Notice in Equation 4.29 that the error term in Simpson’s Rule involves the fourth
derivative of 𝑓, meaning it gives an exact result when applied to a polynomial of degree
three or less. In contrast, the error term of the Trapezoidal rule ( can only give an exact
result for a polynomial of degree one. When choosing a numerical integration technique,
Simpson’s Rule was preferable simply due to its improved accuracy. Aside from the
higher-order derivative in the error term, the midpoint calculation included in Simpson’s
Rule gives the approximation more balance. Returning to the problem, the integration
from x0 and x2 using Simpson’s Rule described in Equation 4.29 are replaced by some
u′(t) from Variation of Parameters (recall Equation 4.26). We obtain the values for each
time point τ by solving u′(t) at an odd number of time points.[5] This integral effectively
replaces the integral portion of the equation since u′(t) is obtained by multiplying the
inverted fundamental matrix by the ‘g vector’ at the given time interval.[7]
𝑡

𝑥(𝑡) = Φ(𝑡)𝑥 0 + Φ(𝑡) ∫𝑡 Φ−1 (𝑠)𝑔(𝑠)𝑑𝑠,
0

(Eq. 4-30)

Once x(t) is calculated, it becomes the new initial condition for the next iteration;
thus becoming a series of initial value problems. The schematic of the general process is
shown in Figure 4-1 and the model code is available in Appendix E.

Figure 4-1: A schematic of the general process of the matrix-based numerical method
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Figure 4-2 shows that the accuracy for larger step sizes is comparable to smaller
ones. The previous examples show that the concept of utilizing an eigenvalue /
eigenvector solution with numerical integration is a valid technique for solving large
systems of ordinary differential equations. However, one of the primary issues with the
physiological system of interest is stiffness.

Figure 4-2: Solutions to 2 x 2 example, solved with three different step-sizes and
compared to the exact solution at each time point. The accuracy compared to the step-size
here demonstrates the negligible loss of accuracy for larger step sizes using this method

For stiff systems, there are even more appropriate numerical integration
techniques that can be implemented to improve efficiency. Similar to the Adaptive-Step
Runge-Kutta-Fehlberg method discussed in Section 4.1.3, numerical integration methods
can be extended to adaptive numerical quadrature methods. Recalling that, in general,
adaptive step methods seek to use the fewest data points while not exceeding a certain
upper bound on error. This goal is rarely achieved with equally spaced points. Instead,
adaptive step methods adjust the step size with each iteration, depending on the amount
of change occurring in that particular 130 time interval. The primary issue with stiffness
is the need to maintain a very small step size in order for the system to be stable.[7, 148]
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A small time step size over long time periods cause concern with computational
efficacy. For the purposes of this work in solving the 44 compartment PBPK model,
using the matrix framework allowed for even models with time intervals spanning up to
96 hours at step sizes of 0.05 to solve within minutes. The issue of stiffness, while still
present in this model system, did not hinder the computation speed enough to justify the
additional effort and complexity. Therefore, a more complex adaptive method would not
add a necessary improvement in this case. Were this method to become necessary for a
particularly stiff physiological system, the following approach would be appropriate for
varying the step size.
4.2.3.1

Adaptive Numerical Integration
If a more efficient option had become necessary, this matrix method could be

further generalized by equipping the method to solve both stiff and non-stiff systems. For
large systems with significant changes in some time intervals and not in others, the issue
of stiffness could be remedied by implementing an adaptive numerical integration
technique to increase computation efficiency. Since the structure of Simpson’s Rule was
already present for the matrix method, it would be intuitive to choose the adaptive step
method corresponding to Simpson’s Rule - Adaptive Composite Simpson’s Rule. First,
we must briefly explain the structure of Composite Simpson’s Rule in order to move on
to the adaptive version. The primary difference in Simpson’s Rule and Composite
Simpson’s Rule is how the step-size h is calculated. While Simpson’s Rule calculates h
as (b − a)/2, Composite Simpson’s Rule uses h = (b − a)/n for any positive even integer
n. This gives the flexibility of subdividing the interval [a, b] into n even sub-intervals
instead of 2 in regular Simpson’s Rule’s. In general, Newton-Cotes methods like
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Simpson’s Rule, Trapezoidal rule, and the like, are less suitable for long integration
intervals than piece-wise methods. Composite Simpson’s Rule is one such method that
uses a lower-order Simpson’s Rule. To maintain accuracy over a large interval, a highdegree formula would be required since higher-degree polynomials tend to oscillate.
Coefficients for high-order formulas are difficult to obtain, so using a lower-order
Newton-Cotes formula like Simpson’s Rule for a piece-wise approach is beneficial. The
lower order derivative The lower order derivative in the error term is compensated for by
the ability to make the step-size h considerably smaller for intervals with considerably
more change. This method is outlined in Section 4.4 of Burden’s Numerical Analysis,
specifically in Algorithm 4.1. Composite Simpson’s Rule is the most frequently used
quadrature algorithm for general purposes.[5]
Then, with the added advantage of choosing an even integer value for n, Adaptive
Composite Simpson’s Rule uses Algorithm 4.3 in Section 4.6 of Burden’s Numerical
Analysis to continue to divide sub-intervals into increasingly more sub-intervals for areas
where there is great change until the error is below some tolerance. In Algorithm 4.3, the
error is determined using the difference between the approximation of Simpson’s Rule
and the approximation for the summation of the approximations for the halved subintervals. In other words, if the total interval a to b is bisected by c, then the Algorithm
calculates from a to midpoint c with a midpoint between. The same process is done for
the sub-interval c to b. The sum of the approximations of those two halves are compared
against the original Simpson’s Rule approximation to see if error falls within a tolerance.
If it does, the approximation is accepted, and the integration progresses to the next timestep. If it does not, each half sub-interval is halved again, and the process described above
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is carried out on each of the two new halves.[5] For very tricky systems, this algorithm
could be a great solution, and it may be interesting to consider for future work.

4.3

Comparison of Methods

Unlike the traditional numerical methods, this matrix method is not susceptible to
issues with stiffness since the analytical solution for each time interval is calculated and
then numerically integrated using Adaptive Composite Simpson’s rule. It allows the
modeler to use an adaptive time step, maintaining fewer mesh points for the same
accuracy. Thus, any linear or approximately linear system can be described using this
method in a more efficient way than traditional adaptive-step methods. This textbook
example solved analytically and using this matrix-based numerical approach served as an
initial validation for the R code. As mentioned in earlier sections, the overall process for
solving any system of linear ordinary differential equations is broken down into a few
matrices that go into one simple function and output a matrix of concentrations from the
initial time to the final time at increments of two times the step size (Figure 4-3). The
increments are twice the step size due to the numerical integration in Composite Simpson
rule. The function in R contains all the matrix manipulation shown in the sections for
Variation Parameters along with the implementation of Simpson’s 1/3 Rule for the
integration over time.
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Figure 4-3: A more detailed flow of the inputs and outputs of the matrix-based numerical
method

4.4
4.4.1

Compartmental Model Examples

Three-Compartment PK Model Example
Once the functions for calculating the solutions were trustworthy, we were wary

of making a jump from a 2 x 2 matrix example to a 40 x 40 complex physiological
system without an intermediate step. From the literature, a simple three-compartment
pharmacokinetic model of Remifentanil was chosen.[151] This model was described by
three coupled first-order ordinary differential equations that were clearly published in the
paper with all necessary parameters and plots, making it ideal for reproduction for
validation. The equations shown below describe the model in Figure 4-4.
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Figure 4-4: A traditional representation of a three-compartment pharmacokinetic model
described by Cascone et al

Central Compartment
V1

𝑑𝐶𝑝
𝑑𝑡

= −CL1C1 + k21V2C2 + k31C3V3 − [(k12 + k13 + k10)C1]V1 + I(t)

Highly Perfused Compartment
V2

𝑑𝐶2
𝑑𝑡

= k12C1V1 − k21C2V2 − Cl2C2

Scarcely Perfused Compartment
𝑑𝐶

V3 𝑑𝑡3 = k13C1V1 − k31C3V3 − Cl3C3
Instead of representing the system in the traditional equation format, the same
equations can be represented in matrix format as shown below, where the matrix A
represents the rate coefficients and parameters, x represents the initial conditions, or in
this case, the initial concentrations, g(t) is the dose vector, and x′ is the solution to the
system at a given time.[7]
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𝐶𝑙1

(

𝑘21 𝑉2 /𝑉1

𝑘31 𝑉3 /𝑉1
− (( 𝑉 ) + 𝑘12 + 𝑘13 + 𝑘10 )
1
𝐶𝑙2
0
−(( 𝑉 ) + 𝑘21 )
𝐶𝑙
3
2
𝑘12 𝑉1 /𝑉2
−(( 𝑉 ) + 𝑘31 )
0
3
𝑘 𝑉 /𝑉
13 1

3

( 0 )

𝐶2

+

) (𝐶3 )

𝑑𝐶1 /𝑑𝑡

𝐼(𝑡)
0

𝐶1

=

𝑑𝐶2 /𝑑𝑡

(Eq. 4-31)

(𝑑𝐶3 /𝑑𝑡)

Instead of attempting to solve directly for the analytical solution over the twohour span of observations, a plot from the paper digitized paper and compared it to the
solution generated by our matrix method. The observations overlaid on our model
predictions using the author’s parameters are shown in Figure 4-5. As you can see, the
model fit is good, and the curve is comparable to the curve generated by the original
authors. [151] The source R code for this model example is available in Appendix C.

Figure 4-5: Plot of observed versus model predicted values for the human Remfentanil
model, illustrating that the pbpkme method works at least as well as traditional numerical
methods on classic compartmental pharmacokinetic models
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4.4.2

Physiologically-Based Pharmacokinetic (PBPK) Example
The solutions from the three-compartment model were validation enough to move

forward to this forty compartment PBPK model of doxorubicin (DOX) from literature,
which is the model of interest. There were too many equations to reasonably list them all
for the purpose of this paper, but the full equations can be found in the online
Supplementary Material from the original paper.[8] The general schematic of the PBPK
model (Figure 4-6) is complex in itself, including both bound and unbound drug for five
non-metabolizing compartments, two blood compartments, two metabolizing
compartments with three sub-compartments each, for both the parent drug, doxorubicin,
and the metabolite, doxorubicinol.

Figure 4-6: Plot of observed versus model predicted values for the human Remfentanil
model, illustrating that the pbpkme method works at least as well as traditional numerical
methods on classic compartmental pharmacokinetic models

The metabolism from DOX to DOXol in this model is described by MichaelisMenten kinetics[83], and for DOX, the substrate concentration is negligibly smaller than
the Michaelis constant.[17, 66, 128] This means the reaction rate and concentration are
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directly proportionate to each other, the reaction remains first-order linear. The two
equations highlighted in Figure 4-6 show that these types of models, while described by
first-order ordinary differential equations, have considerable complexity in addition to
dimensionality.
It should be little surprise that a system like this would run into issues of stiffness
and computational efficiency. Just like in the previous three-compartment model, we
represent the differential equations in matrix format. The detail in a model this large
complex would make the actual matrix unreadable here, but the structure is shown above.
The matrix components, A, x, g(t),and xt retain the same meaning as in the threecompartment model.[7, 151] This matrix structure is universal no matter how many
ordinary differential equations are in the system, which makes it generalizable. With the
variety and complexity of mathematical models needed throughout the field of
pharmaceutical sciences, this structure is ideal for application in pharmacometrics.
(

−(𝑄1 /𝑉1 ) ⋯
⋮
⋱
−(𝑄1 /𝑉𝑛 ) ⋯

(𝑄𝑛 /𝑉1 ) 𝐶10
𝑑𝐶10 /𝑑𝑡
⋮
⋮
)( ⋮ ) = (
)
(𝑄𝑛 /𝑉𝑛 ) 𝐶𝑛0
𝑑𝐶𝑛0 /𝑑𝑡

(Eq. 4-32)

No exact solution can be computed for this model, so another visual predictive
check was implemented for validation. A plot from the original paper[8] was digitized
and compared to the solution generated by the matrix-based method, and the results are
shown in Figure 4-7. The red dashed line is from literature, and the matrix solution is in
blue – you can see they overlay almost exactly, which was an excellent validation that
this method works.
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Figure 4-7: Predictions from the model solved with the matrix-based numerical method
overlaid on the predictions generated by the digitized predictions from Dubbelboer et al.

4.5

Conclusion

Linear systems of ordinary differential equations have limitless application in all
fields of study and in countless real-world problems. Combining two established methods
– Variation of Parameters[7] and Simpson’s 1/3 Rule[5] – gives an elegant framework for
solving any linear system of ordinary differential equations, but especially those dealing
with stiffness and long computation time. In those cases, this matrix-based numerical
method is likely to perform better than many traditional methods when solved in R. Stiff,
high-dimensional ODE systems are unsurprisingly common in PK and PBPK models,
since they are characterizing a physiological system. One limitation to this method is that,
as briefly mentioned in Section 2.2.1, there is an assumption of linearity. The systems of
equations for most PBPK models can be assumed to be linear or can be linearized. This
assumption can generally be made since there is physiological reality tied to the bounds
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on the parameters. These bounds are generally of such small magnitude that in practice,
concentration values never reach a point that the behavior cannot be captured with linear
or first-order kinetics.[36, 68, 152] Most often, non-linearity occurs when, at some time
point, a critical concentration is reached where the binding or metabolism kinetics causes
non-linear clearance.[153] If a non-linear system of differential equations is necessary to
describe the system, several approaches have been applied successfully to these PBPK
models. Some of these approaches include Runge-Kutta methods and inductive methods
of generating approximations for these non-linear systems using iterative linearization as
described by Duffull.[152] PK and PBPK modeling are becoming standard of practice for
many regulatory agencies, and because of that, most major players in the pharmaceutical
industry prefer to use PK and PBPK modeling at some point in their pipeline.[154]

CHAPTER 5
INTER-SPECIES SCALING
In the previous sections, a whole-body minimal PBPK model of DOX was
developed by modifying a previous porcine model from literature.[8] The purpose of the
PBPK model was to estimate the behavior of DOXol in the heart in order give better
insight into dose adjustments for DOX due to its limiting cardiotoxicity. Next, a matrixbased method was developed for efficiently solving large, complex systems of
differential equations that describe the PBPK model.[6, 5] While the ability to achieve
insight into DOXol concentration in the heart of a mouse, a rat, or even a pig is useful for
gaining a deeper understanding of DOX, it is less useful clinically. Since the availability
of data of DOXol in the heart is virtually non-existent in humans, it becomes necessary to
accurately scale the parameters in the model from the sub-clinical species that do have
the heart DOXol concentrations. In the case of the data collected for this dissertation, the
only DOXol concentration versus time data in the heart available was in a mouse model.
Thankfully, extrapolation across species of common pre-clinical animals is a central
process in pharmaceutical research and development.[155]

5.1

Allometry Concepts

One of the most common ways of this inter-species extrapolation is through
allometry. Allometry is broadly defined as the study of size and its consequences. The
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term first originated in engineering and was coined by Huxley and Tessier in 1936 to
describe properties that change proportionally with size.[156] Just a few years later,
Benedict demonstrated that basal metabolic rate (BMR) did not scale linearly with body
weight by plotting total heat production against body weight. Kleiber defined the
metabolic rate for mammals by the allometric equation:
Pmet = 70 × M 3/4

(Eq. 5-1)

which is still widely used today.[156] The concept of allometric scaling was originally
based on the power-log relationship that exists between the body weight and drug
clearance in mammals. The general form of this power function is:
Y = aWb

(Eq. 5-2)

where Y is the new parameter or parameter of interest, a is the coefficient, W is the body
weight of the subject, and b is the exponent of the allometric equation. The parameters a
and b are fitted empirically where the exponent b is the slope of the regression line when
plotted on a log-log scale.[157]
Allometric scaling methods have been modified and updated for the past several
decades and have become a fast and convenient way to either interpolate or extrapolate
pharmacokinetic parameters between species.[156] It is one of the most commonly used
methods for scaling clearance from sub-clincal species to humans.[158] However, studies
have indicated that drug clearance cannot, in every case, be reliably predicted by just
Equation 5-2.[157]. Some improvements have been made over the years to bolster the
predictive ability of allometric scaling. Adjustments for brain weight (BRW), maximum
life-span potential (MLP), unbound fraction in plasma, liver blood flow (LBF) methods,
and corrections for metabolic clearance.[159, 160, 161, 162, 163] As is true with most
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applied mathematical methods, different allometric scaling methods have advantages and
disadvantages, and in some cases, more sophisticated inter-species scaling methods are
necessary.[156] The main benefit to single-species allometry is its cost effectiveness.[9]
For the model described throughout this work, simple allometry was used to scale
parameters between species.

5.2

Inter-Species Scaling of Doxorubicin

The most common pharmacokinetic parameters extrapolated using allometry are
clearance, volume-of-distribution, and elimination half-life.[164] In DOX, these three
parameters have been identified as having high inter-patient variability as well as interoccasion variability. The inter-species scaling of pharmacokinetic parameters like
clearance is generally well-predicted using simple allometry for both macro-molecule
drugs and small-molecule drugs that are excreted renally. Small molecules that are
hepatically eliminated, however, tend to have higher prediction error using simple
allometry, even with multiple species. The prediction error is generally linked to
hepatically eliminated, small-molecule drugs that have low hepatic extraction ratio
(Eh).[9] The hepatic extraction ratio is a drug-specific parameter that is a combination of
several other drug-specific physiological PK parameters - fraction of unbound drug in
blood, hepatic intrinsic clearance of unbound drug, and hepatic blood flow.[165]
Fortunately, prediction error has been shown to be reduced by correcting the simple
allometric equation by Maximum Life-Span Potential (MLP) or brain weight (BRW).[9]
The MLP and BRW for mouse, rabbit, dog, pig, and human are listed in Table 5-1.
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Table 5-1: Calculated Maximum-Lifespan Potential and Brain Weight - Values
Commonly Used as Correction Factors for Inter-Species Scaling of Hepatically
Eliminated Drugs like DOX in Several Laboratory Animals and to Humans (Source [161,
166, 167, 168, 169])
Correction Factors for Allometric Scaling
Species
Calculated MLP (years)
Brain Weight (% body weight)
Mouse
2.67
1.65
Rat
4.70
0.72
Rabbit
8.00
0.39
Dog
19.70
0.78
Pig
11.40
0.50
Human
93.40
2.00

For small-molecule drugs like DOX, even single species allometry with a fixed
allometric exponent can be useful. Finding a single best value for the allometric exponent
is difficult, but in general, allometric exponent values of between 0.65 and 0.70 give
acceptable predictions for common PK parameters across species and to humans.[9]
5.2.1

Determination of Model Parameters
For the inter-species scaling performed in this work, physiological parameters for

mouse, rat, rabbit, dog, pig, and human were obtained from literature. The data was
collected by digitizing plots using the Quintessa Graph Grabber software.[170] Sampling
times were recorded from literature, when available, and the data series’ pulled from the
graphs were pulled at those time points with reasonable accuracy. Some of the graphs
were from very old studies and had poor image quality. Some graphs for DOX and
DOXol have very long observation times that were measured in hours due to the long
half-lives of DOX and DOXol (recall Table 3-1).[31, 32] In these cases especially, it was
difficult to distinguish between a 5 and 15 minute time point on a graph. It is understood
that some additional variation was introduced with human error. However, for all the
digitized data, the shape and magnitude were congruous with that of the original data
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presentation. Any units for dose or concentration measurements were standardized to µM
for consistency. For weight-adjusted dosing by body weight in kilograms, the reported
mean weight of the subjects was used. If no mean weight in kilograms was reported,
accepted average values were used.[171] Similarly, in larger mammals and in human,
body surface area (BSA) is a common way to adjust dosing by size.[118] If BSA was
used in dose calculations, the BSA was estimated using mass in kilograms with
conversion factors from Nair et al.[171] Dose volumes, if not given explicitly in the paper
or supplementary information, were taken from recommended industry dosing guidelines
for laboratory animals.[172]
Since the original model from which our matrix model was adapted was a pig
model [8], the pig parameters were the initial values used. As such, several specific
parameters that were incorporated into the model were not readily available in literature.
One reason for this is that the Dubbelboer pig model was designed as a minimal PBPK
model, as noted in Section 3.5. A notable advantage in the Dubbelboer model is its
simplified approach to association/dissociation constants - Clon and Cloff - as opposed to
the traditional approach of assigning compartment specific partition coefficients
(generally denoted as Kp,u,tissue). The benefit of this approach is that it helps keep a rather
complex model from becoming over parameterized. The Dubbelboer model also included
several binding parameters which are similar but nuanced. The Fup,DOX and Fup,DOXol
represents the formal fraction of the tissue compartments that were unbound. The
movement between the bound and unbound compartments were dictated by the Clon and
Cloff parameters. The intracellular binding site, designated as bind site, represents the
volume the tissue compartment that was available for binding. It is a surrogate for the
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arbitrary volume for the nucleus of the tissue’s cells, DNA, and cardiolipin. This fraction
represents all intracellular binding sites for DOX and DOXol. The value for bind site was
set to 0.2, to represent the extensive binding of DOX to intracellular structures within
tissues. In other words, effectively 20% of the tissue volume is available for binding in
most compartments. The only exception being the kidney, liver, and heart, in which the
cellular sub-compartment is the only portion that contains intracellular binding sites. This
effect was accomplished by multiplying the volume fraction (Tables 5.2 and 5.3) by bind
site for the bound tissue compartment and (1-bind site) for the unbound tissue
compartment.

Table 5-2: Fraction of Body Weight of Each Sub-Compartment Within the Kidney and
the Liver Originally Determined in the Dubbelboer Pig Model and Used Throughout All
Species in this Inter-Species Scaling (Source [8])
Sub-Compartment Breakdown of Volume in Liver and Kidney
Kidney - Vascular
0.05
Kidney - Extracellular
0.159
Kidney - Cellular
0.791
Liver - Vascular
0.055
Liver - Extracellular
0.159
Liver - Cellular
0.786
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Table 5-3: Fraction of Total Body Weight for Each Respective Compartment for Each
Species used in Inter-Species Scaling of DOX. The Pig Parameters in Both Tables were
Adapted from Dubbelboer.[145] Mouse, Rat, Dog, and Human Parameters were Adapted
from the International Life Sciences Institute Resource.[173] The parameters for the
Rabbit were Adapted from a Meta-Analyses Done by Davies.[174]
Physiological Parameters for Various Sub-Clinical Species
Mouse
Rat
Rabbit
Dog
Volume (Fraction of Total Body Weight)
Blood
0.049
0.075
0.082
0.082
Lung
0.007
0.006
0.0085
0.008
Heart
0.005
0.025
0.003
0.008
Kidney
0.017
0.008
0.0075
0.005
GI/Spleen
0.099
0.071
0.0604
0.08
Liver
0.055
0.035
0.0499
0.033
Slow Perfused
0.726
0.718
0.674
0.779
Rapid Perfused
0.042
0.064
0.115
0.008

Pig

Human

0.0553
0.0109
0.005
0.0055
0.0861
0.0316
0.7154
0.0952

0.079
0.025
0.005
0.004
0.031
0.026
0.794
0.053

However, it posed a challenge for finding equitable parameters in the literature
that represented these universal association and dissociation constants. Additionally,
intra-organ clearance parameters that represented passive diffusion (Pdiff ) and membrane
clearance (Clmem) were universal for all compartments, which is less common in PBPK
modeling. Even more so, the original Dubbelboer model did not include a heart
compartment, which was vital to the research question of this work. In order to maintain
the mass balance of drug in to drug out, original values of the physiological parameters in
the Dubblelboer had to be adjusted.
A wealth of parameter data for a range of species was found in a meta-analysis of
the literature by the International Life Sciences Institute. This resource was used to
properly adjust the volume fractions to a physiologically relevant balance that included
the heart.[173] The exact breakdown of the sub-compartments of the liver and kidney and
the combination of tissues given specific compartments versus lumped into slow or rapid
perfused tissue were unique to the Dubbelboer model. In order to create physiological
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parameter sets analogous to the structure of the Dubbelboer model, values from literature
were used to determine realistic values for each of the compartments included in the
model.[173] The final physiological parameters in the model are listed in Table 5-2,
Table 5-3, and Table 5-4.

Table 5-4: Fraction of Total Cardiac Output for Each Respective Compartment for Each
Species used in Inter-Species Scaling of DOX. The Pig Parameters in Both Tables were
Adapted from Dubbelboer.[145] Mouse, Rat, Dog, and Human Parameters were Adapted
from the International Life Sciences Institute Resource.[173] The Parameters for the
Rabbit were Adapted from a Meta-Analyses Done by Davies.[174]
Physiological Parameters for Various Sub-Clinical Species
Mouse
Rat
Rabbit
Dog
Blood Flow (Fraction of Cardiac Output)
Portal Vein
0.14
0.153
0.264
0.46
Hepatic Artery
0.02
0.021
0.0698
0.251
Lung
1
1
1
1
Heart
0.066
0.049
0.0302
0.046
Kidney
0.091
0.141
0.151
0.173
GI/Spleen
0.14
0.153
0.226
0.046
Liver
0.161
0.141
0.334
0.297
Slow Perfused
0.217
0.528
0.292
0.277
Rapid Perfused
0.033
0.023
0.0604
0.022

Pig

Human

0.21
0.05
1
0.04
0.114
0.21
0.114
0.05
0.536

0.18
0.047
1
0.04
0.175
0.18
0.175
0.342
0.13

The pig parameters in all three tables were adapted from Dubbelboer.[145]
Mouse, rat, dog, and human parameters were adapted from the International Life
Sciences Institute resource.[173] The parameters for the rabbit were adapted from a metaanalyses done by Davies.[174] In Section 3.5, the structure of the sub-compartments of
the metabolizing compartments were illustrated in Figure 3-3 for organs with both
metabolism and excretion - liver and kidney- and Figure 3-4 for metabolism only - the
heart. Note that since the heart compartment was not included in the original model,
equivalent tissue parameter breakdowns for the sub-compartment of the heart as a
metabolizing compartment were not available.[8] The kidney values for the fraction of
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the compartment that is vascular, extracellular, and cellular were used for the heart
compartment. The rationale for this was that the kidney and heart were closer in total
body volume (Table 5-3) and fraction of cardiac output (Table 5-4). Additionally, in
Section 1.3.1, it was discussed higher DOX and DOXol concentrations per gram than the
heart but were not major sites of toxicity. A reason cited for this paradox is that the liver
and kidney contain a greater number of inactivating and binding enzymes that reduce the
toxic effect and eliminate the parent drug. As mentioned, DOX is hepatically eliminated
so one possibility is that the concentration of inactivating and eliminating enzymes is
higher in the liver. The heart tissue does not contain the as high of a concentration per
gram of those enzymes that a true metabolizing and excreting organ would. Thus, the
liver may be a less suitable analog for the heart than the kidney, which is known to be
responsible for less metabolism of DOX. Additionally, Table 1-2 from a human autopsy
study done in humans showed that the concentration per gram of DOX and DOXol in the
heart was more similar to the kidney.[40]
As shown in Table 1-2, the liver and kidney both have higher concentrations per
gram than the heart. Higher DOX and DOXol concentrations in the liver and kidney are
also observed in animal species.[63, 64] However, the liver and kidney are not major
sites of toxicity for patients receiving DOX, which leads to conjecture other factors
differentiating DOX and DOXol behavior in tissues. One such conjecture is that liver and
kidney tissues are rich in binding and inactivating substances due to their excretory and
metabolic functionalities, which prevent DOX and DOXol from causing cellular damage
in those tissues.[40] For example, reduced DOX toxicity is observed in the presence of
glutathione - a common antioxidant found in the liver.[65]
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As mentioned before, the initial parameter set used in the Dubbelboer PBPK
model was the starting point for estimating parameters in the Final PBPK Model. Most
parameters from the Dubbelboer were retained except for a few parameters that were
adjusted to accommodate the addition of the heart compartment, as a metabolizing
compartment, into the model. These parameters were used as the starting values for the
sensitivity analysis in the following section and are listed in Table 5- 5 and Table 5-6.
Table 5-5: Results of Sensitivity Analysis as Shown by Percent Change in the Objective
Function Value (Inner Cells of Table) Given a Percent Change (Top Row in Table) in
Parameter (Leftmost Column), Ranked from Most Change to Least Change
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Table 5-6: The First Section Contains Parameter Values with Variability in Percent
Coefficient of Variation Reported by Dubbelboer Et Al. [8] if no %CV Is Reported, then
the Parameter was Assumed or Taken from Literature by The Authors. The Second
Section Contains Parameters that were Estimated for the New Model, Based on the
Dubbelboer Model, Containing the Heart Compartment. These Parameters Remained
Constant Across All the Data Sets Used in Scaling
Parameters in the Final Model
Parameters Directly from Dubbelboer et al.
Parameter

Value (%CV )

Pdiff,DOX
15
Pdiff,DOXol
15
Clmem,DOXol
0.00357 (52)
Clon,DOXol
0.109 (38)
Cloff,DOX
0.000115 (11)
Clexcr,ki,DOX
0.215 (24)
Clexcr,ki,DOXol
0.0154 (42)
Clexcr,li,DOX
0.213 (450)
Clexcr,li,DOXol
0.178 (65)
SFkidney
14.7 (17)
SFheart
3.39 (240)
SFliver
1.21 (22)
CbCpDOX
1.3
CbCpDOXol
1.3
GFR
2.4
Vmax,liver
337
Km,liver
163
Vmax,kidney
127
Km,kidney
134
Parameters Fitted to Final Model
Clmem,DOX
0.9
Clon,DOX
0.3465
Cloff,DOXol
0.00000284
Vmax,heart
85
Km,heart
15
Fup,DOX
0.00007
Fup,DOXol
0.00007
bind site
0.2

5.2.2

Units
L/min
L/min
L/min
L/min
L/min
L/min
L/min
L/min
L/min
ml/min/kg
pmol/(mg protein ×min)
µM
pmol/(mg protein ×min)
µM
L/min
L/min
L/min
pmol/(mg protein ×min)
µM
-

Extrapolation to Humans
Rather than starting from scratch, allometric equations for DOX existing in

literature were collected and were tested on the observations from literature. Many of the
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papers suggested scaling parameters from a rodent model (i.e. rat or mouse) since that is
generally the earliest in vivo data that is collected in a pharmacokinetic study.[36, 9, 156]
Additionally, the mouse was chosen as the standard for scaling purposes since it is one of
the few data sets that clearly included the metabolite DOXol concentration in the heart
compartment.
The van der Vijgh data set became the basis for all subsequent scaling since it had
both venous blood and heart observations for both DOX and DOXol.[12] The venous
blood DOX concentration and the heart DOXol concentration were the two
concentration-time courses of interest due to the desire to maximize therapeutic effect
(venous blood, DOX) and minimize cardiotoxicity (heart, DOXol).
A sensitivity analysis was carried out on the van der Vijgh data set by varying the
original parameter values by ±5%, ±10%, and ±20% and measuring the percent change in
the objective function. The objective function was a least squares regression
measurement between the observed values of concentration and the model
predictions.[175] These results of this sensitivity analysis are shown in Table 5-5. The
percent change in the objective function value for each respective percent change in the
parameter value was ranked from most change to least change. There is a clear order of
magnitude difference in percent change between the third and fourth parameters in Table
5-5. Thus, the first parameter - B : P- was considered to be sensitive and the others were
fixed. The Blood:Plasma Partition Coefficient (B : P ) is a measurement of a drug
concentration between whole blood and plasma. Plasma measurements are typically the
favored method of measurement in pharmacokinetic studies, which can be misleading if
the drug has a particularly high affinity for binding to red blood cells (RBC) in whole
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blood.[176] It is determined experimentally using an RBC partitioning assay where
whole blood is centrifuged and the concentration of the compound is measured in the
separated fluids - plasma and red blood cells.[177] Understanding a drug’s interaction
with red blood cells is important for whole body PBPK models. Drugs with a high
binding affinity to red blood cells could cause a concentration sink in the whole blood
that is not captured in plasma concentration measurements.[176] DOX has been shown to
heavily interact and bind with red blood cells and even negatively affect their function
and integrity.[178] It is not wholly surprising, then, that this Blood:Plasma Partition
Coefficient (B : P ) was a sensitive parameter in the model. The fraction of DOX bound
to red blood cells directly affects the remaining DOX available in the plasma. The
concentration of DOX in plasma is then divided again into bound and unbound fractions
(Fup,DOX and Fup,DOXol). Recall that only unbound drug in the plasma is bioavailable.
The remaining fixed parameters are listed in Table 5-6. The top section of Table
5-6 contains parameter values with variability in percent coefficient of variation reported
by Dubbelboer et al.[8] If no %CV is reported, then the parameter was assumed or taken
from literature by the authors. The bottom section contains parameters that were
estimated for the new model, based on the Dubbelboer model, containing the heart
compartment. The parameters listed in this table remained constant across all the data sets
used in scaling. A flow chart of the process of developing the model structure and
parameters are shown in Figure 5-1.
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Figure 5-1: Flow chart of the process of developing the model structure and parameters,
starting with Dubbelboer Model[8] and progressing to the mouse model that was used for
inter-species scaling.[12]

The other parameter that was varied between species was cardiac output (CO).
There are a range of values that have been observed in different laboratory animals and in
humans.[179] Cardiac output was one of the most influential physiological parameters
that affected the fit of the various models. The cardiac output (CO) is measured as the
stroke volume times the heart rate in beats per minute. It is difficult to measure cardiac
output since stroke volume is defined as the volume pumped out of the left ventricle
during each systolic contraction.[180] Because of the need for invasive measurement in a
living animal, there is some disagreement around the best way to measure cardiac output
in lab animals.[180, 181, 179, 182] One study done by Cabrales et al. found that for
animals less than 100 grams, cardiac output scales linearly at 197 (ml/min)/kg ±
18.8.[183] For 20 gram mice, that translates to 39.4 ml/min ± 3.76 ml/min which is
consistent with the model fits for the mouse models.[12, 33, 126]) Other factors could
also contribute to variation in cardiac output. Since heart beats per minute directly affects
cardiac output, anesthetized animals, resting animals, and active animals of identical
species and size could have two disjoint ranges of cardiac output measurements.[173] For
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instance, Beznack tested cardiac output of 180 gram - 240 gram laboratory rats in various
states of activity, which wildly varied their cardiac output reporting values as low as 31 ±
5 ml/min and as high as 178 ± 11 ml/min [184]. An early study by Howell found that the
mean cardiac output for dogs was 236 ml/min with a wide range (91 ml/min - 509
ml/min).[185]
Despite the known variability in cardiac output, Figure 5-2 shows a general
upward trend in cardiac output with respect to body weight. First, the most sensitive
parameter B : P was estimated on heart DOXol and venous blood DOX concentration
observations in mice from van der Vijgh et al. using the ’optim’ package in RStudio. A
built-in Brent method within ’optim’ was used to fit the parameter by asking the function
to minimize the least squares objective function.[12, 146, 186] The most important
agreement between observations and predictions from the van der Vijgh data set is the
DOXol concentration in the heart compartment, which is shown in Figure 5-3.

Figure 5-2: Plot of cardiac output by body weight in kilograms of each study used for the
allometric inter-species scaling
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Figure 5-3: Heart DOXol concentration observations from van der Vijgh mouse data set
with model predictions overlaid[12]

Observations for three additional mouse data sets were then used to overlay model
predictions on the observed data to validate the model.[187, 188, 127] The results of
these predictions are shown in Figure 5-4, demonstrating that the model could reasonably
predict DOX concentration in mice.

Figure 5-4: Venous blood DOX concentration observations from four mouse data sets A.) Asperen et al.[126], B.) Dai et al.[189], C.) Formelli et al.[33], and D.) van der Vijgh
et al.[12] - with model predictions overlaid
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Next, the blood:plasma coefficient B : P value was estimated for one data set from
each species using each allometric equation to see how the model performed in scaling
from mouse to the other species. Rahman, Johansen, Oosterbaan, Dubbelboer, and
Krarup were chosen as representative data sets for rats, rabbits, dogs, pigs, and humans,
respectively. The following equation was the first to be tested on these data:
𝐵𝑊

PARnew = PARmouse × (𝐵𝑊 𝑛𝑒𝑤 ) 0.67
𝑚𝑜𝑢𝑠𝑒

(Eq. 5-3)

where PARnew is the scaled parameter for the larger species, PARmouse is the mouse
parameter, BWnew is the body weight for the larger species, BWmouse is the mouse body
weight and the 0.67 is the allometric exponent that was utilized for scaling DOX from
mouse to man in a study by Lee et al. This study who a similar meta-analysis to examine
how specifically DOX PK parameters scaled from a mouse to a human using simple
allometry.[64] Allometric exponents between 0.6 to 0.7 are typically acceptable for
scaling small-molecule drugs across species.[9]
The equation worked well for mouse to rabbit and reasonably well for mouse to
rat, but it did not scale well for mouse to pig, dog, human.[12, 133, 132, 190, 192] This
issue was not entirely surprising though, since it is known that adjustments for BRW or
MLP reduce prediction error in scaling with small-molecules that are hepatically
eliminated.[9] It was also known that DOX is one of these hepatically eliminated smallmolecule drugs that has been characterized as having low, medium, and high hepatic
extraction ratio (ranging from 0.14 to 0.79) by different studies.[11] Due to this range and
the fact that prediction error is linked to low hepatic extraction ratio, the adjustments
suggested in Huh et al. were implemented in order to improve the overall fit of the
models as they were scaled. This study found that there was benefit in implementing the
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correction factor of Maximum Life-Span Potential or Brain Weight for the low hepatic
extraction ratio drugs.[9] An exception can be made if the allometric exponent is < 0.71.
While the allometric exponent estimated in the study by Lee et al. was below that
threshold at 0.67, the decision was made to move forward with adding a correction factor.
The general rule is if the allometric exponent is between 0.71 and 1, MLP is the
appropriate correction factor. If the allometric exponent is > 1, BRW is the appropriate
correction factor. Since Equation 5.3 did fit some of the species well, its general form
was maintained with just the correction factor added. The following equation resulted:
𝐵𝑊

PARnew × MLPnew = PARmouse × (𝐵𝑊 𝑛𝑒𝑤 ) 0.67
𝑚𝑜𝑢𝑠𝑒

(Eq. 5-4)

where MLP is specific to the new species used in scaling as listed in Table 5-1. This
correction factor remedied the poor fits in the pig, dog, and human species and improved
the fit in rats. The plots of the observed and predicted concentration over time for each
species are shown in Figures 5.5 - 5.9. Additional data sets for each species, having
different mean body weights BW , dose regimens, and experiment conditions, to test how
this equation performed. The final parameter values for CO, BW , and the scaling factors
for each of the individual data sets are in Table 5-7 for sub-clinical species and Table 5-8
in humans. The plots of the concentration versus time predictions over the observed data
for each respective data set fit by the allometric scaling are listed in Appendix F.
An important clarification about this allometric equation is that all other species
parameters are scaled from the mouse parameters. In other words, the scaling does not
proceed from mouse to rat, then rat to rabbit, and so on. Instead, the mouse scales to the
rat or to the rabbit or to the human. This approach is cost effective in practice since
mouse studies are generally much less expensive than those in larger animals.
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Figure 5-5: Observed and predicted venous blood DOX concentration in rats after
applying allometric scaling - A.) with MLP Correction Factor and B.) without MLP
Correction Factor to the parameter B : P (Data source: Rahman et al.[45])

Figure 5-6: Observed and predicted venous blood DOX concentration in rabbits after
applying allometric scaling - A.) with MLP Correction Factor and B.) without MLP
Correction Factor to the parameter B : P (Data source: Johansen et al.[117])
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Figure 5-7: Observed and predicted venous blood DOX concentration in dogs after
applying allometric scaling - A.) with MLP Correction Factor and B.) without MLP
Correction Factor to the parameter B : P (Data source: Oosterbaan et al.[192])

Figure 5-8: Observed and predicted venous blood DOX concentration in pigs after
applying allometric scaling - A.) with MLP Correction Factor and B.) without MLP
Correction Factor to the parameter B : P (Data source: Dubbelboer et al.[8])
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Figure 5-9: Observed and predicted venous blood DOX concentration in humans after
applying allometric scaling - A.) with MLP Correction Factor and B.) without MLP
Correction Factor to the parameter B : P (Data source: Krarup et al.[45])
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Table 5-7: Final Parameter Values for CO, BW , and the Scaling Factors for Each of the
Individual Data Sets
Mouse
van der
Vijgh[12]

Formelli[33]

Dai[189]

Asperen[126]

BP

1.5

1.5

1.5

1.5

CO (L/min/kg)

30

50

40

50

BW (kg)

0.002

0.002

0.0035

0.0022

dose

10 mg/kg

5 mg/kg

10 mg/kg

duration (min)

1

1

1

5 mg/kg
1

Rat
Colombo[187]

Rahman[45]

Cusack[127]

BP

7.56

10.16

10.16

9.16

CO (L/min/kg)

260

200

290

205

0.225

0.35

0.35

0.3

23.674

31.829

31.829

4.7

4.7

4.7

BW (kg)
BWrat 0.67
BW mouse

MLP (years)
dose

5 mg/kg

duration (min)

1

6 mg/kg
1

2 mg/kg
1

Yesair[188]

28.707
4.7
10 mg/kg
1

Rabbit

BP
CO (L/min/kg)
BW (kg)
BW rabbit 0.67
BW mouse

MLP (years)

Bachur[190]

Cusack[191]

Brenner[12]

28.36

31.67

31.67

25.18

250.14

200

200

3.45

4.2

4.2

147.451
8

dose
duration (min)

Johansen[117]

168.224
8

5 mg/kg

325
3

168.224
8

5 mg/kg

134.3
8

5 mg/kg

5

1

1

Oosterbaan[192]

Oosterbaan[192]

Baldwin[193]

BP

23.31

22.86

27.31

CO (L/min/kg)

509

509

410

BW (kg)

10.5

10.2

13

BWmouse

310.818

304.840

358.634

MLP (years)

19.7

19.7

19.7

dose

1.5 mg/kg

1.27 mg/kg

1.5 mg/kg

duration (min)

1

1

1

Dog

( BWdog )0.67

Pig
August[194]

Dubbelboer[8]

Dubbelboer[8]

B:P

62.89

76.42

76.42

CO (L/min/kg)

55.14

68.14

85.14

BW (kg)

20

26.7

26.7

BWmouse

478

580.8

580.8

MLP (years)

8

8

8

dose

1 mg/kg

0.6 mg/kg

0.63 mg/kg

duration (min)

90

5.05

50

( BWpig )0.67

3 mg/kg
5
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Table 5-8: Final Model Parameters for 5 Human Data Sets in which Equation 5-4 was
used to Scale B:P by Body Weight
Estimated or Assumed Parameters in Humans Determined with Inter-Species Scaling
Source

[133]

[34]

[34]

[120]

[80]

BP

15.32

17.79

17.79

17.79

17.79

CO (L/min/kg)

107.14

97.1

97.1

97.1

107.14

BW (kg)

56

70

70

70

1107.964

1107.964

93.4

93.4

70

0.67

BWhuman
BWmouse

954.104 1107.964

MLP (years)
dose

93.4

93.4

70 mg/m2 36 mg/m2 30 mg/m2

duration (min) 1

5760

1

15 mg/m2
1

1107.964
93.4
75 mg/m2
15

Additionally, since regulatory agencies require testing to be conducted in a rodent
and non-rodent species before proceeding to humans, having insight into moving from
rodent to non-rodent studies is both cost- and time-efficient. In terms of the Blood:Plasma
Coefficient B : P , an interesting trend was observed when looking at the Log-Log plots
of the B : P values versus the body weight BW of the animals (Figure 5-10).
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Figure 5-10: Plot of Blood:Plasma Partition Coefficient for each study used in the
allometric interspecies scaling - the top plot shows the trend in the parameter with the
Maximum Life-Span Potential (MLP) Correction Factor while the bottom plot shows the
trend in the parameter without the correction factor.

Without the Maximum Life-Span (MLP ) correction factor (bottom plot in Figure
5-10), there is a neat positive correlation of B : P based on body size, which is to be
expected with allometric scaling. However, when the MLP correction factor is added, the
B : P values for the human are much lower. This deviates from pure allometry in that the
parameter scales not only on body weight, but also in longevity. The idea that MLP is an
appropriate corrector for hepatically cleared small-molecule drugs originates from the
inverse correlation between longevity and hepatic cytochrome P450 (CYP450) drug
oxidation rates.[161, 9] In other words, the longer the lifespan of a particular species, the
lower the hepatic oxidation of CYP450.[195] CPR receives an electron from NADPH
and distributes it to CYP450, which then becomes capable of metabolizing drugs.[196]
This detail is particularly interesting for DOX since, while DOXol is metabolized by
aldo-keto- and carbonyl- reductases, both aglycone metabolite formations involve the
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CYP450 enzyme.[4] The aglycone metabolites, doxorubicin deoxyaglycone and
doxorubicin semiquinone radical, are both notably less cardiotoxic than DOXol.[52] The
extent to which the more cardiotoxic metabolite, DOXol, metabolizes versus its aglycone
counterparts could be affected by this correlation of species longevity and CYP450
oxidation rates in the liver. While this is an interesting conjecture, it is beyond the scope
of this work. Whether B : P is the actual parameter that affects the predictive ability of
this model to scale from mouse to rat, rabbit, dog, pig, and human is beyond the scope of
the available data and interest for this work. Overall, B : P affects the availability of DOX
in plasma and by proxy, free DOX in plasma available for metabolism, cell-killing,
clearance, and binding.[68] Whether the effect is direct or indirect, the adjustment of the
B : P parameter has a major effect on the behavior of the DOX and DOXol predictions
with this model across species.
The corresponding R code for the physiological parameters shown in Table 5-3,
Table 5-4, Table 5-2 for each species are available in Appendix G. The equations for the
final model are available in Appendix B and the corresponding R code in Appendix D.

CHAPTER 6
CONCLUSIONS
6.1

Future Work

6.1.1

Therapeutic Drug Monitoring for DOX

6.1.1.1

Therapeutic Index
In earlier chapters, a minimal physiology-based pharmacokinetic model was

constructed that could accurately predict the concentration of DOX and DOXol over
time. Physiologic and pharmacokinetic parameters were established that could predict
specifically the venous blood concentration of DOX and heart concentration of DOXol
using an allometric scaling equation. PBPK models have been recognized as a promising
tool for characterization of tissue-level parameters for better understanding of
individualized pharmacologic response. As previously mentioned, PBPK models are
more likely to be over-parameterized and therefore, less reliable for predictions. More
work is needed in bolstering and validation of the use of PBPK models for drugs with
high inter-patient and inter-occasion variability and narrow therapeutic windows for
drugs with organ-specific toxicities.[197]
The concept of a therapeutic window was introduced in Chapter 2. A related term
that quantifies the width of this “window” is the therapeutic index (TI). The therapeutic
index is defined as the range of doses at which a drug is considered effective without
adverse side effects. In animals, this is measured by the lethal dose of the drug for 50% of
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the population divided by the minimum effective concentration for 50% of the population
as shown in Eq. 6-1.
𝑇𝐼 =

𝐿𝐶50
𝐸𝐶50

(Eq. 6-1)

where LC50 and EC50 is the lethal dose and minimum effective concentration for 50% of
the population, respectively. Equation 6.1 is a very straightforward definition of
therapeutic index, but assessing the therapeutic index in humans requires a larger margin
of safety and is more difficult to define.[197]
In humans, the therapeutic index is the range of doses that were effective in
clinical trials for the median of the participants without unacceptable adverse effects. For
most drugs, this range is wide enough that the maximum plasma concentration Cmax and
area under the plasma concentration-time curve (AUC) fall well above the minimum
therapeutic concentration and well below the toxic concentration. In other words, the
therapeutic index is wide enough that for most people at recommended prescribed doses,
these drugs show clinical efficacy with a healthy margin of safety.[198] The difficulty in
determining the therapeutic index in humans, especially in anticancer drugs, is there is
not a well-defined number that works universally.[44]
6.1.1.2

Therapeutic Drug Monitoring for DOX and DOXol
As mentioned in Chapter 1, despite the known narrow therapeutic index and high

inter-patient and inter-occasion variability of DOX, there are almost no covariates that
significantly inform dose adjustments.[11, 64] Dose adjustments for body mass index
[118], age [32, 135], acidity of urine [117, 133], and hepatic impairment [140] have all
been investigated thoroughly. The only truly significant factor that improves the dose of
DOX is adjustment for hepatic impairment, which is essentially standard practice for
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antineoplastic agents.[140]. This discrepancy further drives the need for more
individualized dosing regimens for drugs with narrow therapeutic windows.[11, 64]
However, the exposure (AUC) and the maximum concentration Cmax in humans
are significantly impacted by the rate and duration of DOX infusions.[44] The dose- and
schedule- dependence of the pharmacokinetic parameters of DOX has been widely
observed.[136, 120] Clinically, the side effects of doxorubicin (nausea, vomiting,
cardiotoxicity) have been shown to decrease as the maximum venous blood concentration
Cmax in venous blood.[44, 141]. The amount of drug in venous blood is directly correlated
to the amount of drug distributed to the various tissues, i.e. the heart, since the venous
blood is the compartment in which the dose is administered.[8] Recall that the total dose
that goes to the venous blood is transported through the lung to be oxygenated and into
the arterial blood. The total dose then moves from the arterial blood into the to the extent
of the flow rate and volume for the vascular compartment of the heart. This
proportionality leads to the idea that a similar reduction in side effects could likewise be
linked to the Cmax in the heart. In a study comparing a homogeneous group of breast
cancer patients receiving DOX either in the conventional IV bolus or a continuous 48 or
96 hour infusion, ≈47% of the patients in the IV bolus group developed severe
morphological changes in cardiac tissue as opposed to only ≈9% of the patients receiving
continuous extended doses.[141] A study done in rabbits showed a 15-fold reduction in
Cmax from an IV bolus injection to a 69 minute IV infusion.[44]
It has been observed that the values of AUC and Cmax are proportional to the total
amount of drug administered in an intravenous bolus under the assumption of linear
kinetics. A similar, more comprehensive study was conducted by Eksborg where the Cmax
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and AUC were calculated from patients receiving I.V. infusions of DOX ranging from 20
to 60 mg/m2 with varying infusion times ranging from 3 minutes to 16 hours. The results
from this study showed that increasing the infusion duration from 45 minutes to 16 hours
showed a relatively unchanged therapeutic exposure (plasma AUC), but a 25-fold
decrease in normalized maximum plasma concentration Cmax at 4 hours and a greater than
65-fold decrease at 16 hours. It has been reported that clinically, side effects were
considered tolerable when Cmax is below 60 ng/ml. This constraint means that a 30 mg/m2
dose should no shorter than 16 hours in order to avoid unacceptable adverse effects, by
their calculations.[44] This type of dose adjustment based on peak concentration could be
especially useful if a peak heart DOXol concentration, extrapolated from a plasma
concentration sample using the PBPK model, could be determined in a similar way.
Referring again to Table 1-1, most doses are given clinically in fractionated,
repeated lower doses, which likely allow for clearance of the drug before the subsequent
dose.[199] However, there may be reason to believe that fractionated dosing has a
detrimental effect on the therapeutic drug effect on tumor cells. This same recovery time
that allows DOX to clear the system may also give tumor cells time to recover between
doses.[142] Additionally, the faster the drug clears, the lower the residence time. Since
tumors are cell-cycle dependent, lower residence time decreases the chance that the drug
will reach the tumor cells during their most vulnerable growth phase.[44] As mentioned
in Chapter 2, the breadth of cancer types that DOX treats makes the relation of
pharmacodynamic response and dosing schedule too broad of a topic to include in the
scope of this work. It would certainly be a compelling next step to find an optimum
balance between tumor killing effect and cardiotoxicity. The extent to which this study
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will contribute to that balance is by developing a framework that can predict
concentration in specific tissues for dose monitoring. In general, there is compelling
evidence in literature that any dose given over a longer time and fractionated doses given
more frequently can reduce the incidence of cardiotoxicity.[141, 142]
A similar approach is taken in this work, except instead of the maximum plasma
concentration, the maximum heart concentration of the metabolite DOXol is extrapolated
from the PBPK model for the assessment of toxicity. PBPK models lend themselves as a
useful tool for modeling metabolism kinetics and concentration in a specific tissue or
organ. The total drug exposure or therapeutic effect, as measured by area under the
concentration-versus-time curve (AUC), was maximized using the PBPK model and
’optimize’ function in R.[200, 146, 8]. This optimization function was a better choice
than other multi-dimensional optimization packages like those used in fitting the PBPK
model parameters (‘optim’), since only one parameter was being maximized for the
function.[186] The ’optimization’ function takes an interval of possible values to search,
the choice of minimization or maximization of the function, the function to be optimized.
The method used by this function utilizes a combination of the golden search method and
successive parabolic interpolation and is designed for continuous functions and onedimensional optimization.[200] The golden search method is similar to bisection methods
and searches within the interval for the extrema within the interval. This is particularly
useful for optimizations like this study which have physiological bounds within these
values must lie. The algorithm can be relatively slow, but it is robust.[201] The ranges in
which the rate or total dose were tested were 9 mg/m2 - 75 mg/m2 based on the extremes
of the ranges which DOX is currently given in humans (Table 1-1).[199]. This equated to
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a range of 32 µM to 350 µM. A range of 30 µM to 500 µM was were implemented as the
upper and lower bounds for possible rates in order to give the optimization more room to
explore higher doses that are still within physiological possibility. Since the rate or total
dose was the parameter being estimated, the optimization was run in intervals of 1, 5, 30,
60, 120, 360, 720, 1440, 2160, 2880, and 4320. These are based on clinical dosing
duration values for DOX in adult humans.[34, 121, 133, 80] A penalty on the objective
function was added for the maximum concentration of DOXol in the heart exceeding
10−3 based on the observed values of DOXol in the mouse heart reported by van der
Vijgh.[12] The values for the physiological and pharmacokinetic parameters in the PBPK
model used for these minimizations are those listed in Table 5-6.
The optimization routine for the PBPK model predictions was run for each
infusion duration listed in Table 6-1 with the goal of maximizing the exposure for that
length of infusion without exceeding 10−3. Figure 6-1 shows a schematic of the iterative
process of the therapeutic dose monitoring approach. Figure 6-2 shows both AUC and
dose given (infusion rate) versus the infusion duration given the maximum concentration
of DOXol in the heart stayed below 10−3. The red vertical line indicates the infusion
rate/dose and infusion duration where the AUC is maximized while still maintaining
Cmax,heart,DOXol of below 10−3. Interestingly, these results show that there is a diminishing
return for increasing the dose for a greater than 2 hour infusion. To maximize therapeutic
efficacy only to the extent that some Cmax,heart,DOXol is not exceeded, a 2 hour infusion
duration at a total dose of 69.3 µM. The plots of this infusion rate and duration
combination are shown in Figures 6.3 and 6.4. The significant binding of DOXol in the
heart is seen in Figure 6-4, since the peak concentration occurs ≈45 hours following the
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end of the infusion. Only then does it begin to clear from the heart tissue, whereas in the
venous blood, the concentration is more than an order of magnitude lower at the same
time point of 2728.25 minutes.

Table 6-1: AUC and Cmax for the Predictions Generated by the PBPK Model
Infusion Time (min)

Total Dose

AUCvb

Cmax,heart,DOXol (µM)

1
5
30
60
120
720
1440
2160
2880
4320

55.0
66.0
68.5
69.0
69.3
69.35
69.4
69.5
70.15
71.0

73.62
75.71
75.80
76.01
76.07
74.71
73.13
71.53
70.38
67.08

0.00099
0.00099
0.00099
0.00099
0.00099
0.00099
0.00099
0.00099
0.00099
0.00099

Figure 6-1: Schematic of the iterative process of the therapeutic dose monitoring
approach outlined in this work for individualizing DOX therapy
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Figure 6-2: Plot of venous blood AUC values versus infusion duration at the maximum
dose that does not exceed Cmax,heart,DOXol of 10−3 -the open circles represent the AUC
values, the closed dark green circle indicates the point at which the AUC is highest; the
solid line represents the infusion rate or maximum total dose for the corresponding
infusion duration, with the blue closed circle indicating the dose at which the AUC is
highest; the vertical line highlights the optimal infusion duration at which AUC is
maximized while still remaining below Cmax,heart,DOXol

Figure 6-3: DOX venous blood concentration versus time plot in humans using the
infusion parameters (infusion rate - 69.3 µM over 120 minutes) from the optimization
shown in Table 6-1 and Figure 6-2 - AUC for the infusion simulated out to 96 hours
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Figure 6-4: DOXol heart concentration versus time plot in humans using the infusion
parameters (infusion rate - 69.3 µM over 120 minutes) from the optimization shown in
Table 6-1 and Figure 6-2 - Cmax,heart,DOXol is reached at 2827.25 minutes but does not
exceed the threshold of 10−3 for the infusion simulated out to 96 hours

6.1.1.3

Use of PBPK Predictions for Therapeutic Dose Monitoring of DOX
Similar to the study done by Eksborg where the Cmax and AUC in plasma were

compared for different infusion durations, a framework such as this could allow for
deeper insight into the relationship between infusion parameters and exposure and
toxicity profiles for DOX. It would be interesting to eventually develop a valid PBPK
model such that a clinical threshold for adverse effects of DOX could be established for
Cmax,heart,DOXol as it has been for Cmax,vb.[202] If achieved, a therapeutic drug monitoring
process could be used to predict the infusion duration necessary to maintain a
Cmax,heart,DOXol below that clinical threshold to significantly reduce the incidence of
cardiotoxicity from a more direct measure. Not only could this predictive framework be
useful for dose improvement based on organ-specific toxicities, but also for toxicity
related to metabolites since PBPK models are well-suited for modeling more complex
mechanistic metabolite activity.[2] The utility of a predictive model such as the one

163
demonstrated here could be extremely useful in any number of narrow therapeutic index
drugs.
The general process of how the predictive PBPK model could be used for
individualized therapeutic drug monitoring is illustrated in Figure 6.1. First, an initial
dose would be given to the patient in accordance with the standard dose calculations for
the respective disease. Plasma samples would be collected at various time points. From
that data, the pharmacokinetic parameters would be estimated for that particular patient.
The infusion rate and duration could then be optimized by fixing the parameters from the
previous step using PBPK model predictions to obtain the desired target exposure that
does not exceed the maximum DOXol concentration in the heart. The next dose would
follow the updated infusion parameters. The knowledge gained from the predictions of a
PBPK model like the one in this study could be used to help individualize DOX dosing
regimens in the future.
6.1.2

Pharmacodynamic Studies
It has been observed that frequent, fractionated doses tend to decrease DOX-

induced cardiotoxicity. Additionally, there is evidence that since a certain Cmax
thresholdis correlated clinically to adverse effects, prolonged infusions may also decrease
carditoxicity for roughly the same exposure (AUC).[44] Some studies claim that
therapeutic efficacy may even be increased for 10 - 96 hour intravenous infusions
compared to the same dose over a shorter period.[203] One reason for this could be that
tumor cells are only in the growth phase, the time when they are most vulnerable to drug
effect, for a short period of time. The circadian pacemaker in the hypothalamus of the
brain guides the daily flux of activity in peripheral organs and is best recognized as the
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“circadian rhythm” that regulates sleep. The circadian rhythm is also known to control
the time Cancer tissues show tissue-specific daily variation in DNA synthesis activity and
are more susceptible to drug effect during different times of the day. Therefore, even the
time of day could effect the potency of a drug on a target tissue depending on the current
phase of the cell cycle. [204] Therefore, there is a possibility that the shorter, intermittent
infusions like those used clinically could be missing the tumor growth phase “window” in
some instances.[44] Since longer infusions also decrease cardiotoxicity, it may be
interesting to see if an optimum exists among infusion rate, infusion duration, exposure,
maximum dose, and therapeutic efficacy.
Future work could include adding a pharmacodynamic component which would
add the concentration-effect piece to the current concentration-time profiles described
here. Having an understanding of how infusion rate and duration affects cardiotoxicity is
useful, but if the therapeutic purpose of the drug is compromised, then the potential
morbidity of the disease being treated quickly outweighs the potential morbidity of
cardiotoxic adverse effects.
6.1.3

Application to Other Drugs
As mentioned before, the utility of this approach is not exclusive to DOX, but

could be extended to any drug with a narrow therapeutic index with a tissue-specific
toxicity. While this may seem like a limited scope, the drugs that fall into this category
are some of the most widely used for their respective indications. For instance,
methotrexate is a competitive inhibitor of dihydrofolate reductase, which is a key enzyme
for synthesizing nucleic acid.[197] It is used in some of the most common forms of
cancer - for example, acute lymphoblastic leukemia (ALL), lung cancer, brain tumors,
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and carcinomas. Toxicities include leukopenia, thrombocytopenia, and acute kidney
injury (AKI).[197, 205] Timed blood draws are needed in order to monitor the renal
clearance of methotrexate, but it may be useful to gain more insight into the methotrexate
concentration in the kidney for more individually tailored dosing. Similarly,
aminoglycoside antibiotics like Streptomycin are used to treat systemic, life-threatening
infections. However, severe nephrotoxicity can occur in patients due to the high interpatient variability in clearance. Perhaps a more interesting application could be the antimanic agent lithium. Therapeutic drug monitoring is vital for lithium for both efficacy
and to prevent brain lithium toxicity. While the blood concentration of lithium has been
known to be approximately analogous to brain concentration, a PBPK model-informed
prediction of brain concentration may improve the understanding of the drug and drugs
similar.[197]

6.2

Conclusion

Pharmacometrics is a discipline that quantifies what the body does to the drug pharmacokinetics - and what the drug does to the body - pharmacodynamics.[67, 69]
Pharmacokinetics (PK) is described as the science of characterizing the time course of
drug concentration through four processes - absorption, distribution, metabolism, and
excretion. These processes are often referred to as ADME processes.[130, 68]
Pharmacokinetic models generally represent different locations in the body as
compartments, which are represented by mathematical equations. Although they are
representative of physiological spaces in the body, they do not hold any true
physiological reality and may not correspond directly to any real tissue or fluid
compartment. Classic PK models are generally broken into a central compartment with a
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few peripheral compartments that allow the system to empirically mimic the complex
time course that a drug actually takes when binding, metabolizing, and clearing the body.
Physiology-based pharmacokinetic (PBPK) modeling are more heavily based on the
physiology of the system and tend to have compartments and inter-compartmental
clearance rates that are more representative of specific tissues and physiological
processes.[1, 2] Some important considerations in the development of PBPK models
include both passive and active diffusion rates across cell membranes, metabolic
pathways, extent of binding to blood components and proteins, and excretion or clearance
parameters which are crucial to building a more mechanistic model.[143, 2]
Doxorubicin (DOX) is the drug of interest for this particular work. DOX is an
anthracycline antibiotic drug that is administered in a wide range of cancer types due to
its potent cytotoxicity. However, with its robust cell-killing properties comes a high
incidence of debilitating cardiotoxicity which can lead to cardiomyopathy and congestive
heart failure linked to accumulated dose.[3, 40] Cumulative doses of 400 mg/m2 to 550
mg/m2 have shown increased incidence of these cardiac adverse events and will
sometimes lead to discontinuation of therapy.[141] Since its development in the late
1960’s, many pharmacokinetic models have been developed to better characterize DOX
and have described its clearance as either a two- or a three- compartment model in subclinical species such as mice, rats, and pigs as well as in humans.[12, 45, 8, 121] It has
been observed experimentally across species that lower doses tend to exhibit bi-phasic
clearance (two-compartment model) while moderate to high doses tend to exhibit triphasic clearance behavior (three-compartment model).[44, 121] The extenuating issue
with DOX is that its cardiotoxicity is related to accumulation of its primary metabolite,
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doxorubicinol (DOXol) in the heart.[40, 12] Since classic compartmental
pharmacokinetic models are not tissue-specific enough to characterize and simulate the
DOXol concentration in the heart, PBPK models of DOX have been developed for better
understanding of the binding of the drug in tissues.[8, 64] A PBPK model of DOX was
constructed by adapting an existing pig model from the literature to include a heart
compartment in order to characterize the DOXol concentration in the heart.[8] Since
cardiotoxicity is known to be related to the accumulation of DOXol in the heart, it was
also designated as a metabolizing compartment.[4]
While classic PK models are generally represented by a few ordinary differential
equations (ODEs), PBPK models can have many ordinary differential equations with a
larger number of parameters to describe the physiological processes involved in the
model.[2] For large systems of ODEs, numerical methods are needed to solve the
system.[147, 5] Each numerical method for solving ODE systems come with benefits and
drawbacks, but the general strategy is to begin with the simplest method possible and add
complexity as needed.[5] Euler’s Method was the first method used to solve the system,
but it proved to require too small of a time step for the needed efficiency.[147] The
fourth-order Runge-Kutta method was the next method used since it has a higher
accuracy and is typically more stable, but it still required a very small time step to capture
the concentration-time profile of DOX. Additionally, it was discovered that the system
had issues with stiffness, so an adaptive Runge-Kutta method was implemented next. The
Runge-Kutta Fehlberg method is a numerical method which varies the length of the time
step according to the amount of change occurring in the time interval, which decreases
the computation time while maintaining the accuracy needed.[5] Unfortunately, the added
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complexity of the equations in this method was still computationally slow when executed
in R.[146] Since matrices tend to be more palatable in R, the system of equation was
converted into matrix format, which consisted of (i) a rate coefficient matrix describing
the rate of change in drug concentration in each compartment relative to each
concentration (A matrix), (ii) an initial conditions matrix representing the amount of drug
in each compartment at the beginning of the respective time interval (x vector), and (iii)
the dose vector representing the dose that will be administered in each respective
tissue/compartment (g vector). Variation of Parameters was used to solve the matrix
system,
Ax + g(t) = x′
at three equidistant time points (t0, t1, and t2). Those three time points were then
numerically integrated over using Composite Simpson’s Rule. That solution xt then
becomes the new initial condition for x for the next iteration of what becomes a series of
initial value problems. [7, 5]
This method was able to solve the PBPK model, represented by a system of a total
of 44 first-order ordinary differential equations, reasonably quickly. Physiological
parameters such as volume and blood flow fractions were obtained from literature for
mice, rats, rabbits, pigs, and humans. [8, 174, 173] First, the parameters were estimated
for a mouse data set that contained concentration versus time data for both the venous
blood and the heart for both DOX and DOXol.[12] These parameters were then fixed and
scaled to predict rat, rabbit dog, pig, and human data sets using an allometric scaling
equation on the blood:plasma partition coefficient B : P .[8, 9, 10] The allometric
equation was derived from a previous inter-species scaling study for DOX which took the
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approach of scaling from mice other rodents, non-rodents, or humans.[64] This equation
successfully scaled using B : P for rat and human data sets, but failed to adequately
predict in rabbits, dogs, or pigs. Another study suggested the addition of the correction
factor of Maximum Life-Span potential for hepatically-eliminated small-molecule drugs
with low hepatic extraction ratios (Eh). DOX has been described as such a drug. [9] The
addition of this correction factor allowed for the mouse parameter set to adequately
predict the DOX concentration in venous blood (Cvb,DOX) and the DOXol concentration in
the heart (Cheart,DOXol). The ultimate goal was to scale from mouse to humans for
therapeutic drug monitoring. Additional validation for the equation came from the fact
that the allometric equation also fit for rats, rabbits, dogs, and pigs.
Despite numerous studies and pharmacokinetic models of DOX, there are almost
no covariates that consistently improve the dose of DOX, with the exception of dose
reduction for hepatic impairment.[11, 140] However, dosing schedule – infusion rate and
duration- have been shown to affect both drug efficacy and incidence of
cardiotoxicity.[11] A study done in data from cancer patients receiving DOX at different
infusion durations showed that increasing the infusion length did not greatly affect
exposure (AUC) but did significantly decrease the maximum concentration (Cmax).
Clinically, values of Cmax above a certain threshold have been correlated to adverse
effects. This study suggested extending the infusion length for the necessary dose in order
to avoid exceeding that Cmax value since there was no noticeable loss in therapeutic
exposure.[202]
A framework similar to the one in this study such as could allow for deeper
insight into the relationship between infusion parameters and exposure and toxicity
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profiles for DOX. However, in this case, the criterion for decreasing incidence of
cardiotoxicity was maintaining a sub-toxic Cmax,heart,DOXol in the heart while maximizing
exposure, represented by area under the concentration-time-curve (AUC). The PBPK
model was was optimized at 10 time points between 1 minute and 72 hours (4320
minutes). The ’optimize’ function in R was given an interval of 30µM to 500µM to
search, which is approximately the range which DOX is given clinically.[146, 200, 199]
The goal of the optimization was to maximize the value of (AUC) without the
Cmax,heart,DOXol value of 10−3 Using these predictions, by way of a penalty on the objective
function value.
Especially since many other covariates have failed to improve dosing schedules
for DOX, understanding the relationship of infusion rate and duration on exposure and
toxicity of DOX is invaluable. The potential for reduction of cardiotoxicity without
compromising the therapeutic exposure of DOX could inform future studies and improve
outcomes for the many patients who are treated with DOX for various cancer types.[11,
202] During a patient’s first dose of DOX with standard dosing parameters, plasma
samples could be collected and a concentration-time profile for the individual patient
could be created. The PBPK model predictions could provide AUC and Cmax,heart,DOXol
data, and an assessment could be made whether or not the infusion rate and duration are
appropriate for maximum therapeutic effect without elevating the risk for cardiotoxic
adverse effects. If necessary, the infusion parameters could then be adjusted for that
patient’s next dose. Clinical thresholds for Cmax,vb have been established for incidence of
adverse effects, and in future work, perhaps a similar threshold for cardiotoxicity could
also be established using tissue-specific measures. As the use of PBPK models in drug
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discovery and drug delivery increase, it is not unreasonable to think that this approach to
therapeutic drug monitoring is feasible in the near future.[143] The knowledge gained
from the predictions of a PBPK model like the one in this study could be used to help
individualize DOX dosing regimens in the future.
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